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Abstract 
The phosphatidylinositol 3-kinase (PI3K)/PTEN (phosphatase and tensin homologue 
deleted on chromosome 10) pathway is activated upon stimulation of receptor tyrosine kinases 
(RTKs) and regulates downstream pathways involved in cell survival, cell growth, cell cycle 
progression, and protein expression.  The protein p85 is uniquely positioned to both positively 
and negatively regulate the PI3K/PTEN pathway through its interactions with various protein 
partners including p110, PTEN, and Rab5.  The PI3K/PTEN pathway has been shown to be 
dysregulated in a variety of cancers, including cancers of the breast, prostate, endometrium, and 
urothelial tract.  A better understanding of the interaction between p85 and its various binding 
partners can further elucidate the mechanisms through which cancer-associated mutations lead 
to dysregulation of the PI3K/PTEN pathway.  To this end we pursued obtaining crystal structure 
data for the p85 BH domain, alone and in complex with binding partners PTEN and Rab5.  Crystal 
structures were successfully obtained for the bovine p85 BH domain wild-type, individual 
cancer-associated mutations (E137K, E217K, R262T, E297K), and the engineered mutation 
R228E.  Protein complexes between the p85 BH domain and PTEN or Rab5 were not purified in 
suitable concentrations for crystallography experiments, and so no structural data was collected 
for these complexes.  Within the p85 BH domain structure a pair of highly coordinated regions 
of electron density were observed, likely sulfate molecules based on the composition of the 
crystallization buffer.  These regions were coordinated by the p85 residues K224, R228, H234, 
W237, and Q241.  These two highly coordinated regions of electron density were visible for all 
structures obtained, except the engineered R228E mutant, in which one of these densities was 
absent.  Due to the consist presence of these densities, it was proposed that this region may serve 
as a potentially uncharacterized binding pocket.  Crystallization solutions were prepared exposing 
crystals of the p85 BH domain to nucleotides, phosphorylated amino acids, or phospholipids, 
based on the structural similarity between phosphate and sulfate ions.  No bound compounds 
were visible within the determined structures, although high levels of sulfate in the crystallization 
buffer may have prevented binding of the lower concentration additives.  To test p85 for lipid 
binding in the absence of sulfate, experiments were performed using phosphatidylinositol lipid 
strips.  Direct binding of p85 to lipids present on the lipid strips was detected, with the p85 BH 
domain alone being sufficient for lipid binding.  These results suggest a novel function for the 
p85 BH domain in direct binding to lipid, which may play a role in regulation of binding partners 
such as PTEN. 
iii 
 
Acknowledgements 
 
 I would like to thank my supervisor Dr. Deborah Anderson for her boundless support, and 
providing another perspective and suggestions that helped lead my research to being the best that 
it could be.  Thanks to Dr. Stanley Moore for guiding me through the intricate path of X-ray 
crystallography and allowing me to see the world in a way that most never know.  Also I would 
like to thank my other committee members Dr. Linda Chelico, Dr. Erique Lukong, and Dr. 
Yuliang Wu for their feedback and recommendations across the years.  To all the members of the 
Anderson Lab and Moore Lab I thank you for your help in teaching me new techniques, providing 
a welcoming forum for trouble-shooting questions or fresh perspective on my tasks at the 
moment, as well as reminding me the importance of having some fun and not taking myself too 
seriously.  Also, without the assistance of the staff at the Canadian Light Source Synchrotron, 
and the Protein Characterization and Crystallization Facility on campus, I would not have been 
able to collect much of the data that is presented within this thesis.  Finally, to my family and 
friends that have been with me over the course of this journey, providing your support, 
excitement, and energy while I bombarded you with excessive details regarding the various 
successes and difficulties over the course of my degree, know that your support means the world 
to me and I cannot thank you enough.  I wouldn’t be where I am today without all of you. 
  
iv 
Dedication 
This thesis is dedicated to everyone that has helped and supported me along the path that has 
lead here.  Through the most exciting moments of joy, and the most insufferable moments of 
frustration, we have made this journey together and I would not be here without all of you. 
This mutual journey has brought great magic to my life, and I hope that I have succeeded in 
capturing a semblance of that magic within these pages to share with you all. 
v 
 
TABLE OF CONTENTS 
Permission to Use………………………………………………………………………………..i 
Abstract………………………………………………………………………………………....ii 
Acknowledgements…………………………………………………………………………….iii 
Dedication……………………………………………………………………………………....iv 
Table of Contents……………………………………………………………………………….v 
List of Tables…………………………………………………………………………………...ix 
List of Figures…………………………………………………………………………………...x 
List of Abbreviations………………………………………………………………………….xii 
1.0 INTRODUCTION………………………………………………………………………….1 
   1.1 Role of signaling pathways in eukaryotic cells…………………………………………….1 
   1.2 Receptor tyrosine kinase signaling………………………………………………………....1 
      1.2.1 Phosphatidylinositol 3-kinase/PTEN signaling pathway……………………………….3 
      1.2.2 The PI3K/PTEN pathway in cancer…………………………………………………….5 
      1.2.3 Endocytosis of receptor tyrosine kinases……………………………………………….5 
      1.2.4 Rab mediated vesicle trafficking……………………………………………………….6 
         1.2.4.1 Rab5………………………………………………………………………………..7 
         1.2.4.2 GAP proteins……………………………………………………………………….7 
   1.3 Phosphatidylinositol 3-kinase……………………………………………………………...8 
   1.4 Phosphatase PTEN…………………………………………………………………………9 
   1.5 Structural studies of p85 and binding partners…………………………………………….11 
      1.5.1 Structural studies of p110……………………………………………………………..13 
      1.5.2 Structural studies of PTEN……………………………………………………………16 
      1.5.3 Structural studies of Rab5……………………………………………………………..19 
2.0 HYPOTHESIS AND OBJECTIVES……………………………………………………..24 
   2.1 Rationale………………………………………………………………………………….24 
   2.2 Hypothesis………………………………………………………………………………...24 
   2.3 Objectives…………………………………………………………………………………24 
3.0 MATERIALS AND METHODS………………………………………………………….25 
   3.1 Materials…………………………………………………………………………………..25 
      3.1.1 Bacterial cells and culture……………………………………………………………..25 
vi 
 
      3.1.2 Plasmids………………………………………………………………………………25 
      3.1.3 Primers………………………………………………………………………………..25 
      3.1.4 Antibodies…………………………………………………………………………….27 
      3.1.5 Crystallization condition screening kits………………………………………………27 
      3.1.6 Other reagents………………………………………………………………………...27 
   3.2 Methods…………………………………………………………………………………...28 
      3.2.1 Generation of GST-tagged protein fragments…………………………………………28 
         3.2.1.1 Generation of GST-tagged bovine p85 protein fragments………………………...28 
         3.2.1.2 Generation of GST-tagged p85 mutants…………………………………………..29 
         3.2.1.3 Generation of GST-tagged PTEN (7-353, Δ286-309 C124S)……………………..29 
         3.2.1.4 Generation of GST-tagged Rab5 (15-184)………………………………………..29 
      3.2.2 Protein expression, purification and tag cleavage of GST-tagged protein fragments…30 
         3.2.2.1 Individual batch protein purification……………………………………………...30 
         3.2.2.2 Large scale ÄKTA Purifier Glutathione-Sepharose column purification…………31 
         3.2.2.3 Anion exchange chromatography of p85 protein fragments………………………32 
      3.2.3 Protein visualization and concentration determination………………………………..33 
         3.2.3.1 Coomassie Blue staining………………………………………………………….33 
         3.2.3.2 Western blot analysis……………………………………………………………...33 
         3.2.3.3 Nano drop protein concentration determination………………………………….34 
      3.2.4 Crystallization condition screening for bovine p85 protein fragments………………..35 
         3.2.4.1 Automated sparse matrix screens…………………………………………………35 
         3.2.4.2 Hanging-drop vapour diffusion condition optimization screens………………….35 
         3.2.4.3 Crystal seeding and streak seeding………………………………………………..36 
      3.2.5 X-ray diffraction data collection, processing, and structure refinement……………….36 
         3.2.5.1 X-ray diffraction data collection and processing………………………………….36 
         3.2.5.2 Structure refinement using PHENIX and Coot software………………………….37 
         3.2.5.3 PyMOL image generation………………………………………………………...37 
         3.2.5.4 Generation of electron density maps in CCP4 for visualization in PyMOL……….37 
      3.2.6 Size exclusion chromatography and Native PAGE……………………………………38 
         3.2.6.1 Complex formation experiments between p85-BH and Rab5……………………..38 
         3.2.6.2 Oligomerization determination of recombinant full-length human p85  
vii 
 
  and mutants……………………………………………………………………..38 
      3.2.7 Multi-angle light scattering…………………………………………………………...39 
      3.2.8 Phosphatidylinositol phosphate lipid strip analysis…………………………………...39 
4.0 RESULTS………………………………………………………………………………….41 
   4.1 Purification and crystallization trials for GST-tagged bovine p85 protein fragments…….41 
      4.1.1 Crystallization of p85 fragments containing SH3 and BH domains, and the BH 
  domain alone……………………………………………………………………………41 
      4.1.2 Crystallization of p85-BH containing cancer-associated point mutations…………….45 
      4.1.3 Crystallization of p85-BH containing engineered point mutations……………………49 
      4.1.4 Crystallization with addition of nucleotide, phosphoamino acids, or phospholipids….51 
      4.1.5 Observations of C146 in the p85-BH protein structure……………………………….54 
      4.1.6 Crystallization of p85 (78-319) in presence of 8 carbon PI4,5P2……………………..55 
   4.2 Purification of PTEN (7-353, Δ286-309)………………………………………………….59 
   4.3 Size exclusion chromatography analysis of complex formation between 
  bovine p85 fragments and Rab5………………………………………………………...60 
   4.4 Size exclusion chromatography and Native PAGE of recombinant  
 full-length human p85 wild-type and mutants…………………………………………..61 
   4.5 MALS analysis of recombinant full-length human p85…………………………………..63 
   4.6 Lipid binding of p85 SH3 and BH domains using phosphatidylinositol phosphate 
  lipid strips………………………………………………………………………………66 
      4.6.1 Determination of p85 regions required for lipid binding………………………………67 
      4.6.2 Determination of concentration dependence of observed p85 lipid binding………….67 
5.0 DISCUSSION……………………………………………………………………………...70 
   5.1 Combining High Resolution Structural Data with Protein Function Studies……………..70 
   5.2 Insights from bovine p85 BH domain crystal structures…………………………………..70 
      5.2.1 Observations from nucleotide, phosphoamino acid, and phospholipid additive 
  Analysis………………………………………………………………………………..71 
         5.2.1.1 Future experiments to check for binding between additives and p85……………..73 
      5.2.2 Interpretation and future analysis of potential post-translational modification  
 of C146………………………………………………………………………………….75 
      5.2.3 Effect of cancer-associated and engineered mutations on the bovine p85  
viii 
 
 BH domain……………………………………………………………………………...77 
      5.2.4 Observed potential novel binding pocket……………………………………………..79 
         5.2.4.1 Comparison of potential binding pocket region in bovine and human p85……….79 
         5.2.4.2 Effect of mutations on potential binding pocket…………………………………...80 
         5.2.4.3 Future experiments for characterization of potential binding pocket…………….82 
   5.3 Purification progress of PTEN (7-353, Δ286-309)………………………………………..82 
      5.3.1 Additional purification steps for PTEN (7-353, Δ286-309)…………………………..84 
   5.4 Complex formation progress between bovine p85 protein fragments and Rab5  
 as analyzed by SEC and Western blot analysis………………………………………….84 
      5.4.1 Future experiments for p85-BH:Rab5 co-crystal screening…………………………...85 
   5.5 Dimerization status of full-length human p85 wild-type and mutants using SEC 
  and MALS……………………………………………………………………………...86 
      5.5.1 Future experiments for examining the role of concentration and mutations  
 in determining the oligomeric state of p85………………………………………………87 
   5.6 Binding of lipid by p85 through PIP strip analysis………………………………………..88 
      5.6.1 Potential physiological significance for observed lipid binding………………………88 
      5.6.2 Comparison of p85-BH SO4 positions with inositol head groups…………………….89 
   5.7 Computer modelling of the p85-BH homodimer and PTEN complex…………………….90 
6.0 REFERENCES…………………………………………………………………………...101 
  
ix 
 
List of Tables……………………………………………………………………...Page Number 
Table 3.1 Sequencing Primers…………………………………………………………………..25 
Table 3.2 Primers for p85, Rab5, and PTEN fragment generation………………………………26 
Table 3.3 Primers for GST-p85 and GST-PTEN mutagenesis………………………………….26 
Table 3.4 Primary and secondary antibodies used………………………………………………27 
Table 3.5 Protein fragments, calculated MW, and extinction coefficients………………………34 
Table 4.1 Summary of crystallization results for bovine p85 fragments………………………..43 
Table 4.2 Data collection and refinement statistics for p85 (1-319), p85 (105-319)  
 and p85-BH……………………………………………………………………………..47 
Table 4.3 Data collection and refinement statistics for p85-BH cancer-associated mutants……50 
Table 4.4 Data collection and refinement statistics for p85-BH R228E……………….………..52 
Table 4.5 Data collection and refinement statistics for p85 (78-319) with 8 carbon PI4,5P2…….57 
Table 4.6 Elution volumes and corresponding MW for SEC analyzed p85.……………………65 
Table 4.7 Elution volumes and corresponding MW for MALS analyzed full-length p85………65 
Table 5.1 ClusPro output cluster statistics………………………………………………………91 
Table 5.2 Potential hydrogen bonding sites between PTEN and p85 based on docking results…95 
  
x 
 
List of Figures……………………………………………………………………..Page Number 
Figure 1.1 Diagram of a RTK…………………………………………………………………….2 
Figure 1.2 Model of the PI3K/PTEN pathway……………………………………………………3 
Figure 1.3 Domain diagram and homodimerizaton of p85……………………………………….9 
Figure 1.4 Domain diagram of PTEN…………………………………………………………...10 
Figure 1.5 Crystal structures of human p85 SH3 and BH domains……………………………...12 
Figure 1.6 Crystal structures of human p85 SH2 domains………………………………………13 
Figure 1.7 Crystal structure of human p85 110B domain in complex with human p110……….14 
Figure 1.8 Crystal structure of human p85 110B domain in complex with bovine p110  
 adaptor binding domain…………………………………………………………………15 
Figure 1.9 Crystal structure of human PTEN (7-353, Δ286-309) and the catalytic pocket……..17 
Figure 1.10 Altered PTEN binding of p85 mutants……………………………………………..18 
Figure 1.11 Crystal structures of human Rab5 alone and in complex with effector binding  
 partners………………………………………………………………………………….20 
Figure 1.12 Comparison of the human p85 BH domain with BH domains of other GAP  
 proteins………………………………………………………………………………….22 
Figure 1.13 Potential interface region between p85 BH domain and Rab5…………………….23 
Figure 4.1 Sequence alignment of human and bovine p85 N-terminal domains…………….…..42 
Figure 4.2 Crystals and crystal structures for bovine p85 (1-319) and p85-(105-319).…………44 
Figure 4.3 Crystal structure of p85-BH to 2.25 Å resolution highlighting the residues  
 that form the potential novel binding pocket……………………………………………46 
Figure 4.4 Overlay of crystal structures for p85-BH wild-type and cancer-associated 
  point mutants…………………………………………………………………………...48 
Figure 4.5 Potential binding pocket comparison between p85-BH and p85-BH-R228E……….51 
Figure 4.6 Structures of additives used in p85 crystallization solutions…………………………53 
Figure 4.7 Structures of 8 carbon PIP lipids added to p85 crystallization solutions……………54 
Figure 4.8 Examination of a modified cysteine at p85-BH residue 146…………………………56 
Figure 4.9 Comparison of p85-BH and p85 (78-319) crystal structures………………………...58 
Figure 4.10 SEC chromatograms for p85-BH:Rab5 complex formation experiments………….61 
Figure 4.11 Western blot analysis of p85-BH and Rab5 complex formation SEC  
 experiments...........................................................……………………………………...62 
xi 
 
Figure 4.12 Size exclusion chromatography chromatograms for full-length p85 and 
  mutants…………………………………………………………………………………63 
Figure 4.13 Native PAGE analysis of SEC fractions for full-length human p85 and  
 mutants………………………………………………………………………………….64 
Figure 4.14 Multi-angle light scattering chromatograms for full-length p85……………………66 
Figure 4.15 PIP strip analysis of p85 lipid binding……………………………………………...68 
Figure 4.16 Concentration dependence on p85 (78-319) PIP strip binding…………………….69 
Figure 5.1 Crystal packing of p85 (78-319)……………………………………………………..72 
Figure 5.2 Homodimerization region overlay of human and bovine p85 BH domains…………78 
Figure 5.3 Overlay of potential binding pocket for bovine and human p85…………………….80 
Figure 5.4 p85-BH potential binding pocket with overlaid inositol head group………………..90 
Figure 5.5 ClusPro docking results for p85 BH domain homodimer binding PTEN……………92 
Figure 5.6 Examination of ClusPro Cluster 4 of the p85 BH dimer PTEN complex……………94 
Figure 5.7 Docking analysis interface between p85 BH domain dimer and PTEN C2 domain…96 
Figure 5.8 Potential cavity leading to PTEN catalytic pocket…………………………………..97 
Figure 5.9 Examination of the PTEN phosphatase catalytic pocket, with spatial 
  comparison to p85 BH domain potential binding pocket………………………………98 
Figure 5.10 Interface between PTEN and p85 near the p85 potential binding pocket………….99  
xii 
 
List of Abbreviations 
110B   inter-SH2 domain region important for binding p110 
310 Helix  form of α-helical in which 3 residues are present per helix turn and 10 
   atoms are present between the hydrogen bond donor and acceptor 
AEBSF  4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride 
Bad   Bcl-2-associated death promoter 
Bcr   Breakpoint cluster region 
BH   Breakpoint cluster region homology 
BSA   bovine serum albumin 
CDK2   cyclin-dependant kinase 2 
CLS   Canadian Light Source 
CMCF-BM  Canadian Macromolecular Crystallography Facility 08B1-1 
CMCF-ID  Canadian Macromolecular Crystallography Facility 08ID-1 
CV   column volume 
DTT   dithiothreitol 
EDTA   Ethylenediaminetetraacetic acid 
EEA1   early endosomal antigen-1 
FoxO1   forkhead box protein O1 
GAP   GTPase activating protein 
GDI   guanine nucleotide dissociation inhibitor 
GEF   guanine nucleotide exchange factor 
GppCp   Guanosine-5`-[(ß,ɣ)-methyleno]triphosphate 
GSK3β  glycogen synthase kinase 3 beta 
GST   Glutathione S-transferase 
GTPase  guanosine triphosphate phosphatase 
IPTG   isopropyl ß-D-1-thiogalctopyranoside 
MALS   multi-angle light scattering 
MDM2  mouse double minute 2 homologue 
mTORC1  mammalian target of rapamycin complex 1 
MW   molecular weight 
p85   85 kDa regulatory subunit of phosphatidylinositol 3-kinase p85α 
xiii 
 
p85-BH-K224-5E p85-BH-K224E-K225E 
p110   110 kDa catalytic subunit of phosphatidylinositol 3-kinase p110α 
pAKT   phosphoAKT 
PASE   phosphatase 
PBS   phosphate buffered saline 
PCCF   Protein Characterization and Crystallization Facility 
PDB   Protein Data Bank 
PDK1   phosphoinositide-dependent kinase 1 
PDZ   post synaptic density protein, Drosophila disc large tumour suppressor, 
   zonula occludens-1 protein 
PEG   polyethylene glycol 
PIP   phosphatidylinositol phosphate 
PI3P   phosphatidylinositol 3-phosphate 
PI4P   phosphatidylinositol 4-phosphate 
PI3,4P2  phosphatidylinositol 3,4-bisphosphate 
PI4,5P2  phosphatidylinositol 4,5-bisphosphate 
PI3,4,5P3  phosphatidylinositol 3,4,5-trisphosphate 
PTEN   phosphatase and tensin homologue deleted on chromosome 10 
PTEN Crystal  PTEN (7-353, Δ286-309) 
pTyr   phosphorylated tyrosine 
SDS-PAGE  sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SEC   size exclusion chromatography 
SH2   Src homology 2 
SH3   Src homology 3 
SNAREs  soluble N-ethylmaleimide-sensitive attachment protein receptors 
TCEP-HCl  tns (2-carboxyethyl) phosphine hydrochloride
1 
 
1.0 Introduction  
 
1.1 Role of signaling pathways in eukaryotic cells 
 Intracellular and extracellular signaling pathways play critical roles in the monitoring and 
regulation of countless cellular processes and functions.  By monitoring nutrient levels within 
and outside the cell, detecting hormones and growth factors, and responding to antigens and signs 
of infection, these signaling pathways trigger many intracellular changes. These responses 
include alterations to cellular metabolism, import and export of molecules, alterations in gene 
expression and protein production/degradation, regulating cellular replication, initiating 
apoptosis, or transmitting information to cells distant from the site of the initial stimulation or 
signal.  Multi-cellular organisms depend upon the well-coordinated transmission of information 
between different cells. 
 Disruption of cellular signalling pathways can be detected in a wide variety of human 
malignancies and diseases, including metabolic syndromes and cancers.  Individuals with type 2 
diabetes mellitus show decreased sensitivity to insulin signaling for various cells, including 
adipocytes and skeletal muscle, resulting in the abnormal glucose metabolism observed in the 
disease (Hojlund, 2014; Kashiwagi et al., 1983).  The phosphatidylinositol 3-kinase 
(PI3K)/PTEN (phosphatase and tensin homologue deleted on chromosome 10) is activated upon 
stimulation of various receptor tyrosine kinase (RTK) proteins (Liu et al., 2009; Vogt et al., 2010; 
Yuan and Cantley, 2008; Zhao and Vogt, 2008).  Disruption to normal function of the 
PI3K/PTEN pathway has been shown in cancers of the breast, endometrium, prostate, and 
urothelial tract (Carnero, 2010; Carracedo and Pandolfi, 2008; Chalhoub and Baker, 2009; 
Cheung et al., 2011; Liu et al., 2014; Miled et al., 2007; Ross et al., 2013; Vasudevan and 
Garraway, 2010; Vivanco and Sawyers, 2002).  
 
1.2 Receptor tyrosine kinase signaling 
 RTK signaling is governed by transmembrane receptor proteins that bind to specific 
growth factors and hormones.  Example RTKs include epidermal growth factor receptor, insulin 
receptor, and platelet derived growth factor receptor.  At least 58 unique RTKs have been 
identified and they are divided into 20 subfamilies (Gschwind et al., 2004).  Across the various 
subfamilies of RTKs there are conserved structural features shared between the different proteins.  
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RTKs contain an external ligand binding domain, a transmembrane domain, and an internal 
tyrosine-kinase domain.  A schematic diagram for a general RTK is provided in Figure 1.1. 
 
 
Figure 1.1 Diagram of a RTK.  Domain illustration of a general RTK.  A RTK has an external 
ligand binding domain, a transmembrane domain, and an internal tyrosine-kinase domain.  
Without ligand bound RTKs exist as monomers in the plasma membrane.  Ligand binding 
stimulates dimerization of the RTKs, resulting in auto-phosphorylation of Tyr residues on the 
receptors.  The phosphorylated Tyr residues provide binding sites for proteins containing SH2 
domains, resulting in protein relocalization and the activation of various downstream 
pathways. 
 
 When unstimulated, RTKs are present as monomers.  Upon binding of their ligand RTKs 
dimerize, forming homodimers or heterodimers depending on the specific RTKs, through binding 
to the same ligand complex and/or intermolecular interactions stimulated upon ligand binding 
(Gschwind et al., 2004).  Upon dimerization the tyrosine-kinase domains auto-phosphorylate 
tyrosine residues present on the other receptor, providing binding sites for proteins that contain 
SH2 domains.  Binding of these proteins then results in changes to the activation of numerous 
downstream cellular pathways, including pathways important for cell survival and proliferation 
(Alessi et al., 1997; Stephens et al., 1998). 
 Due to their role in the regulation of numerous cellular pathways, disruption of RTK 
signaling regulation is commonly observed in cancers.  RTK overexpression and mutations 
3 
 
leading to constitutively active RTKs are observed in leukemia and breast, colorectal, and ovarian 
cancers (Gschwind et al., 2004).  There are also numerous cancers that have dysregulation in the 
various pathways governed by RTK activation, such as the PI3K/PTEN signaling pathway. 
 
1.2.1 Phosphatidylinositol 3-kinase/PTEN signaling pathway 
 A proposed model for the PI3K/PTEN signaling pathway is provided in Figure 1.2. 
 
 
Figure 1.2: Model of the PI3K/PTEN pathway.  Activation of the PI3K/PTEN pathway 
begins with RTK binding their ligand, followed by receptor dimerization and auto-
phosphorylation of tyrosine residues.  The p85 protein of the PI3K complex binds these pTyr 
residues, relieves its repressor function on the p110 catalytic subunit of the PI3K complex, and 
p110 phosphorylates PI4,5P2 to PI3,4,5P3 which serves as a lipid signaling molecule to 
promote downstream activation of pathways involved in protein translation, cell growth, cell 
cycle entry and progression, and cell survival.  PI3,4,5P3 is converted back to PI4,5P2 by the 
PTEN lipid phosphatase, preventing sustained downstream activation of the various pathways.  
The binding of p85 to PTEN has been shown to stimulate PTEN phosphatase activity.  
Activated RTKs can also be trafficked to early endosomes through Rab-mediated pathways, 
where they are either recycled back to the cell membrane or else trafficked for degradation in 
lysosomes.  It has been shown that p85 binds to Rab5, a key protein in early endosome 
trafficking, and stimulates the intrinsic GTPase (guanosine triphosphate phosphatasePAS) 
activity that converts Rab5 from an active GTP bound form to an inactive GDP bound form. 
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 The PI3K protein complex is composed of a 110 kDa catalytic subunit (p110) and an 85 
kDa regulatory subunit (p85). 
 RTKs including platelet derived growth factor receptor, epidermal growth factor 
receptor, and insulin receptor, stimulate class 1A PI3Ks which consist of a p85α and p110α 
subunit (Liu et al., 2009; Vogt et al., 2010; Yuan and Cantley, 2008; Zhao and Vogt, 2008).  
Binding of their ligands results in receptor auto-phosphorylation of tyrosine residues present on 
the receptor, which serve as binding sites to allow for the relocalization of the PI3K protein 
complex to the plasma membrane (Liu et al., 2009; Vogt et al., 2010; Yuan and Cantley, 2008; 
Zhao and Vogt, 2008).  Binding of the p85 protein to the phosphorylated tyrosine (pTyr) 
residues of the receptor relieves the repression on the associated p110 protein, allowing p110 to 
phosphorylate the lipid phosphatidylinositol 4,5-bisphosphate (PI4,5P2) to generate 
phosphatidylinositol 3,4,5-trisphosphate (PI3,4,5P3) (Miled et al., 2007; Yu et al., 1998).  
PI3,4,5P3 acts as a lipid messenger that binds signaling proteins such as 3-phosphoinositide 
dependent protein kinase-1 (PDK1) and Akt (also known as protein kinase B), helping them 
relocate to the plasma membrane (Cantley, 2002; Toker and Cantley, 1997).  Once relocated 
Akt is activated by phosphorylation by PDK1 (Alessi et al., 1997).  Phosphorylated Akt then 
proceeds to phosphorylate various binding partners, leading to downstream activation of 
various pathways important for cell growth, cell cycle entry and progression, protein 
translation, and cell survival (Alessi et al., 1997; Stephens et al., 1998).  Targets of Akt include: 
the apoptosis promoting protein Bad (Bcl-2 associated death promoter) preventing Bad from 
associating with binding partners, the cell cycle regulatory protein CDK2 (cyclin-dependent 
kinase 2) which plays a role in the G1 to S phase transition in cells, the transcription factor 
FoxO1 (forkhead box protein O1) which results in localization of FoxO1 to the cytoplasm 
instead of the nucleus, the regulatory protein GSK3β (glycogen synthase kinase 3 beta) leading 
to altered cell metabolism and increased survival, the ubiquitin E3 ligase Mdm2 (mouse double 
minute 2 homologue) which increases degradation of the apoptosis inducing protein p53, and 
the mTORC1 (mammalian target of rapamycin complex 1) which increases the mTORC1 
kinase activity (Brunet et al., 1999; del Peso et al., 1997; Desbois-Mouthon et al., 2002; 
Ogawara et al., 2002; Rani et al., 1997; Scott et al., 1998). 
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 Activity of the PI3K/PTEN pathway is counteracted by the lipid phosphatase PTEN 
which dephosphorylates PI3,4,5P3 back to PI4,5P2, preventing sustained downstream activation 
of the Akt pathway (Myers et al., 1997; Vazquez et al., 2001; Vazquez et al., 2006). 
 
1.2.2 The PI3K/PTEN pathway in cancer 
 The PI3K/PTEN pathway is dysregulated in a large number of cancers, including those 
that occur in the breast, endometrium, prostate, and urothelial tract (Cantley, 2002; Carnero, 
2010; Carracedo and Pandolfi, 2008; Chalhoub and Baker, 2009; Cheung et al., 2011; Liu et al., 
2009; Ross et al., 2013; Vivanco and Sawyers, 2002; Yuan and Cantley, 2008).  These activating 
mutations can occur in various components of the PI3K/PTEN pathway.  Oncogenic mutations 
occur in RTKs leading to constitutive activation, mutations in PI3K catalytic subunit p110α 
(hereafter referred to as p110) or regulatory subunit p85α (hereafter referred to as p85) that leads 
to PI3K continuous activation, and mutations leading to a lack of expression or loss of function 
of PTEN (Carnero, 2010; Carracedo and Pandolfi, 2008; Chalhoub and Baker, 2009; Cheung et 
al., 2011; Liu et al., 2014; Miled et al., 2007; Ross et al., 2013; Vasudevan and Garraway, 2010; 
Vivanco and Sawyers, 2002; Vogt et al., 2010; Yuan and Cantley, 2008).  Various treatments 
and drugs have been developed to treat dysregulation of the PI3K/PTEN pathway, many targeting 
PI3K and other kinases that are often constitutively activated in cancer cells (Garcia-Echeverria 
and Sellers, 2008; Liu et al., 2009; Wong et al., 2010). 
 
1.2.3 Endocytosis of receptor tyrosine kinases 
 Reviews of RTK endocytosis by Goh and Sorkin, and of the role of endocytosis in cancers 
by Mellman and Yarden provide overviews of current understanding towards endocytosis in 
healthy and disease states (Goh and Sorkin, 2013; Mellman and Yarden, 2013). 
 Briefly, levels of RTKs found at the cell surface are regulated through the balance 
between protein expression and receptor transport through endocytosis leading to degradation in 
lysosomes.  In the absence of growth factor stimulation this turnover rate is slower, allowing 
increased presence of RTKs at the cell surface.  Following growth factor stimulation of RTKs 
the auto-phosphorylation of the receptors provide binding sites for proteins that lead to 
downstream activation of clathrin-mediated and clathrin-independent endocytosis, transporting 
the activated RTK to an early endosome (Beattie et al., 2000; Gorden et al., 1978; Haigler et al., 
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1979; Huang et al., 2004; Orth et al., 2006).  From the early endosome the RTK is sorted to either 
be recycled back to the plasma membrane to be stimulated and signal again, or transported to a 
lysosome for degradation.  This sorting is regulated by various factors, including post-
translational modification of the endocytosed RTK such as phosphorylation or ubiquitination, 
and various protein partners including members of the Rab family GTPases. 
 Motifs present within the transmembrane domains of the RTKs serve as binding regions 
for clathrin adaptor protein complexes, leading to the internalization of the RTKs through 
clathrin-mediated endocytosis (Goh and Sorkin, 2013).  Ubiquitination of activated RTKs and 
interaction with ubiquitin ligase proteins such as Cbl, which binds to phosphorylated RTK 
directly or indirectly through the adaptor protein Grb2, promotes the internalization of the 
activated receptors (Huang et al., 2006; Li et al., 2007).  Sorting of internalized epidermal growth 
factor receptor for degradation was decreased by mutations at sites of ubiquitin-conjugation and 
Cbl binding (Huang et al., 2006).  Recycling of RTKs to the plasma membrane can occur for 
receptor-ligand complexes upon saturation of the degradation pathway resulting in sustained 
signaling (French et al., 1994; Sorkin et al., 1991).  Recycling of RTKs can also occur when 
ligand dissociates from the receptor following endocytosis, allowing the inactive RTK to be 
returned to the plasma membrane (Masui et al., 1993). 
 
1.2.4 Rab mediated vesicle trafficking 
 The Rab family of proteins are small GTPases and contains more than 70 members in 
humans (Tzeng and Wang, 2016).  These proteins, through interactions with a variety of binding 
partners, play key roles in cell growth, cytoskeleton organization, and numerous stages of cellular 
vesicle trafficking including both exocytosis of molecules from the trans-Golgi network and 
endocytosis of molecules from the plasma membrane.  The activity of Rab proteins is regulated 
based on the state of bound nucleotide present, with the proteins active while bound to GTP, and 
inactive while bound to GDP.  Interaction with guanine nucleotide exchange factors (GEF) 
promotes the exchange of GDP bound to Rab proteins with GTP, converting them to their active 
forms that interact with downstream effector proteins.  GTPase activating proteins (GAP) 
promote the intrinsic GTPase activity of the Rab proteins, to stimulate the hydrolysis of bound 
GTP to GDP and switching them to an inactive conformation. 
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 Rab proteins are a unique group of GTPases in that although they are lipid modified to 
facilitate membrane association, their lipid moiety can be masked through interactions with a 
guanine nucleotide dissociation inhibitor (GDI) protein, allowing them to come off membranes 
(Cherfils and Zeghouf, 2013; Soldati et al., 1993). GDI displacement factors are thought to help 
recruit Rab GTPases to specific membrane locations (Cherfils and Zeghouf, 2013; Ingmundson 
et al., 2007).  
 
1.2.4.1 Rab5 
 Rab5 is a small GTPase protein of ~24 kDa.  While in a GDP bound inactive form the 
Rab5 protein is localized within the cytosol of cells.  Like other Rab proteins, interaction with 
GEFs promotes the exchange of GDP with GTP so that Rab5 assumes its active conformation.  
Active Rab5 localizes to the plasma membrane and the membrane surface of early endosomes 
(Ali et al., 2004).  While present at these membranes GTP-bound Rab5 provides a binding site 
for effector proteins involved in endocytosis and membrane fusion, such as early endosomal 
antigen-1 (EEA1).  EEA1 is able to bind GTP-bound Rab5 and phosphatidylinositol 3-phosphate 
(PI3P) lipid present on early endosome membranes through different domains, and serves as a 
tether between two early endosomes.  With the two early endosomes held in close proximity it 
allows for the membrane bound proteins soluble N-ethylmaleimide-sensitive attachment protein 
receptors (SNAREs) to interact between membranes to draw the two early endosomes together 
and mediate membrane fusion (Woodman, 2000). 
 
1.2.4.2 GAP proteins 
 GAP proteins stimulate the intrinsic GTPase activity of their small GTPase protein 
binding partners through the contribution of a catalytic Arg residue at the site of catalysis, which 
serves as an Arg finger to catalyze the conversion of the proteins to their inactive GDP bound 
state (Bos et al., 2007; Cherfils and Zeghouf, 2013; Peck et al., 2002).  Different GAP proteins 
act on specific small GTPases, and are grouped based on their different binding motifs (Bos et 
al., 2007; Cherfils and Zeghouf; Peck et al., 2002). 
 The Breakpoint cluster region (Bcr) protein has a molecular weight (MW) of ~140 kDa, 
displays GAP activity for the proteins RAC1 and CDC42, and also possesses serine/threonine 
kinase activity (Diekmann et al., 1991; Maru and Witte, 1991).  The Bcr GAP activity was 
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identified in a C-terminal domain of the protein observed in a number of other proteins that 
possess GAP activity, providing domains with this structure the name Bcr homology (BH) 
domains (Bos et al., 2007; Peck et al., 2002).  Other proteins that possess BH domains and GAP 
activity include CDC42GAP, N-chimaerin, GRAF-2, Myosin 9b, and the regulatory subunit of 
PI3K, p85 (Bos et al., 2007; Peck et al., 2002). 
 
1.3 Phosphatidylinositol 3-kinase 
 The p110 catalytic subunit of PI3K phosphorylates PI4,5P2 to generate PI3,4,5P3 in the 
PI3K/PTEN pathway (Carpenter et al., 1990).  It is composed of five domains: an N-terminal 
adaptor binding domain, a Ras binding domain, a C2 domain, a helical domain, and a kinase 
domain.  The p110 protein is mutated in a wide range of cancers, with most mutations found 
within the helical and kinase domains of the protein and result in increased catalytic activity or 
loss of regulatory functionality of bound protein partners such as p85 (Liu et al., 2014; Miled et 
al., 2007; Vogt et al., 2010). 
 The p85 regulatory subunit of PI3K binds directly to p110 and inhibits the phosphatase 
activity of p110; this inhibition is relieved upon activation of cellular RTKs (Carpenter et al., 
1990; Yu et al., 1998).  Other binding partners of p85 include PTEN and Rab5 (Chagpar et al., 
2010; Chamberlain et al., 2004).  The p85 protein is composed of five domains, a Src homology 
3 (SH3), BH, N-terminal Src homology 2 (nSH2), an inter-SH2 domain region important for 
binding to p110 (110B), and a C-terminal Src homology 2 (cSH2) domain (Backer, 2010).  Both 
the SH3 and BH domains of p85 are involved in the interaction between p85 and PTEN (Chagpar 
et al., 2010).  The nSH2 and cSH2 domains are responsible for p85 binding to the pTyr residues 
of activated RTKs (Backer, 2010).  It has also been shown that the nSH2 and 110B domains 
interact with p110 to form the PI3K protein complex (Backer, 2010; Huang et al., 2007). 
 A domain diagram of p85 is shown in Figure 1.3 A. 
 When not bound to other proteins the p85 protein has been shown to homodimerize 
through two mechanisms as illustrated in Figure 1.3 B (Harpur et al., 1999).  The first mechanism 
is through the interaction of the SH3 domain of one p85 protein binding the PXXP motif present 
in the inter-domain region between the SH3 and BH domains on a second p85 protein, which has 
a dissociation constant in the µM range (Harpur et al., 1999).  The second mechanism is through  
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Figure 1.3 Domain diagram and homodimerization of p85.  A.  Domain diagram of p85 
displaying amino acid ranges and regions important for binding protein partners.  B.  Diagram 
of the two different mechanisms behind p85 homodimerization.  One involves the binding of 
one p85 SH3 domain with the PXXP motif present in the inter-domain linker of the other p85.  
The other mechanism is through direct interaction between the BH domain of each protein. 
 
interaction of two BH domains on separate p85 proteins forming a relatively weak interaction 
with a dissociation constant in the mM range (Harpur et al., 1999). 
 Regulation of the PI3K protein complex is achieved through protein interaction between 
the p85 regulatory and p110 catalytic protein subunits.  Binding of p85 to p110 represses the 
catalytic activity of p110 until binding to the pTyr residues of activated RTKs relieves this 
repression (Miled et al., 2007; Yu et al., 1998).  In the absence of binding p85, the p110 protein 
has been shown to be unstable, leading to rapid degradation within cells (Yu et al., 1998).  
Binding of p85 to p110 stabilizes the p110 protein, resulting in a decreased rate of degradation 
and more prolonged presence within the cell (Yu et al., 1998). 
 
1.4 Phosphatase PTEN 
 PTEN is an ~55 kDa protein with dual lipid/protein phosphatase activity, with substrates 
including the focal adhesion kinase and PI3,4,5P3 (Myers et al., 1997; Tamura et al., 1998).  
PTEN is comprised of 5 domains: a plasma membrane binding domain that binds PI4,5P2, a dual 
lipid/protein phosphatase domain, a C2 domain, a Ser/Thr rich regulatory domain, and a PDZ 
10 
 
(post synaptic density protein, Drosophila disc large tumour suppressor, zonula occludens-1 
protein) binding domain.  A domain diagram of PTEN is shown in Figure 1.4. 
 
 
Figure 1.4 Domain diagram of PTEN.  PTEN is composed of five domains: an N-terminal 
plasma membrane binding domain that binds PI4,5P2, a catalytic phosphatase domain, a C2 
domain, a regulatory domain rich in Ser/Thr residues which can be phosphorylated, and a C-
terminal PDZ binding motif.  The catalytic C124 residue in the phosphatase domain and 
Ser/Thr residues that are phosphorylated in the regulatory domain are indicated. 
 
 In the absence of growth factor stimulation, PTEN is constitutively phosphorylated on 
residues S370, S380, T382, T383, and S385 within the PTEN regulatory domain by casein kinase 
2, GSK3ß, PICT-1, and ROCK kinases (Tamguney and Stokoe, 2007).  These phosphorylated 
residues interact with basic residues found in the phosphatase (R161, K163, K164) and C2 (K260, 
K263, K266, K267, K269) domains to form a closed conformation (Rahdar et al., 2009).  The 
closed conformation of PTEN keeps it localized in the cytosol and increases the stability of the 
protein (Vazquez et al., 2001).  Stimulation from upstream activating signals triggers the 
dephosphorylation of PTEN which assumes an open conformation for interacting with lipids at 
the plasma membrane (Das et al., 2003; Lee et al., 1999; Rahdar et al., 2009; Vazquez et al., 
2001; Vazquez et al., 2006).  Relocalization of PTEN to the plasma membrane is mediated by 
the PTEN plasma membrane binding domain (binding to PI4,5P2 lipids) and electrostatic 
interactions between negatively charged membrane lipids and basic residues in the phosphatase 
(PASE) domain (R161, K163, and K164) (Das et al., 2003; Rahdar et al., 2009).  The PTEN PDZ 
binding motif can also interact with a variety of scaffold proteins that contain PDZ domains. 
These scaffold proteins also bind to activated RTKs, further localizing PTEN to sites of PI3,4,5P3 
11 
 
lipid generation (Bonifant et al., 2007; Takahashi et al., 2006; Tolkacheva et al., 2001; Wu et al., 
2000a; Wu et al., 2000b). 
 Following its relocalization, the PTEN protein dephosphorylates the 3-position of 
PI3,4,5P3 to PI4,5P2, and turning off the PI3K/PTEN pathway by preventing downstream 
activation of Akt (Myers et al., 1997; Vazquez et al., 2001; Vazquez et al., 2006).  PTEN has 
also been shown to dephosphorylate proteins such as focal adhesion kinase, inactivating the 
protein and preventing promotion of cellular mobility (Tamura et al., 1998). 
 
1.5 Structural studies of p85 and binding partners 
 All five domains of the human p85 protein have had their crystal structures solved 
individually, and the nSH2 domain and 110B domain were cocrystallized together with the p110 
catalytic subunit of PI3K although the nSH2 was not visible within the crystal structure 
(Hoedemaeker et al., 1999; Huang et al., 2007; Liang et al., 1996; Musacchio et al., 1996; Nolte 
et al., 1996). 
 The human p85 SH3 domain (Figure 1.5 A-B) is composed of five beta strands, one alpha 
helix, and two 310 helices (form of α-helix with three residues per helix turn and 10 atoms between 
the hydrogen bond donor and acceptor) connected by flexible loop regions (Liang et al., 1996).  
SH3 domains serve as sites of protein-protein interactions through their binding to proline rich 
motifs (e.g. PXXP where X is any amino acid) and are found in a variety of proteins including 
tyrosine kinases such as Src, adaptor proteins such as Grb2, regulatory proteins such as GAPs 
and p85, and structural proteins such as α-spectrin (Pawson and Gish, 1992).  The SH3 domain 
has also had its crystal structure solved bound to a proline-rich peptide, revealing minimal 
conformational changes upon ligand binding (Figure 1.5B) (Batra-Safferling et al., 2010). 
  The human p85 BH domain (Figure 1.5 C-D) is composed of eight alpha helices 
and one 310 helix which are connected by flexible loop regions (Musacchio et al., 1996).  In the 
p85 BH domain crystal structure a homodimer of BH domains was observed, with the M176 of 
one monomer interacting with a hydrophobic pocket formed by the L161, I177, and V181 of the 
other monomer (Musacchio et al., 1996).  In the bovine sequence of p85, residue 177 is a 
phenylalanine in place of the isoleucine, preserving the hydrophobic nature of this residue. 
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Figure 1.5 Crystal structures of human p85 SH3 and BH domains.  Crystal structures of 
the: p85 SH3 domain (A, PDB ID# 1PHT; Liang et al., 1996), p85 SH3 with bound Pro-rich 
peptide (B, PDB ID# 3I5R; Batra-Safferling et al., 2010), p85 BH domain monomer and 
homodimer (C and D, PDB ID# 1PBW; Musacchio et al., 1996 ).  Residues important for 
ligand binding in SH3 domains, and homodimerization in BH domains, are indicated and 
shown in stick format.  Pro-rich peptide is shown in stick format in violet. 
The human p85 nSH2 domain (Figure 1.6) is composed of 4 beta strands, 4 alpha helices, 
and one 310 helix connected by flexible loop regions (Nolte et al., 1996).  The human p85 cSH2 
domain (Figure 1.6) is composed of six beta strands, two alpha helices, and two 310 helices 
connected by flexible loop regions (Hoedemaeker et al., 1999).  Both SH2 domains were shown 
to be able to bind proteins containing pTyr residues, with the nSH2 structure determined both 
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Figure 1.6 Crystal structures of human p85 SH2 domains.  Crystal structures of the: p85 
nSH2 domain without peptide (A, PDB ID# 2IUG; Nolte et al., 1996) and with a pTyr peptide 
bound (B, PDB ID# 2IUI; Nolte et al., 1996), and the p85 cSH2 domain (C, PDB ID# 1QAD; 
Hoedemaeker et al., 1999).  Residues important for ligand binding are indicated and shown in 
stick format.  The pTyr peptide is shown in stick format in magenta. 
with and without bound phosphopeptide (Hoedemaeker et al., 1999; Nolte et al., 1996).  The 
cSH2 domain was crystallized in the absence of ligand and had a very similar structure to the 
nSH2 domain (Hoedemaeker et al., 1999). 
1.5.1 Structural studies of p110 
The human p110 protein has been crystallized in complex with a human p85 fragment 
containing the nSH2 and 110B regions, although the nSH2 domain was not visible within the 
structure, to examine the regions and residues important for complex formation between the two 
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proteins (Huang et al., 2007).  The crystal structure is shown in Figure 1.7.  Examination of 
cancer-associated mutations within p110 was used to determine if these mutations likely affected 
binding between the two proteins, such as p110 residues N345 and Q453 being located at the 
interface between p110 and the coiled-coiled p85 110B region (Huang et al., 2007).  Using this 
structural data they also examined suspected regions important for p110 binding to the plasma 
membrane, and which residues of p85 are nearest to the p110 catalytic site (Huang et al., 2007). 
Figure 1.7 Crystal structure of human p85 110B domain in complex with human p110.  
Crystal structure of the p85 110B domain (red) in complex with p110 (purple) (PDB ID# 
2RD0; Huang et al., 2007) including a close up view of the interface region.  Cancer associated 
mutants in p110 are shown in yellow, p85 interface residues are in green, p110 residues are 
labelled in black, p85 residues are labelled in blue, and bond distances are in Angstroms. 
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Miled et al. used a combination of crystallographic and biochemical analysis to examine 
mutations in p110 and p85 to understand the mechanisms behind oncogenic mutations and 
identify important contact residues (Miled et al., 2007).  They crystallized the adaptor binding 
domain of bovine p110 with the 110B domain of human p85 to examine the residues important 
for the interaction between the two regions, and the location of oncogenic p110 mutants (Miled 
et al., 2007).  This crystal structure is shown in Figure 1.8. 
Figure 1.8 Crystal structure of human p85 110B in complex with bovine p110 adaptor 
binding domain.  Crystal structure of the p85 110B domain (red) in complex with the p110 
adaptor binding domain (purple) (PDB ID# 2V1Y; Miled et al., 2007).  The polar residue patch 
identified in the p110 adaptor binding domain is indicated, with cancer-associated mutations 
shown in yellow. 
Two residues of oncogenic p110 mutations, R38 and R88, were present within a highly 
conserved patch of mostly polar residues on the p110 adaptor binding domain surface apart from 
the interaction region with p85 110B domain, where the oncogenic mutations could interfere with 
proper association between this surface region and other domains of the p110 protein (Miled et 
al., 2007).  Lipid kinase assays of full-length p110 with a p85 fragment containing the nSH2 and 
110B domains was used to identify important residues in the p85 nSH2 domain through testing 
charge reversal mutants (Miled et al., 2007).  These experiments demonstrated that p85 mutants 
R340E and K379E no longer performed their inhibitory role upon binding to p110, suggesting 
they form critical inhibitory contacts with p110 (Miled et al., 2007).  They also demonstrated that 
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the p85 nSH2 and 110B fragment containing K379E mutant was able to restore its inhibitory 
function upon binding to p110 E545K oncogenic mutant, where wild-type nSH2 and 110B p85 
showed no inhibitory function, with this charge reversal restoring the critical inhibitory contact 
site (Miled et al., 2007). 
1.5.2 Structural studies of PTEN 
A crystal structure of human PTEN (7-353, Δ286-309) containing the phosphatase and 
C2 domains has been previously determined with a tartrate molecule bound within the 
phosphatase catalytic pocket (Lee et al., 1999).  Tartrate was included due to its similar structure 
to a portion of the phosphatidylinositol lipid head group.  The crystal structure of PTEN (7-353, 
Δ286-309) including a closer examination of the phosphatase pocket is shown in Figure 1.9. 
The catalytic pocket within the PTEN phosphatase domain is composed of residues D92, 
H93, K125, A126, G127, K128, T167, I168, and Q171, with a catalytic C124 residue (Lee et al., 
1999).  Bound within the catalytic pocket was a tartrate molecule which helped to determine the 
residues responsible for forming the pocket and coordinating potential substrate molecules (Lee 
et al., 1999).  Cancer associated mutants that alter PTEN catalytic activity, including C124S 
which completely disables PTEN phosphatase activity and G129E which disables PTEN lipid 
phosphatase activity but maintains activity for phosphorylated peptides, are commonly located 
in the PTEN catalytic pocket or the surrounding region (Liaw et al., 1997; Myers et al., 1997).  
Mutation to the basic residues in the phosphatase domain (R161, K163, K164, Figure 1.9) can 
reduce the ability of PTEN to localize to the plasma membrane (Das et al., 2003). 
Dimerization of PTEN has been shown to play a role in its lipid phosphatase 
activity, with mutations that inhibit this activity functioning in a dominant negative fashion (Papa 
et al., 2014).  It has also been shown that the p85 interacts directly with PTEN and that this 
interaction improves the stability and stimulates the catalytic activity of the PTEN protein 
(Chagpar et al., 2010; Cheung et al., 2015; Rabinovsky et al., 2009).  The recent study by Cheung 
et al. further identified that the PTEN protein binds specifically to p85 homodimers, and that 
disruption of p85 homodimerization prevents binding to PTEN (Cheung et al., 2015).  Using 
deletion mutants of various domains of the two proteins it was shown that the SH3 and BH 
domains of p85, and the phosphatase domain for PTEN, were important for the interaction 
between the two proteins (Chagpar et al., 2010; Cheung et al., 2015). 
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Figure 1.9 Crystal structure of human PTEN (7-353, Δ286-309) and the catalytic pocket.  
Crystal structure or PTEN (7-353, Δ286-309) solved by Lee et al. PDB ID# 1D5R (Lee et al., 
1999).  The phosphatase domain is shown in yellow and the C2 domain is shown in orange. 
Residues important for lipid binding and that form the catalytic pocket are shown in stick 
format, with catalytic pocket forming residues shown in brown and the catalytic C124 residue 
in magenta.  The tartrate molecule bound in the catalytic pocket is shown in violet. 
Determining the amino acids important for p85 and PTEN binding would allow for a 
better understanding of the interaction interface between the two proteins.  To this end Xuan 
Ruan, Dielle Whitecross, and Dr. Paul Mellor of the Anderson lab generated a series of tagged 
p85 mutants that were either FLAG-tagged and transfected into COS-1 cells and pull-down 
experiments performed using cell lysates, or the mutant proteins were GST-tagged, expressed in 
BL21 bacteria, purified, the GST-tag cleaved, and then used for pull-down experiments.  All pull-
down experiments were performed using Glutathione S-transferase (GST)-tagged PTEN, or GST 
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alone as a control.  The results of these experiments are shown in Figure 1.10 (Ruan et al., 
Unpublished Data). 
Figure 1.10 Altered PTEN binding of p85 mutants.  Pull-down experiments of p85 proteins 
containing various mutants bound by GST-tagged PTEN, or GST alone as a negative control. 
Protein was detected through western blot analysis using an anti-FLAG or anti-p85 primary 
antibody and an infrared-linked secondary antibody (Ruan et al., Unpublished Data).  A.  
FLAG-tagged p85 wild-type or mutant proteins were expressed in COS-1 cells, the cells lysed 
and the lysate used for pull-down analysis.  Mutants in dark blue showed consistent decreases 
in binding, while those in light blue showed larger variation between experiments.   B.  GST-
tagged p85 wild-type or mutant proteins were expressed in BL21 bacteria cells, purified, 
cleaved from GST and the purified protein used for pull-down analysis. 
Results of initial pull-down experiments using COS-1 cell lysates showed several p85 
mutants that had decreased PTEN binding: E212R, K224E+K225E, R228E, and K249E.  As 
COS-1 cells still possess some endogenous p85 there were concerns that dimerization between 
mutant p85 and wild-type endogenous p85 could affect the results of the experiments, such as 
masking the effects that some mutations might have upon PTEN binding through the formation 
of a p85 mutant and p85 wild-type heterodimer.  To this end further pull-down experiments were 
performed using GST-tagged p85 wild-type and mutant proteins purified from Escherichia coli 
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(E. coli) strain BL21 bacterial cells and cleaved from GST.  Using purified p85 protein resulted 
in a smaller number of mutants showing a decrease in PTEN binding: D168R, E212R, H234D, 
and Q241D, with three in common between the two experimental approaches. 
In addition to their mutagenesis studies Cheung et al. also pursued structural modeling of 
the p85 SH3 and BH domains, followed by modeling this arrangement of the p85 BH domain 
with PTEN (Cheung et al., 2015).  Since small angle X-ray scattering data for the p85 SH3 and 
BH domain together was not available, they generated simulated small angle X-ray scattering 
results and performed several modeling iterations to obtain this model. Further experimental 
analysis will be required to validate the accuracy of the suggested orientation.  Determination of 
the crystal structure of the p85 BH domain in complex with PTEN would provide direct 
experimental identification of residues important for the interaction between these two proteins. 
The structure of the complex would also help identify p85 residues that stimulate PTEN catalytic 
activity, similar to the insights provided by Huang et al. structure of p85 110B region in complex 
with p110 (Huang et al., 2007). 
1.5.3 Structural studies of Rab5 
The crystal structure of the human Rab5 GTPase domain (amino acids 15-184) has been 
solved for the protein alone, as well as in complex with fragments of effector binding partners 
EEA1 and Rabaptin5 (Mishra et al., 2010; Terzyan et al., 2004; Zhu et al., 2003; Zhu et al., 
2004).  The solved crystal structures are shown in Figure 1.11. 
The Rab5 GTPase domain is composed of five alpha helices and two beta sheets that each 
contain three beta strands, with the catalytic pocket of the protein composed of various flexible 
loops including 2 switch loops that change orientation based on binding GDP or GTP (Zhu et al., 
2003).  A magnesium ion is present within the catalytic pocket of Rab5, and conformational 
changes are observed in the switch loops that help form the catalytic pocket depending on if GTP 
or GDP is bound by the protein (Zhu et al., 2003).  Mutation of A30 present in one of the loops 
that form the catalytic pocket to an arginine residue resulted in an increased rate of conversion of 
GTP to GDP, but this increase in catalysis was inferior to that observed from the arginine finger 
provided by bound GAP proteins (Zhu et al., 2003). 
Structural data obtained for Rab5 in complex with its effector Rabaptin5 C-terminal 
domain identified residues important for protein-protein interactions, which allowed mutagenesis 
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studies and pull-down experiments to validate these observations (Zhu et al., 2004).  Based on 
these observations they generated a Y82A mutant of Rab5, transfected cells with this mutant, and 
showed that it impaired Rab5 endosomal fusion activity (Zhu et al., 2004).  Comparison of the 
structure of Rab5-GTP bound to Rabaptin5 with the structure of Rab5-GDP also allowed for the 
observation of conformational changes that occur in the different nucleotide-bound states of 
Rab5, providing potential reasons for the specificity of Rabaptin5 only binding to GTP-bound 
Rab5 and not the GDP-bound protein (Zhu et al., 2004). 
Figure 1.11 Crystal structures of human Rab5 alone and in complex with effector binding 
partners.  Crystal structures of: Rab5 (15-184) with bound GTP analogue (A, PDB ID# 1N6H; 
Zhu et al., 2003), Rab5 (15-184) in complex with the C2H2 zinc finger of human EEA1 (B, 
PDB ID# 3MJH; Mishra et al., 2010), and two Rab5 (15-184) molecules in complex with a 
dimer of the C-terminal domain of human Rabaptin 5 (C, PDB ID# 1TU3; Zhu et al., 2004).  
Magnesium ions are shown as green spheres, zinc ions are shown as gold spheres, and bound 
GTP analogues are shown in violet. 
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The crystal structure determined for Rab5 in complex with the EEA1 C2H2 zinc finger 
domain allowed for the closer examination of Rab5 binding to an effector proteins that plays an 
important role in endosome fusion.  This allowed for further characterization of residues 
important for interaction between the two proteins, as well as conserved binding interface regions 
between Rab5 and binding partners that take advantage of conserved hydrophobic residues 
present on one of the switch regions of Rab5 (L85 and M88) (Mishra et al., 2010).  Based on 
these observed structural contact points mutagenesis and binding experiments were performed to 
observe the effects mutation of these residues had on Rab5:EEA1 binding in order to further 
support their role in binding (Mishra et al., 2010).  In addition to their structural studies, Mishra 
et al. also performed binding affinity experiments to compare the binding of EEA1 with Rab5 
and other members of the Rab protein family, showing that EEA1 binds with high specificity to 
Rab5 and had much weaker binding with other Rab proteins, including those that are most closely 
related to Rab5 (Mishra et al., 2010).  
The p85 protein has been shown to bind Rab5 and serve as a GAP to stimulate the intrinsic 
GTPase activity of Rab5 (Chamberlain et al., 2004).  There are currently no crystal structures for 
Rab5 in complex with one of its GAP proteins.  Crystal structures of human p85 BH domain and 
the BH domains of other GAP proteins have been solved individually for Myosin 9b (PDB ID# 
5C5S) and N-chimaerin (PDB ID# 2OSA), and a crystal structure of CDC42GAP in complex 
with CDC42 (PDB ID# 2NGR) was also solved (Kong et al., 2015; Nassar et al., 1998) (Walker 
et al., Unpublished).  A comparison of the BH domain structures of p85, Myosin 9b, N-chimaerin, 
and CDC42GAP is shown in Figure 1.12.  Cheung et al. modeled a potential interaction between 
p85 and Rab5 based on superimposing the crystal structures of the p85 BH domain and Rab5 
over the crystal structure of CDC42 bound to CDC42GAP (Cheung et al., 2015).  This potential 
orientation placed p85 residue R151 at the interface to serve as the catalytic residue stimulating 
Rab5 GTPase activity.  Previous mutagenesis studies performed had shown that mutation of R151 
lead to a slight decrease in p85 GAP activity, while mutating R274 completely removed p85 GAP 
activity, leading to the interpretation that R274 was the catalytically critical residue (Chamberlain 
et al., 2004).  A potential orientation of the p85 BH domain and Rab5, generated based on 
overlaying these structures with the CDC42 and CDC42GAP structure as performed by Cheung 
et al., with R151 and R274 of p85 indicated is shown in Figure 1.13.  The R274 residue is located 
distant from the Rab5 catalytic site, positioned between several helices and loops.  It is possible 
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that mutation of this residue resulted in a destabilization of structural elements of the p85 BH 
domain, leading to the observed loss of GAP activity.  Determination of a crystal structure 
between the p85 BH domain and Rab5 would better determine the accuracy of this model, 
identify specific residues important for the interaction, confirm the identity of the catalytic Arg, 
and how mutations affect binding. 
Figure 1.12 Comparison of the human p85 BH domain with BH domains of other GAP 
proteins.  A.  The p85 BH domain (green) alone, PDB ID# 1PBW (Musacchio et al., 1996).  
B. Overlay of the p85 BH domain and the human Myosin 9b BH domain (yellow), PDB ID#
5C5S (Kong et al., 2015).  C.  Overlay of the p85 BH domain and the human N-chimaerin
BH domain (magenta), PDB ID# 2OSA (Walker et al., Unpublished).  D.  Overlay of the p85
BH domain with the human CDC42GAP BH domain (tan) bound to human CDC42 (purple),
PDB ID# 2NGR (Nassar et al., 1998).  The magnesium ion in the CDC42 binding site is
shown as a grey sphere.
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Figure 1.13 Potential interface region between p85 BH domain and Rab5.  Possible 
orientation of the p85 BH domain and Rab5 complex, determined by aligning the crystal 
structures of the p85 BH domain (green, PDB ID# 1PBW; Musacchio et al., 1996) and Rab5 
(gray, PDB ID# 1N6H; Zhu et al., 2003) with the crystal structure of CDC42 bound to 
CDC42GAP (PDB ID# 2NGR; Nassar et al., 1998; structure not shown).  R151, located at 
the potential interface, and R274, the previously proposed GAP catalytic residue, are shown 
in stick format, with magnesium shown as a teal sphere and the bound GTP analogue shown 
in magenta. 
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2.0 Hypothesis and Objectives 
2.1 Rationale 
Combining high-resolution structural data with results of biochemical experiments can 
provide a deeper insight into the mechanisms of function and disease.  The crystal structures of 
p85 110B domain in complex with the p110 adaptor binding domain or the full-length p110 
protein were used to examine how known cancer-associated mutations could alter the binding of 
the two proteins based on their positions within the structure, and additional biochemical 
experiments to characterized binding residues (Huang et al., 2007; Miled et al., 2007).  The p85 
BH domain and its known binding partners PTEN and Rab5 have not seen the same examination, 
with recent modeling and biochemical analysis by Cheung et al. beginning a deeper examination 
(Cheung et al., 2015).  High resolution structural data of the interactions between these protein 
complexes can allow for greater understanding of the residues involved and how cancer-
associated mutations affect their binding and function. 
2.2 Hypothesis 
Detailed structural information for the p85 BH domain, several cancer-associated and 
engineered mutants, and complexes involving binding partners PTEN and Rab5, will allow us to 
better understand the function and regulation of this protein. 
2.3 Objectives 
1. Obtain crystal structure data for the p85 BH domain wild-type, and containing a number
of cancer-associated and engineered mutations.
2. Determine the crystal structure of the p85 BH domain in complex with the previously
crystallized PTEN (7-353, Δ286-309) or Rab5 (15-184) protein fragments.
3. Determine the effect of various cancer-associated and engineered mutations on p85
dimerization.
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3.0 Materials and Methods 
3.1 Materials 
3.1.1 Bacterial cells and culture 
DNA amplification was performed within E. coli strain TOP10 [F-, mcrA, D(mrr-
hsdRMS-mcrBC), f80lacZDM15 DlacX74, deoR, recA, araD139 D(ara-leu)7697, galK, 
rpsL(StrR), endA1, nupG] cells (Invitrogen).  GST-fusion proteins were overexpressed in 
protease-deficient BL21 [E. coli B, F-, dcm, ompT, hsdS(rb-ms-), gal] cells (Amersham).  Both 
strains were grown in Miller Luria Bertani Broth (LB, EMD Millipore; Billerica, MA), 
supplemented with 100 µg/mL ampicillin (Sigma-Aldrich), at 37°C in a shaking incubator.  For 
obtaining higher yields of GST-fusion proteins some batches of BL21 bacteria were grown in 
Hyper Broth (AthenaES; Baltimore, MD), supplemented with 100 µg/mL ampicillin, at 37°C in 
a shaking incubator.  GST-fusion proteins of PTEN (7-353, Δ286-309) and Rab5 (15-184) were 
also overexpressed in protease-deficient Rosetta [F- ompT hsdSB(rB-mB-) gal dcm pRARE 
(CamR)] cells (Novagen).  Rosetta cells were grown in LB or Hyper Broth media supplemented 
with 100 µg/mL ampicillin and 34 µg/mL chloramphenicol, at 37°C in a shaking incubator. 
3.1.2 Plasmids 
The various cDNAs used were subcloned separately into the pGEX6P1 vector 
(Amersham).  All GST-p85 mutants and GST-PTEN (7-353, Δ286-309 C124S) were generated 
within this plasmid. 
3.1.3 Primers 
Table 3.1 Sequencing primers.  All primers were custom-ordered through Invitrogen Life 
Sciences.  The GST-seq primers were used for sequencing all pGEX6P1 plasmids. 
Sequencing Primers 
Primer Name Sequence 
5`-GST-seq TTTGCAGGGCTGGCAAGC 
3`-GST-seq TTCACCGTCATCACC 
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Table 3.2 Primers for p85, Rab5, and PTEN fragment generation. The 5`-p85 primer was 
previously purchased from the University of Alberta oligonucleotide synthesis service 
(Edmonton, AB).  All other primers were custom-ordered through Invitrogen Life Technologies. 
Restriction enzyme sites for cloning into desired vectors are indicated with the recognition site 
underlined.  Codons are separated by spaces. 
Primer Name Sequence 
Primers for p85 
5`-p85 TCAGGATCC ATG AGT GCC GAG GGG TA 
5-BamHI-p85bv-105 TCAGGATCC GAA GCA GAC AGT GAG CA 
3-p85bv-319+stopEco CGAGAATTC TCA GTT GGC TAC AGT AGT GGG 
5`BCR ACCACAAAGGATCC GGA AGG AAA AAG ATC TCG CCT 
CCC A 
Primers for PTEN 
5-PTENhu-BamHI-7 GCAGGATCC GAG ATC GTT AGC AGA AAC 
3-PTENhu-EcoRI-353 CGGGAATTC TCA CTC CTC TAC TGT TTT TGT G 
Primers for Rab5 
5-Rab5hu-BamHI-15 GCAGGATCC GGA AAT AAA ATA TGC CAG 
3-Rab5dog-EcoRI-184 CCAGAATTC TCA GTT CTT TGG CAA CTT TTT AGC
Table 3.3 Primers for GST-p85 and GST-PTEN mutagenesis.  All primers were custom-
ordered through Invitrogen Life Technologies.  All mutagenesis primers were utilized in sense-
antisense pairs.  The mutation site is indicated by the nucleotide(s) underlined.  Codons are 
separated by spaces. 
Primer Name Sequence 
Mutagenesis Primers for p85 
5-p85hE137K C AAG CTC GTG AAA GCC ATT G 
3-p85hE137K C AAT GGC TTT CAC GAG CTT G 
5-p85bv-F177N GAC TTG GAG ATG AAC GAT GTG CAC 
3-p85bv-F177N GTG CAC ATC GTT CAT CTC CAA GTC 
5-p85bv-E217K G CAG AGT TCT AAA GAA TAC ATC CAG 
3-p85bv-E217K CTG GAT GTA TTC TTT AGA ACT CTG C 
5-p85bv-R262T CTG AAT GCA ACA GTA CTT TCT GAA C 
3-p85bv-R262T G TTC AGA AAG TAC TGT TGC ATT CAG 
5-p85bv-K288Q CAC CTC ATA CAA ATT ATA GAA ATC 
3-p85bv-K288Q GAT TTC TAT AAT TTG TAT GAG GTG 
5-p85bv-E297K ATC TCC ACC AAA TGG AAT GAA CGC 
3-p85bv-E297K GCG TTC ATT CCA TTT GGT GGA GAT 
Mutagenesis Primers for PTEN 
5` PTEN C124S GCA ATT CAC AGT AAA GCT GG 
3` PTEN C124S CC AGC TTT ACT GTG AAT TGC 
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3.1.4 Antibodies 
 The anti-p85 BH primary antibody was generated in a rabbit by our laboratory to a protein 
peptide corresponding to a region of the p85 BH domain (amino acids 78-332) (Chagpar et al., 
2010). These anti-p85 BH antibodies were purified from rabbit serum first by isolating all IgGs, 
then by affinity purification through binding and elution to the protein antigen used for the 
antibody generation.  The anti-Rab5 antibodies were purchased from Cell Signaling Technology.  
Secondary antibodies used were goat anti-rabbit conjugated to infrared dye (LI-COR 
Biosciences; Lincoln, NB) and were visualized using LICOR ODYSSEY infrared scanner and 
analyzed using ODYSSEY software V3.0.  Antibodies used are summarized in Table 3.4. 
 
Table 3.4 Primary and secondary antibodies used 
Antibody Name, species Company and Cat. # Figure(s) Concentration 
Anti-p85 BH, rabbit Lab generated 4.11, 4.15, 4.16 0.726 µg/mL 
Anti-Rab5, rabbit Cell Signaling 
Technology, 2143 
4.11 1:1000 
IRDye 680 anti-rabbit, goat LI-COR Biosciences, 
926-32221 
4.11, 4.15, 4.16 0.132 µg/mL 
 
3.1.5 Crystallization condition screening kits 
 The following commercially available sparse matrix crystallization conditions screening 
kits were used during initial crystallization trials: WIZARD I (Rigaku Reagents), WIZARD II 
(Rigaku Reagents), Pact Suite (QIAGEN), Index Suite HR2-144 (Hampton Research), PEG-Ion 
(Hampton Research), Crystal Screen HR2-110 (Hampton Research), JCSG+ Suite (QIAGEN), 
and AmSO4 Crystal Screen (QIAGEN). 
 
3.1.6 Other reagents 
 Phosphatidylinositol phosphate (PIP) strips were purchased from Echelon Biosciences 
Inc. (Salt Lake City, UT).  Non-hydrolyzable GTP analogue GppCP was purchased from Jena 
Bioscience.  It was obtained as a sodium salt and dissolved in water.  All other chemicals and 
reagents were purchased from Sigma-Aldrich or VWR and were analytical grade or higher unless 
otherwise specified. 
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3.2 Methods 
 
3.2.1 Generation of GST-tagged protein fragments 
3.2.1.1 Generation of GST-tagged bovine p85 protein fragments 
 Previously Dr. Deborah Anderson had generated a pGEX6P1 vector containing a cDNA 
coding for the full length bovine p85, which possesses 96.8% sequence identity with the human 
protein (701 of 724 amino acids).  Using this plasmid as a template I PCR generated p85 
fragments coding for amino acids 1-319 (primers 5`-p85 and 3-p85bv-319+stopEco), 78-319 
(primers 5` BCR and 3-p85bv-319+stopEco), or 105-319 (primers 5-BamHI-p85bv-105 and 3-
p85bv-319+stopEco), with all primers used found in Table 3.2.  The bovine p85 (1-319) protein 
fragment has 94.4% sequence identity with the human (301 of 319 amino acids), the p85 (78-
319) has 93.0% sequence identity (225 of 242 amino acids), and the p85 (105-319) has 92.6% 
sequence identity (199 of 215 amino acids).  The PCR reaction mixtures contained KOD Hot 
Start DNA Polymerase Buffer (EMD Millipore), 1.5 mM MgSO4, 0.2 mM each dNTP, 0.3 µM 
each of 5` and 3` primers, 10 ng template DNA, 1 µL KOD Hot Start Enzyme (EMD Millipore), 
and water up to a total volume of 50 µL.  All PCR reactions were performed in an Applied 
Biosystems 2720 Thermo Cycler with polymerase activation by 2 mins at 95°C, followed by 30 
cycles of 95°C for 20 seconds for DNA denaturing, 43°C for 10 seconds for primer annealing, 
and 70°C for 20 seconds for extension, followed by storage at 4°C.  These DNA fragments were 
purified following the PCR using a clean-up kit (QIAgen) and restriction digested with 10 U 
BamHI and 10 U EcoRI for 1 hour at 37°C.  The digested fragments were removed from enzyme 
and buffer using the clean-up kit.  The digested DNA was ligated into BamHI and EcoRI digested 
pGEX6P1 vector using 1 µL Quick Ligase (New England Biolabs) in Quick ligation buffer (New 
England Biolabs) to a final volume of 20 µL, incubated at 25°C for 30 minutes.  The ligated DNA 
was transformed into competent TOP10 cells (Hanahan et al., 1991), that were grown on LB 
plates supplemented with 100 µg/mL ampicillin for selection.  Plasmid DNA from the resulting 
colonies was isolated using a QIAgen Plasmid Miniprep Kit (QIAgen) and sent for sequence 
verification of the entire insert region at the Plant Biosciences Institute using the 5`-GST-seq and 
3`-GST-seq primers (Table 3.1).  Sequence confirmed plasmids were transformed into BL21 
competent cells for later use in protein expression and purification. 
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3.2.1.2 Generation of GST-tagged p85 mutants 
 Six point-mutations were introduced into the pGEX6P1-p85 (105-319) vector using Pfu 
DNA polymerase (Thermo Scientific).  The reaction mixture contained Pfu buffer with MgSO4, 
100 ng template DNA, 125 ng 5` mutagenic primer and 125 ng 3` mutagenic primer (Table 3.3), 
2 mM dNTPs, and 2.5 U/mL Pfu DNA polymerase to a final volume of 50 µL.  Mutagenesis 
reaction mixtures were heated to 95°C for 30 seconds for the initial denaturation of the DNA, 
followed by 16 cycles of; 95°C for 30 seconds for DNA denaturation, 55°C for 1 minute for 
primer annealing, and 68°C for 5 minutes for DNA extension in an Applied Biosystems 2720 
Thermo Cycler.  The DNA was treated with 10 U DpnI at 37°C for 1 hour to digest the methylated 
wild type DNA used as the template.  Following DpnI digestion 40 µL of the DNA amplification 
reaction was used for transformation and sequence verification as described above. 
 
3.2.1.3 Generation of GST-tagged PTEN (7-353, Δ286-309 C124S) 
 Previously the Anderson lab generated a pGEX6P1 vector containing the cDNA coding 
for human PTEN (7-353, Δ286-309), the fragment previously used for PTEN crystallization 
studies (Lee et al., 1999).  It has been shown in other phosphatases possessing conserved active 
site sequence (I/V HCXAGXXR S/T G) that mutation of the active site Cys residue inactivates 
the protein phosphatase activity while still allowing binding to target ligand (Jia et al., 1995; 
Streuli et al., 1989). Based on this knowledge we generated a fragment coding for PTEN (7-353, 
Δ286-309, C124S) (PTEN Crystal) via mutagenesis using pGEX6P1-PTEN (7-353, Δ286-309) 
as the template, and the mutagenesis primers 5` PTEN C124S and 3` PTEN C124S (Table 3.3) 
to assist in complex formation experiments.  Mutagenesis reaction mixture, DNA treatment, 
bacterial transformation, and sequencing were performed as described above. 
 Sequence confirmed plasmids were also transformed into Rosetta cells for later use in 
protein expression and purification to maximize the yield of soluble protein. 
 
3.2.1.4 Generation of GST-tagged Rab5 (15-184) 
 Previously the Anderson lab generated a pGEX6P1 vector containing the cDNA coding 
for the full length canine Rab5 protein.  Using this plasmid as a template I PCR generated a 
fragment encoding Rab5 (15-184), the same fragment used in previous crystallization studies of 
Rab5 (Zhu et al., 2003).  Human and canine Rab5 share 100% amino acid identity across this 
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region.  Primers used were 5-Rab5hu-BamHI-15 and 3-Rab5dog-EcoRI-184 (Table 3.2).  
Purification, bacterial transformation, and sequencing were performed as described above. 
 Sequence confirmed plasmids were also transformed into Rosetta cells for later use in 
protein expression and purification to maximize yield of soluble protein. 
 
3.2.2 Protein expression, purification, and tag cleavage of GST-tagged protein fragments 
3.2.2.1 Individual batch protein purification 
 BL21 cells transformed with our protein expression vectors of interest were used to 
inoculate 100 mL cultures of LB supplemented with 100 µg/mL ampicillin and grown for 16 
hours at 37°C in a shaking incubator.  These 100 mL cultures were then used to inoculate 1 L 
cultures of LB supplemented with 100 µg/mL ampicillin and incubated at 37°C until they reached 
an optical density at 600 nm of between 0.6-0.8, determined using a Pharmacia Biotech Ultrospec 
300 UV/Visible Light Spectrophotometer.  Protein overexpression was induced with addition of 
0.1 mM isopropyl ß-D-1-thiogalactopyranoside (IPTG).  The culture was incubated for 16 hours 
at 25°C.  Cultures were centrifuged at 6000 X g for 15 mins at 4°C in a JA-10 rotor using an 
Avanti J-E Centrifuge (Beckman Coulter).  Pellets were collected and their weight recorded. 
 For PTEN Crystal and Rab5 (15-184) being expressed in Rosetta cells, these bacteria 
were used to inoculate 100 mL cultures of LB supplemented with 100 µg/mL ampicillin and 34 
µg/mL chloramphenicol.  Other growth conditions and pelleting were performed as described 
above for the BL21 cells. 
 Bacterial pellets were lysed using Prescission buffer (50 mM Tris pH 7.0, 150 mM NaCl, 
1 mM Ethylenediaminetetraacetic acid (EDTA), 1 mM dithiothreitol (DTT), the protease 
inhibitors 10 µg/mL aprotinin, 10 µg/mL leupeptin, and 1 mM 4-(2-aminoethyl)benzenesulfonyl 
fluoride hydrochloride (AEBSF)) with 1 µg/mL lysozyme.  Following resuspension of the 
bacterial pellet in lysis buffer they were incubated at 4°C for 1 hour.  The bacteria were further 
lysed and the viscosity was reduced via sonication on ice. Six 10 second sonications were 
performed with 60 seconds between each sonication, using a setting of 2.5 on a Branson Sonifier 
450.  The sonicated cell debris was pelleted via centrifugation at 24000 X g for 30 mins at 4°C 
in a JA-25.5 rotor using an Avanti J-E Centrifuge.  The lysate was filtered through 0.8 µm 
Nalgene syringe filters (Thermo Scientific). 
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 For every 40 mL of protein lysate we added 1 mL of 50% Glutathione-Sepharose beads 
in phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM 
KH2PO4, pH 7.3).  The GST-tagged proteins were allowed to bind to the beads for 1 hour at 4°C.  
Samples were centrifuged at 500 X g for 5 minutes at 4°C using an Eppendorf Centrifuge 5810 
R.  Supernatant was aspirated, and the beads were washed 5 times using 40 mL Prescission buffer 
(50 mM Tris pH 7.0, 150 mM NaCl, 1 mM EDTA, and 1 mM DTT).  Washed beads were 
transferred to microcentrifuge tubes with addition of 900 µL Prescission buffer for every 500 µL 
of packed Glutathione-Sepharose beads.  To every tube we added 60 µL of 3C Prescission 
Protease (Sigma-Aldrich), and the samples were incubated for 72 hours at 4°C.  3C Prescission 
Protease is a genetically engineered fusion of human rhinovirus 3C protease and GST that cleaves 
between the Gln and Gly residues of the recognition sequence LEVLFQGP. 
 Samples were centrifuged at 500 X g for 5 minutes at 4°C and supernatant containing the 
cleaved protein was collected.  Beads had 1 mL cold Prescission buffer added and were agitated 
at 4°C for 15 minutes before centrifuging and the supernatant containing the cleaved protein was 
collected.  We collected 5 washes from the beads to recover additional cleaved protein. 
 Samples and each wash were analyzed using sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE) with Coomassie Blue staining to check for protein purity and 
yield.  Pooled samples were concentrated and buffer exchanged into the desired storage buffer 
using Millipore Amicon 10 kDa centrifugal filter units.  Proteins were stored at 4°C until further 
purification or experiments. 
 
3.2.2.2 Large scale ÄKTA Purifier Glutathione-Sepharose column purification 
 Initial bacterial culture growth and lysis was performed as per 3.2.2.1 Individual batch 
protein purification.  For larger protein yields the larger 1 L cultures were grown in Hyper Broth 
to obtain larger bacterial pellets. 
 Following filtration through the 0.8 µm Nalgene syringe filters, the bacterial lysate was 
loaded into a Superloop (GE Healthcare) equilibrated in PBS.  The Superloop was connected to 
the ÄKTA Purifier attached to an HR 16/10 column loaded with Glutathione-Sepharose high 
performance media (GE Healthcare, column bed height 8.0 cm, column bed diameter 1.6 cm, 
column volume 16 mL).  The lysate was injected onto the column with PBS buffer, using protocol 
settings of 1 mL/min flow rate, pressure limit of 0.5 MPa, and collecting 5 mL fractions while 
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unbound proteins were washed off across 5 Column Volumes (CV) buffer.  Washing was 
maintained until the A280 UV absorbance was less than 20 mAU, to ensure non-specifically 
bound protein had all been removed from the column.  The collected fractions allowed analysis 
to ensure our GST-tagged protein of interest was not being removed from the column during 
washing steps. 
 GST-tagged proteins were eluted from the column using Elution Buffer (50 mM Tris pH 
8.0, 150 mM NaCl, and 10 mM reduced glutathione).  This elution step was performed at the 
same flow rate and pressure limit as protein binding, and was performed over 5 CV while 
collecting 2 mL fractions. 
 Presence of desired protein was confirmed using SDS-PAGE analysis with Coomassie 
Blue staining. 
 Fractions containing protein were pooled and transferred to Spectra/Por molecularporous 
membrane tubing (Spectrum Medical Industries Inc.; Los Angeles, CA) with a MW cut-off of 
6000-8000 Da.  The protein was then dialyzed for 16 hours in 50 mM Tris pH 8.0, 150 mM NaCl, 
1 mM EDTA buffer.  Following dialysis we added 60 µL 3C Prescission Protease and incubated 
the samples for 72 hours at 4°C. 
 We purified our liberated protein from the cleaved GST-tag using the HR 16/10 
Glutathione-Sepharose column used previously by binding the GST portion to the column and 
allowing the desired cleaved protein to flow through without binding.  Samples were added to 
the column using PBS buffer, with a flow rate of 1 mL/min, pressure limit of 0.5 MPa, and 
collecting 1 mL fractions.  Fractions collected containing the desired cleaved protein were 
checked for protein purity and yield using SDS-PAGE with Coomassie Blue staining.  Samples 
containing purified protein were concentrated and buffer exchanged into the desired storage 
buffer using Millipore Amicon 10 kDa centrifugal filter units.  Proteins were stored at 4°C until 
further purification or experiments. 
 
3.2.2.3 Anion exchange chromatography of p85 protein fragments 
 Proteins purified using Glutathione-Sepharose affinity chromatography were further 
purified using anion exchange chromatography.  Protein samples were buffer exchanged into 
Source Q Anion A Buffer (50 mM Tris pH 8.0, 50 mM NaCl, 2 mM DTT) and loaded onto an 
HR 16/10 Column packed with Source Q Anion Exchange Media (GE Healthcare, column bed 
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height 10 cm, column bed diameter 1.6 cm, column volume 20.1 mL).  Protein was injected onto 
the column and washed with 2 CV Source Q Anion A Buffer to remove unbound protein with a 
flow rate of 3 mL/min and a pressure limit of 0.5 MPa.  Bound protein was eluted starting from 
Source Q Anion A Buffer across a gradient of 0-100% Source Q Anion B Buffer (50 mM Tris 
pH 8.0, 1 M NaCl, 2 mM DTT) across 3 CV while collecting 1 mL fractions.  After completing 
the gradient an additional 2 CV of Source Q Anion B Buffer were used to ensure full elution of 
any remaining bound proteins. 
 Fractions were analyzed using SDS-PAGE analysis and Coomassie Blue staining to 
verify protein purity and yield.  Fractions containing purified protein were pooled and 
concentrated and buffer exchanged into the desired storage buffer using Millipore Amicon 10 
kDa centrifugal filter units.  Proteins were stored at 4°C until used for experiments. 
 
3.2.3 Protein Visualization and concentration determination 
3.2.3.1 Coomassie Blue staining 
 Proteins were visualized using SDS-PAGE (7.5, 10, or 15% acrylamide, Fisher Scientific) 
(Laemmli, 1970) and Coomassie blue staining (0.14% [w/v] Coomassie Blue R-250 [Bio-Rad], 
41.4% [v/v] methanol, and 5.4% [v/v] acetic acid).  Unbound Coomassie blue was removed by 
washing the gels with destain solution (41.4% [v/v] methanol, 5.4% [v/v] acetic acid).  Following 
cleavage of the GST-tag, bands corresponding to the following MW were expected for each 
protein:  p85 (1-319; ~36 kDa), p85 (78-319; ~27 kDa), p85 (105-319) (p85-BH; ~24 kDa), Rab5 
(1-215 ~24 kDa), Rab5 (15-184; ~19 kDa), and PTEN (7-353 ∆286-309; ~38 kDa).  Presence of 
other bands were interpreted as presence of contaminating proteins, presence of cleaved GST, or 
signs of protein degradation.  Gel images were recorded using a ChemiDoc imaging system (Bio-
Rad). 
 
3.2.3.2 Western blot analysis 
 For western blot analysis protein resolved by SDS-PAGE were transferred to a 
nitrocellulose membrane (Amersham) in transfer buffer (48 mM Tris-HCl pH 9.2, 0.028% [w/v] 
SDS, and 20% [v/v] methanol) using a Trans-Blot Turbo Transfer System (Bio-Rad).  The 
transfer was arrayed as follows: 3 pieces of 3 mm filter paper (Whatman) soaked in transfer 
buffer, nitrocellulose membrane hydrated with water, SDS-PAGE gel, and 3 pieces of 3 mm filter 
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paper soaked in transfer buffer.  Any air bubbles present were removed by applying a roller across 
the top.  The system was operated at 2.5 A, 25 V for 20 minutes to perform the transfer. 
 The nitrocellulose membrane was incubated in blocking solution (5% [w/v] Carnation 
skim milk powder [Safeway] in PBS) for 1 hour at room temperature with agitation.  The 
membrane was then incubated with 10 mL primary antibody (appropriate primary antibody from 
Table 3.4 in blocking solution above) solution for 1 hour at room temperature.  The blot was 
washed three times for 10 minutes in PBST.  The IRDye 560 anti-rabbit secondary antibody 
(Table 3.4) was prepared in 10 mL blocking solution and the membrane incubated in secondary 
antibody for 1 hour at room temperature in the dark.  The membrane was washed as above, in the 
dark, with an additional wash performed using PBS.  The membrane was scanned using a LI-
COR ODYSSEY infrared scanner (LI-COR Biosciences) and analyzed with the ODYSSEY V3.0 
software. 
 
3.2.3.3 Nano drop protein concentration determination 
 Concentrations of purified proteins were determined by measuring UV absorbance at 280 
nm with a Nanodrop 2000c Spectrophotometer (Thermo Scientific) with corresponding 
extinction coefficients calculated based on protein sequence using the ExPASy ProtParam tool.  
The corresponding protein storage buffer was used as a blank for the machine prior to analysis 
of the purified proteins.  Determined protein concentrations were confirmed by SDS-PAGE and 
Coomassie blue staining compared to known concentrations of bovine serum albumin (BSA). 
 Protein fragments, calculated MW, and extinction coefficients are provided in Table 3.5. 
 
Table 3.5 Protein fragments, calculated MW, and extinction coefficients 
Protein Fragment Name Calculated MW (kDa) Extinction Coefficient (M-1 cm-1) 
GST 24.50 42860 
p85 full-length 83.60 99130 
p85 (1-319) 35.72 35870 
p85 (78-319) 26.98 19940 
p85 (105-319) 24.15 19940 
Rab5 (1-215) 23.66 18450 
Rab5 (15-184) 18.97 18450 
PTEN (7-353, Δ286-309) 38.43 42290 
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3.2.4 Crystallization condition screening for bovine p85 protein fragments 
3.2.4.1 Automated sparse matrix screens 
 Identification of initial crystal conditions was performed via preparation of sitting drop 
vapour diffusion screens of commercially available sparse matrix crystallization condition 
screening kits against 15 mg/mL samples of our protein of interest.  These sparse matrix screens 
were set up using the GRYPHON robot (Art Robbins Instruments) operated by the Protein 
Characterization and Crystallization Facility (PCCF) of the University of Saskatchewan.  
Training on the operation of the GRYPHON robot was provided by Dr. Maia Cherney and Dr. 
Michal Boniecki of the PCCF.  The GRYPHON robot generated 0.4 µL sitting drops by mixing 
0.2 µL protein solution in crystal holding buffer (20 mM Bis-Tris Propane pH 6.5, 100 mM NaCl, 
2 mM tns [2-carboxyethyl] phosphine hydrochloride [TCEP-HCl]) with 0.2 µL crystallization 
mother liquor in 96-well 2-well intelliplates (Art Robbins Instruments) with 100 µL of 
crystallization mother liquor deposited in the well reservoir.  Plates were sealed with clear 
cellophane tape to prevent evaporation.  Plates were incubated at room temperature and crystal 
growth was monitored using a Nikon SMZ1000 light microscope.  Promising conditions were 
used as the basis for hanging-drop vapour diffusion condition optimization screens. 
 
3.2.4.2 Hanging-drop vapour diffusion condition optimization screens 
 Larger volume hanging-drop vapour diffusion condition optimization screens discussed 
in (McPherson, 1976) were prepared using 24-well VDX plates with sealant (Hampton 
Research).  Using promising conditions from the sparse matrix screens, these screens altered pH 
values, salt concentrations, and presence/levels of additives such as glycerol or polyethylene 
glycols (PEG) of various MW.  Altering these conditions allowed for improved crystal growth in 
order to obtain crystals suitable for X-ray diffraction data collection.  The crystallization drops 
were formed on plastic cover slips with the mixture of 1 µL 5-15 mg/mL purified protein solution 
in crystal holding buffer added to 1 µL crystallization mother liquor and sealed above 1 mL of 
crystallization mother liquor.  Plates were incubated at room temperature and crystal growth was 
monitored using a Nikon SMZ1000 light microscope. 
 Conditions that yielded crystals for our p85-BH fragment and mutants were 0.1 M Sodium 
Cacodylate pH 6.0-6.2, 1.3-1.7 M Li2SO4, and 4-8% Glycerol. 
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3.2.4.3 Crystal seeding and streak seeding 
 Some mutants of p85 produced small crystals or showers of very small crystals under the 
initial crystallization conditions.  Crystal seeding and streak seeding were used to obtain larger 
crystals more suitable for diffraction data collection. 
 For crystal seeding a single small crystal was extracted from the existing crystallization 
drop and transferred to a fresh drop of crystallization mother liquor to rinse the crystal and remove 
any small crystals that may have been present on its edges.  This washed crystal was then 
transferred to a fresh drop containing protein and crystallization mother liquor as a seed crystal 
for further hanging-drop vapour diffusion crystallization.  The seed crystal serves as a scaffold 
for additional protein to crystallize on, resulting in the growth of a larger crystal. 
 For streak seeding multiple very small crystals were transferred to a fresh crystallization 
drop containing protein and crystallization mother liquor by moving the whisker of a cat from 
one side of the initial crystal drop to the other, and then immediately moving the cat whisker 
through the fresh drop.  This streak seeded drop was then sealed and incubated using the hanging-
drop vapour diffusion method.  The very small crystals introduced to this fresh drop serve as 
nucleation sites to encourage additional crystal growth, resulting in the production of larger 
crystals. 
 
3.2.5 X-ray diffraction data collection, processing, and structure refinement 
3.2.5.1 X-ray diffraction data collection and processing 
 Crystals were taken to the Canadian Light Source (CLS, Saskatoon, SK) to collect 
diffraction data.  Diffraction data was collected using the Canadian Macromolecular 
Crystallography Facility 08B1-1 (CMCF-BM) (Fodje et al., 2014), or the Canadian 
Macromolecular Crystallography Facility 08ID-1 (CMCF-ID) (Grochulski et al., 2011) 
beamlines.  Drops containing crystals to be analyzed had cryoprotectant solution (0.1 M Sodium 
Cacodylate pH 6.0, 1.5 M Li2SO4, 18% [w/v] glycerol) added prior to data collection.  Crystals 
were extracted using nylon loops attached to mounting pins, which were then connected to the 
goniometer. 
 Diffraction data were collected with a detector distance of 280 mm, in 0.5° or 1° wedges 
for a total collection of 180°.  No beam attenuation was applied for data collected using CMCF-
BM, while 40-50% beam attenuation was applied for data collected using CMCF-ID.  X-ray 
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detectors equipped at the beamlines were a Rayonix MX300 HE CCD for the CMCF-BM and a 
Rayonix MX300 CCD for the CMCF-ID.   Processing of collected data was performed using 
HKL2000 software (Otwinowski and Minor, 1997) installed at the CLS. 
 
3.2.5.2 Structure refinement using PHENIX and Coot software 
 Using the files generated following HKL2000 processing structure determination was 
performed using PHENIX software (Adams et al., 2010).  As the human p85 BH domain crystal 
structure has previously been solved (Musacchio et al., 1996) we used molecular replacement 
with PDB structure 1PBW as the initial probe to determine the phases of the collected data by 
determining the best agreement of the calculated diffraction data from the probe and the observed 
diffraction data experimentally collected.  Determined structures were examined using Coot 
software (Emsley et al., 2010) and manual adjustments applied to increase agreement with the 
observed electron density.  Repeated cycles of phenix.refine and manual adjustments in Coot 
were performed to further improve the structure.  Improvement to the structure was determined 
by examining validation tools in Coot and the Rfree score following phenix.refine. 
 After determination of the p85-BH structure, this was used as the starting structure for 
refinement of other structural data collected. 
 
3.2.5.3 PyMOL image generation 
 Final images of obtained crystal structures were generated using the PyMOL Molecular 
Graphics System, Version 1.4.1 Schrödinger, LLC. 
 
3.2.5.4 Generation of electron density maps in CCP4 for visualization in PyMOL 
 To generate electron density maps for use in PyMOL for visualization we used CCP4 
version 6.5.008 (Winn et al., 2011) using fft (Immirzi, 1966; Eyck, 1973; Read and Schierbeek, 
1988).  Generated 2Fo-Fc maps that covered all atoms present within the source PDB files.  2Fo-
Fc maps presented in PyMOL were contoured to 1.0 Sigma. 
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3.2.6 Size exclusion chromatography and Native PAGE 
3.2.6.1 Complex formation experiments between p85-BH and Rab5 
 Before any co-crystallization trials could be performed we first needed to show complex 
formation between p85-BH and Rab5, as well as purify yields of this complex suitable for 
crystallization trials.  Equimolar amounts of p85-BH and Rab5 purified protein solutions were 
mixed and incubated at room temperature for 5 or 20 mins, then underwent size exclusion 
chromatography (SEC).  Using a Superdex 200 Increase column (column bed height= 30 cm, 
column bed diameter= 1 cm, Total Volume= 24 mL, Void Volume= 8 mL, GE Healthcare) 
connected to an ÄKTA Purifier unit 0.5 mL of this protein mixture at a concentration of 4 mg/mL 
was loaded.  SEC was performed using a buffer of 50 mM Tris pH 7.0, 250 mM NaCl, and 2 mM 
DTT, at a flow rate of 0.750 mL/min, a pressure limit of 3.80 MPa, and collecting 0.5 mL 
fractions.  A chromatogram was recorded based on the absorbance at 280 nm for each fraction. 
 MW of observe absorption peaks were determined using the formulas below: 
 Kav= (Elution Volume – Void Volume)/(Total Volume – Void Volume)                  (3.1) 
 LogMW= -3.199(Kav) + 3.0564                                                                                  (3.2) 
 Void Volume and Total Volume are determined based on the column used (8 mL and 24 
mL respectively for our Superdex 200 Increase).  The numerical values found in Equation 3.2 
were determined by observing the elution volumes of several known MW proteins (ß-amylase, 
alcohol dehydrogenase, BSA, carbonic anhydrase, and cytochrome c) that were used to calibrate 
the Superdex 200 Increase column. 
 Due to the similar MW of the p85-BH (~24 kDa) and Rab5 (~24 kDa) determination of 
which proteins were present in the various fractions was done using Western blot analysis as 
described above.  
 
3.2.6.2 Oligomerization determination of recombinant full-length human p85 and mutants 
 In order to determine potential oligomeric states of our p85 proteins, and the changes that 
mutations may have on these arrangements, we used SEC.  Using our Superdex 200 Increase 
column connected to an ÄKTA Purifier unit 0.5 mL of protein at a concentration of 0.7 mg/mL 
was loaded.  This protein underwent SEC using the same buffer and conditions as described 
above.  A chromatogram was recorded based on the absorption at 280 nm for each fraction. 
39 
 
 In order to confirm the MW determined by SEC and verify the oligomerization of the 
proteins, we used Native PAGE.  Samples of the SEC protein input and the peak fraction were 
loaded onto Native PAGE 4-16% Bis-Tris gradient Gels (Life Technologies) and were 
electrophoresed at 150 V for 95 mins.  Protein was fixed in the gels with addition of destain 
solution and microwaved for 45 seconds, then incubated at room temperature with agitation for 
30 minutes.  The gels were treated with Coomassie blue stain to visualize the protein, microwaved 
and incubated as above.  To remove unbound Coomassie blue stain from the gels destain was 
added, gels were microwaved as above, and incubated at room temperature with agitation until 
protein bands were clearly visible. Gel images were recorded using a ChemiDoc imaging system 
(Bio-Rad). 
 
3.2.7 Multi-angle light scattering 
 Multi-angle light scattering (MALS) experiments were performed using the MALS-RI 
(Wyatt Technology) operated by the PCCF, with training and experimental assistance by Dr. 
Michal Boniecki.  The MALS-RI was connected with the PCCF ÄKTA Purifier to allow for 
SEC-MALS tandem experiments.  Protein solutions of 4 mg/mL, 2 mg/mL, 1 mg/mL, 0.7 mg/mL 
or 0.5 mg/mL were injected onto the Superdex 200 Increase (dimensions provided above) column 
using a buffer of PBS with 250 mM NaCl, a flow rate of 0.5 mL/min, and a pressure limit of 4.00 
MPa.  Data analysis and processing, using the mean square radius of the proteins present across 
the various elutions to determine their corresponding MW, was performed using ASTRA 6.1.2.84 
software. 
 
3.2.8 Phosphatidylinositol phosphate lipid strip analysis 
 PIP lipid strips were used to test protein fragments for the ability to bind various lipids 
that were immobilized on nitrocellulose.  The PIP strips are spotted with 15 different lipids 
(lysophosphatidic acid; lysophosphocholine; sphingosine-1-phosphate; PI; PI3P; PI4P; PI5P; 
PI3,4P2; PI3,5P2; PI4,5P2; PI3,4,5P3; phosphatidylethanolamine; phosphatidylcholine; 
phosphatidic acid; phosphatidylserine) at 100 pmol per lipid spot.  PIP strips were incubated in 
blocking buffer (3% [w/v] fatty acid free BSA [Sigma-Aldrich, Cat#A6003], 10 mM Tris pH 8.0, 
150 mM NaCl, 0.01% Tween-20) for 1 hour at room temperature with agitation.  All incubations 
for PIP strips were performed in the dark.  The PIP strips were incubated for 16 hours at 4°C with 
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the protein fragment of interest diluted in blocking buffer.  PIP strips were washed 6 times, each 
wash lasting 5 minutes at room temperature, in PBST.  PIP strip were probed with anti-p85 BH 
primary antibody (Table 3.4) in blocking buffer for 1 hour at room temperature with agitation.  
The PIP strips were washed as described above.  PIP strips were incubated in IRDYE 680 anti-
rabbit secondary antibody (Table 3.4) in blocking buffer for 90 mins at room temperature with 
agitation.  The PIP strips were washed as described above.  Protein bound to the PIP strips were 
detected and visualized using a LI-COR ODYSSEY infrared scanner and analyzed with the 
ODYSSEY V3.0 software. 
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4.0 Results 
4.1 Purification and crystallization trials for GST-tagged bovine p85 protein fragments 
The primary objectives of my research were to 1) obtain crystal structure data for the SH3 
and BH domains of the bovine p85 protein wild-type, 2) obtain crystal structure data for the p85 
BH domain containing cancer-associated point mutations, and 3) obtain crystal structure data for 
the p85 BH domain containing mutations to residues important for interaction with the PTEN 
protein. To accomplish these objectives we generated and purified GST-tagged protein fragments 
of varying amino acid length as well as containing various cancer-associated or engineered point 
mutations.  Cancer-associated mutations were identified through bioinformatics analysis of 
cancerous tissues against wild-type matched tissues (Cheung et al., 2011; Ross et al., 2013).  
Initial crystallization trials were performed using the automated Arts Robbins Instrument 
GRYPHON Robot for rapid screening of commercially available sparse matrix screen 
crystallization condition suites.  Promising conditions were used as the basis of manually 
prepared optimization screens that utilized the hanging-drop vapour diffusion method of crystal 
growth.  Crystals were taken to the CLS for data collection using the beamlines of the Canadian 
Macromolecular Crystallography Facility.  Diffraction data was processed on site using 
HKL2000 software, and crystal structures were refined and processed using PHENIX and COOT 
software.  Images were generated using PyMOL. 
A sequence alignment of the SH3 and BH domains of the p85 human and bovine proteins 
is provided in Figure 4.1 generated using MacVector version 12.5.0, indicating locations of 
cancer-associated point mutations and residues where mutations affect p85 binding to PTEN. 
A summary of the progress made for the various bovine p85 fragments can be found in 
Table 4.1. 
4.1.1 Crystallization of p85 fragments containing SH3 and BH domains, and the BH domain 
alone 
Initial crystallization experiments were performed on bovine p85 protein fragments 
containing amino acids 1-310 or 1-319.  Small rectangular prism-shaped crystals, commonly 
forming in clusters, were obtained for both fragments using 0.1 M Sodium Cacodylate pH 6.0-
6.3, 1.5 M Li2SO4, and 4% (w/v) glycerol.  Manipulation of the p85 (1-310) crystals resulted in  
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Figure 4.1 Sequence alignment of human and bovine p85 N-terminal domains.  Alignment 
generated using MacVector version 12.5.0 displaying the first 320 amino acids for the human 
and bovine p85 proteins.  The SH3 domain is labeled in green and the BH domain is labelled 
in purple.  The proline rich region important for SH3 domain based p85 homodimerization is 
labelled in blue.  Residues that form the BH domain homodimerization interface are indicated 
using yellow triangles.  Cancer-associated mutations sites are indicated using red triangles. 
Residues shown to reduce PTEN binding are indicated using blue triangles. 
the crystals crumbling so further optimization was only performed using p85 (1-319).  Initial p85 
(1-319) crystals reached maximum dimensions of approximately 100 µm by 50 µm by 50 µm 
after 7-10 days of incubation at room temperature.  These crystals were used for crystal seeding, 
and following an additional 7 days of incubation they reached final dimensions of approximately 
500 µm by 100 µm by 100 µm.  Crystals are shown in Figure 4.2 A.  The analyzed crystal had 
unit cell dimensions of 83.92, 92, 50, 92.98, 90, 90, 90; had P212121 symmetry, and diffracted to 
2.70 Å. 
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Table 4.1: Summary of crystallization results for bovine p85 fragments 
Protein Plasmid 
Made 
Protein 
Purification 
Optimized 
Crystal 
Trial 
Progress 
Crystal 
Resolution 
(Å) 
R-merge 
(Highest 
resolution shell 
in brackets) 
p85 (105-319) Y Y Y 2.45 8.5 (60.2) 
p85 (105-319) 
[p85-BH] + 
PI4P 
   2.25 9.4 (65.9) 
p85 (78-319) 
+ PI4,5P2 
Y Y Y 3.1 13.5 (73.1) 
p85-BH-
I177N 
Y Y In Progress   
p85-BH-
E137K 
Y Y Y 2.40 7.0 (45.3) 
p85-BH-
E217K 
Y Y Y 2.20 6.0 (42.0) 
p85-BH-
R262T 
Y Y Y 2.70 8.9 (50.1) 
p85-BH-
K288Q 
Y Y N   
p85-BH-
E297K 
Y Y Y 2.30 6.9 (42.6) 
p85-BH-
K224-5E 
Y Y Y   
p85-BH-
R228E 
Y Y Y 2.40 8.5 (60.1) 
p85-BH-
H234D 
Y Y Y   
p85-BH-
Q241D 
Y Y Y   
 
 Amino acids 113-297 of p85 were visible forming a homodimer within the solved crystal 
structure.  This corresponded to the BH domain dimer visualized in the human p85 BH domain 
structure previously solved (Musacchio et al., 1996).  The SH3 domain of the protein was not 
visible in the structure.  The crystal structure determined is shown in Figure 4.2 B. 
 Within the observed structure a pair of highly coordinated SO4 ions from the 
crystallization solution could be seen near residues K224, R228, H234, W237, and Q241.  As the 
conditions used to crystallize the human p85 BH domain were 3.6 M sodium formate, pH 5.0, 
there were no SO4 molecules visible within their structure.  The highly coordinated nature of the 
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Figure 4.2 Crystals and crystal structures for bovine p85 (1-319) and p85 (105-319).  A.  
Initial protein crystals obtained for the bovine p85 (1-319) protein fragment were small (top) 
and used as seed crystals to generate the larger crystals used for X-ray diffraction data 
collection (bottom).  B.  Crystal structure with a resolution of 2.70 Å obtained from p85 (1-
319) crystals.  A homodimer of BH domains were visible containing residues 113-297 for both
components of the dimer.  Residues corresponding to the SH3 domain did not have solvable
electron densities.  C.  Example cluster of protein crystals obtained for the p85 (105-319)
protein fragment.  D.  Overlay of the p85 (1-319) crystal structure (magenta) with the crystal
structure solved to 2.40 Å for the p85 (105-319) protein fragment (green).
previously unseen interaction suggests that the region is potentially a novel binding pocket within 
the p85 BH domain. 
Due to the absence of the SH3 domain in our obtained structure, and the presence of this 
potential novel binding pocket, efforts of future crystallization experiments were focused on the 
bovine p85 BH domain exclusively.  To this end we used a p85 fragment containing amino acids 
105-319 for further crystallization experiments.
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Crystals of p85 (105-319) were grown in 0.1 M Sodium Cacodylate pH 6.0, 1.5 M Li2SO4, 
and 4% (w/v) glycerol.  These crystals formed as triangular prisms, often in clusters, and reached 
maximum dimensions after approximately 7 days of incubation.  An example cluster of crystals 
is shown in Figure 4.2 C.  The analyzed crystal had unit cell dimensions of 85.14, 91.83, 93.27, 
90, 90, 90; had P212121 symmetry, and diffracted to 2.45 Å. 
The solved crystal structure also appeared as a dimer of BH domains, and the potential 
novel binding pocket observed in the crystal structure from p85 (1-319) was present in p85 (105-
319) structure as well.  A comparison of the p85 (1-319) and p85 (105-319) crystal structures is
shown in Figure 4.2 D.
The highest resolution structure of the bovine p85 BH domain obtained was using the p85 
(105-319) protein fragment and the crystallization conditions 0.1 M Sodium Cacodylate pH 6.0, 
1.5 M Li2SO4, 4% (w/v) glycerol, and 10 mM short chain soluble 8 carbon PI4P lipid.  The crystal 
analyzed had unit cell dimensions of 85.83, 91.74, 93.78, 90, 90, 90; had P212121 symmetry, and 
diffracted to a resolution of 2.25 Å.  Residues 169-171 and 277-279 did not have visible electron 
density in either chain, and Pro 276 did not have visible electron density in Chain A.  As this 
determined structure had the highest resolution collected we will refer to this structure determined 
as p85-BH and all other structures obtained were compared to this structure.  The determined 
structure of p85-BH and a closer examination of the potential novel binding pocket observed are 
shown in Figure 4.3. 
Data collection and refinement statistics for p85 (1-319), p85 (105-319), and p85-BH are 
provided in Table 4.2. 
4.1.2 Crystallization of p85-BH containing cancer-associated point mutations 
Having obtained the crystal structure for the bovine p85 BH domain our next step was to 
observe the structural changes caused by several human cancer-associated point mutations 
(E137K, I177N, E217K, R262T, K288Q, and E297K) (Cheung et al., 2011; Ross et al., 2013). 
In bovine p85 amino acid 177 is a phenylalanine in place of an isoleucine found in the human 
p85. 
The p85-BH-F177N mutant crystal condition optimization is still ongoing.  Currently the 
most promising condition obtained is 0.1 M Tris pH 7.0, 2.0 M (NH4)2SO4, 0.2 M Li2SO4, leading 
to the formation of tiny crystals lacking in the smooth sides and defined corners that normally  
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Figure 4.3 Crystal structure of p85-BH to 2.25 Å resolution highlighting residues that 
form the potential novel binding pocket.  A. 2.25 Å resolution crystal structure obtained 
using p85-BH protein fragment treated with cryoprotectant containing 8 carbon chain PI4P. 
The two BH domains present in the homodimer are differentially coloured for easier 
differentiation.  B.  Close up view of the potential novel binding pocket observed in the p85-
BH structure.  Sulfate molecules and the sidechains of amino acids involved in their binding 
(K224, R228, H234, W237, and Q241) are shown in stick representation. 
suggest crystals that may diffract well.  None of the currently obtained crystals were suitable for 
X-ray diffraction data collection.
The p85-BH-K288Q fragment has been generated and produced in bacterial expression 
systems, but crystal condition trials have not been performed on this mutant. 
For p85-BH-E137K, p85-BH-E217K, p85-BH-R262T, and p85-BH-E297K we have 
successfully crystallized, collected diffraction data, and determined their crystal structures.  An  
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Table 4.2 Data collection and refinement statistics for p85 (1-319), p85 (105-319) and p85-
BH 
p85 (1-319) p85 (105-319) p85-BH 
Beamline CMCF-ID CMCF-BM CMCF-ID 
Resolution range (Å) 46.61 – 2.698 (2.795 
– 2.698)
35.68 – 2.449 (2.537 
– 2.449)
46.89-2.248 
(2.329-2.248) 
Space group P212121 P212121 P212121 
Unit cell 84.798 92.505 93.222 
90 90 90 
85.142 91.826 93.274 
90 90 90 
85.825 91.737 
93.778 90 90 90 
Total reflections 153810 203440 264033 
Unique reflections 20779 (2052) 27520 (2676) 35590 (3471) 
Multiplicity 7.4 (7.5) 7.4 (7.5) 7.4 (7.2) 
Completeness (%) 99.97 (99.66) 99.94 (99.37) 99.13 (97.86) 
Mean I/sigma(I) 32.5 (4.74) 19.95 (3.68) 24.23 (3.00) 
Wilson B-factor 52.36 40.36 33.63 
R-merge 11.3 (53.4) 8.5 (60.2) 9.4 (63.8) 
R-work 0.2085 (0.2611) 0.1955 (0.2412) 0.2011 (0.2239) 
R-free 0.2424 (0.3229) 0.2363 (0.2945) 0.2263 (0.2517) 
Number of non-
hydrogen atoms 
2769 2829 2924 
     macromolecules 2745 2804 2829 
     non-water solvent 20 20 20 
     water 4 5 75 
Protein residues 349 360 358 
RMS (bonds) 0.006 0.003 0.002 
RMS (angles) 1.00 0.67 0.62 
Ramachandran 
favoured (%) 
94.26 92.73 93.57 
Ramachandran 
outliers (%) 
2.42 3.78 3.22 
Rotamer outliers (%) 5.54 1.61 0.00 
Clashscore 4.86 3.89 1.22 
Average B-factor 51.17 46.40 44.25 
     macromolecules 50.68 46.04 44.03 
     non-water solvent 119.43 99.42 93.71 
     solvent 41.20 38.97 39.57 
Statistics for highest-resolution shell are shown in parentheses 
overlay of the crystal structures for p85-BH and the above mutant structures is shown in Figure 
4.4. 
The p85-BH-E137K crystals were grown in 0.1 M Sodium Cacodylate pH 6.0, 1.4 M 
Li2SO4, and 6% (w/v) glycerol.  The analyzed crystal had unit cell dimensions of 85.36, 91.92, 
93.27, 90, 90, 90; had P212121 symmetry, and diffracted to a resolution of 2.40 Å.  The p85-BH- 
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Figure 4.4 Overlays of the crystal structures for p85-BH wild-type and cancer-associated 
point mutants.  Overlays of the crystal structures for p85-BH wild-type (green, 2.25 Å) and 
cancer-associated point mutants (yellow).  Mutant sidechains and potential novel binding 
pocket residues are shown in stick representation.  A.  E137K mutant (2.40 Å).  B.  E217K 
mutant (2.20 Å).  C.  R262T mutant (2.70 Å).  D. E297K mutant (2.30 Å).  Lack of density for 
the K297 sidechain prevented inclusion of the sidechain, and a placeholder Ala replaces it in 
the structure. 
E217K crystals were grown in 0.1 M Sodium Cacodylate pH 6.0, 1.3 M Li2SO4, and 6% (w/v) 
glycerol.  The analyzed crystal had unit cell dimensions of 85.47, 91.65, 93.56, 90, 90, 90; had 
P212121 symmetry, and diffracted to a resolution of 2.20 Å.  The p85-BH-R262T crystals were 
grown in 0.1 M Sodium Cacodylate pH 6.2, 1.5 M Li2SO4, and 6% (w/v) glycerol which resulted 
in large numbers of very small crystals forming, with select crystals transferred to fresh 
crystallization drops as seed crystals to obtain larger crystals for data collection.  The larger 
crystal analyzed had unit cell dimensions of 85.45, 91.64, 93.57, 90, 90, 90; had P212121 
symmetry, and diffracted to a resolution of 2.70 Å.  The p85-BH-E297K crystals were grown in 
0.1 M Sodium Cacodylate pH 6.2, 1.4 M Li2SO4, and 6% (w/v) glycerol which resulted in large 
numbers of very small crystals forming, with select crystals transferred to fresh crystallization 
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drops as seed crystals to obtain larger crystals for data collection.  The larger crystal analyzed 
had unit cell dimensions of 85.64, 91.26, 93.32, 90, 90, 90; had P212121 symmetry, and diffracted 
to a resolution of 2.30 Å.  The K297 sidechain lacked electron density to be modeled, likely due 
to its highly flexible nature and the residue being present near the edge of our resolved structure, 
so an Ala residue serves as its placeholder.  All four mutants lacked visible electron densities for 
residues 167-171 in both chains, and lacked density for residues 277-279 in Chain B.  The p85-
BH-E137K also lacked residue residues 276 and 280 in Chain B.  The p85-BH-217K also lacked 
residues 167 and 280 in Chain B.  The p85-BH-R262T also lacked residues 276-280 in Chain A.  
The p85-BH-E297K also lacked residue 298 at the terminus of Chain A. 
No major structural differences were observed between these mutants and the wild-type 
protein. 
Data collection and refinement statistics for p85-BH mutants are provided in Table 4.3. 
4.1.3 Crystallization of p85-BH containing engineered point mutations 
Having observed a potential novel binding pocket in the p85 BH domain, we generated a 
series of engineered point mutations to determine their structural effect on this region and the BH 
domain as a whole.  The mutants p85-BH-K224E-K225E (p85-BH-K224-5E), p85-BH-R228E, 
p85-BH-H234D, and p85-BH-Q241D were generated and crystallized. 
The p85-BH-K224-5E crystals were grown in 0.1 M Sodium Cacodylate pH 6.0, 1.6 M 
Li2SO4, and 4% (w/v) glycerol.  X-ray diffraction data was not collected for these crystals. 
The p85-BH-R228E crystals were grown in 0.1 M Sodium Cacodylate pH 6.0, 1.5 M 
Li2SO4, and 4% (w/v) glycerol.  The crystal analyzed had unit cell dimensions of 85.19, 92.70, 
93.12, 90, 90, 90; had P212121 symmetry, and diffracted to a resolution of 2.4 Å.  Visible densities 
were not present for residues 168-171 for both chains and residues 277-279 in Chain B.  In this 
crystal structure one of the SO4 ions clearly visible in the other structures was absent, and the 
remaining SO4 ion reoriented itself within the pocket region.  An overlay of the p85-BH and p85-
BH-R228E crystal structures of the potential binding pocket region is shown in Figure 4.5.  No 
other major structural differences were observed. 
The p85-BH-H234D crystals were grown in 0.1 M Sodium Cacodylate pH 6.0, 1.5 M 
Li2SO4, and 4% (w/v) glycerol.  These conditions formed small crystals that were transferred to 
fresh crystallization drops as seed crystals to obtain larger crystals for data collection.  These  
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Table 4.3 Data collection and refinement statistics for p85-BH cancer-associated mutants 
p85-BH E137K p85-BH E217K p85-BH R262T p85-BH E297K 
Beamline CMCF-BM CMCF-BM CMCF-BM CMCMF-BM 
Resolution 
range (Å) 
35.76 - 2.407 
(2.493 – 2.407) 
35.79 – 2.203 
(2.282 – 2.203) 
35.8 – 2.7 
(2.796 – 2.7) 
35.8 – 2.301 
(2.384 – 2.301) 
Space group P212121 P212121 P212121 P212121 
Unit cell 85.364 91.924 
93.274 90 90 90 
85.474 91.647 
93.556 90 90 90 
85.449 91.637 
93.574 90 90 90 
85.643 91.26 
93.324 90 90 90 
Total 
reflections 
214849 280322 153261 244247 
Unique 
reflections 
28760 (2716) 37651 (3647) 20646 (2012) 33018 (3189) 
Multiplicity 7.5 (7.6) 7.4 (7.5) 7.4 (7.5) 7.4 (7.5) 
Completeness 
(%) 
98.88 (95.50) 99.62 (98.35) 99.35 (98.87) 99.80 (98.03) 
Mean 
I/sigma(I) 
23.65 (5.51) 24.43 (5.37) 19.91 (4.65) 22.45 (4.72) 
Wilson B-factor 35.79 34.85 40.94 34.84 
R-merge 7.0 (45.3) 6.0 (42.0) 8.9 (50.1) 6.9 (42.6) 
R-work 0.2133 (0.2472) 0.2123 (0.2492) 0.2003 (0.2263) 0.2150 (0.2388) 
R-free 0.2509 (0.2892) 0.2433 (0.2888) 0.2427 (0.2798) 0.2542 (0.3232) 
Number of non-
hydrogen atoms 
2858 2907 2840 2877 
macromolecules 2802 2812 2790 2808 
     non-water 
solvent 
20 20 20 15 
     water 36 75 30 54 
Protein 
residues 
358 358 355 358 
RMS (bonds) 0.026 0.004 0.003 0.004 
RMS (angles) 1.56 0.78 0.69 0.87 
Ramachandran 
favoured (%) 
91.18 92.11 94.66 92.69 
Ramachandran 
outliers (%) 
3.82 3.22 2.97 4.39 
Rotamer 
outliers (%) 
0.00 0.64 0.63 0.00 
Clashscore 6.53 4.91 2.30 6.35 
Average B-
factor 
41.59 42.61 43.16 41.76 
macromolecules 41.35 42.41 42.90 41.59 
     non-water 
solvent 
87.18 84.47 92.74 91.63 
     solvent 34.49 38.99 34.36 36.86 
Statistics for highest resolution shell are shown in parenthesis 
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Figure 4.5 Potential binding pocket comparison between p85-BH and p85-BH-R228E.  
Overlay of the potential binding pocket region of the p85-BH wild-type (green, 2.25 Å) and 
p85-BH-R228E engineered mutant (yellow, 2.40 Å).  Sidechains of pocket residues and SO4 
molecules are shown in stick representation, with the SO4 present in the p85-BH-R228E 
coloured magenta for differentiation. 
crystals only diffracted well across a 10° range of angles within the X-ray beam, preventing us 
from collecting enough X-ray diffraction data to solve its structure. 
The p85-BH-Q241D crystals were grown in 0.1 M Sodium Cacodylate pH 6.0, 1.7 M 
Li2SO4, and 4% (w/v) glycerol.  Diffraction data was not collected for these crystals. 
Data collection and refinement statistics for p85-BH R228E are shown in Table 4.4. 
4.1.4 Crystallization with addition of nucleotide, phosphoamino acids, or phospholipids 
In order to identify physiological binding partners for the potential binding pocket 
observed we treated crystals with cryoprotectant solutions containing various mixtures of 
nucleotide, phosphoamino acids, or phospholipids, immediately prior to X-ray diffraction data 
collection.  These phosphate containing compounds were chosen due to the structural similarity 
between PO4 and the SO4 ions observed within our crystal structures. 
Structures for SO4, cacodylate, PO4, and the additives used for crystallization trials are 
shown in Figure 4.6. 
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Table 4.4 Data collection and refinement statistics for p85-BH R228E 
Beamline CMCF-ID 
Resolution range (Å) 46.56-2.40 (2.44-2.40) 
Space group P212121 
Unit cell 85.187 92.697 93.117 90 90 90 
Total reflections 217767 
Unique reflections 29393 (1454) 
Multiplicity 7.4 (7.5) 
Completeness (%) 99.8 (99.8) 
Mean I/sigma(I) 33.0 (4.84) 
Wilson B-factor 40.39 
R-merge 8.5 (60.1) 
R-work 0.2073 (0.2368) 
R-free 0.2287 (0.2853) 
Number of non-hydrogen atoms 2850 
     macromolecules 2801 
     non-water solvent 10 
     solvent 39 
Protein residues 360 
RMS (bonds) 0.006 
RMS (angles) 1.54 
Ramachandran favoured (%) 92.73 
Ramachandran outliers (%) 3.20 
Rotamer outliers (%) 0.32 
Clashscore 4.27 
Average B-factor 49.37 
     macromolecules 49.03 
     non-water solvent 176.68 
     solvent 41.37 
Statistics for highest resolution shell are shown in parenthesis 
To test for binding of these additives crystals of p85-BH were treated with cryoprotectant 
solution containing either: 32 mM total nucleotides ATP, GTP and GppCp;  32 mM total 
phosphoamino acids pSer, pThr, and pTyr; or  12 mM total inositol lipid head groups inositol 
1,3-bisphosphate, inositol 1,4-bisphosphate, inositol 1,5-bisphosphate, and inositol 1,3,5-
trisphosphate as phospholipid representatives.  Crystals were successfully obtained and X-ray 
diffraction data collected for all three additive soak conditions, and structures determined. 
There were no electron densities present within any of the solved structures to suggest the 
presence of bound additives, but the high concentrations of SO4 ions present in the crystallization 
solution may have prevented binding of the additives, which were present at much lower 
concentration. 
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Figure 4.6 Structures of additives used in p85 crystallization solutions.  Structures of 
sulfate (A) and cacodylate (B) present in our crystallization solution for all solved structures, 
with phosphate (C) for comparison of structural similarity.  Other structures belong to 
nucleotides (D-F), phosphoamino acids (G-I), and phosphorylated inositol lipid head groups 
(J-M) used for additive cocktails to test binding of compounds with p85 protein.  Structures 
obtained from www.sigmaaldrich.com (D, E, G-I), www.jenabiosciences.com (F), or 
www.echelon-inc.com (J-M). 
Due to the role of the p85 protein in the PI3K/PTEN pathway we also treated p85-BH 
crystals with 10 mM individual short chain soluble 8 carbon PIP lipids.  We hoped that the 
addition of the 8 carbon tail to the lipid head groups would increase the likelihood of the lipids 
binding despite the high SO4 ion concentration present. 
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Structures of the 8 carbon tail PIP lipids investigated are shown in Figure 4.7. 
Figure 4.7 Structures of 8 carbon PIP lipids added to p85 crystallization solutions.  
Structures of short chain lipids added to cryoprotectant solutions prior to collection of X-ray 
diffraction data.  Structures were obtained from www.echelon-inc.com 
Crystals were successfully obtained for all four soluble 8 carbon PIP lipids pursued: PI4P, 
PI3,4P2, PI4,5P2, and PI3,4,5P3.  X-ray diffraction data was collected and crystal structures 
determined for each lipid soak and crystal structures were determined.  For all four of these crystal 
structures there were no increased electron densities to suggest the presence of bound lipid.  Once 
again the high concentrations of SO4 ions may have out competed any binding that may have 
otherwise occurred. 
4.1.5 Observations of C146 in the p85-BH protein structure 
Within our p85-BH structure we noticed a region of extra electron density between amino 
acids C146 and H180.  Based on the surrounding structure and allowed conformations of peptide 
bonds and sidechains C146 and H180 were unable to satisfactorily fill this excess density.  We 
therefore began looking for explanations to this excess density. 
To this end we examined possible post-translational modifications of the cysteine residue 
that would explain the observed density.  In Coot software the C146 residue was replaced with 
the various oxidation states of cysteine; sulfenic acid (-SOH), sulfinic acid (-SO2H), and sulfonic 
acid (-SO3H).  We also replaced them with the nitrosylated S-nitrosocysteine (-SNO).  These 
modified structures then underwent batches of phenix.refine to determine the quality of their fit 
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within the experimentally determined electron density.  To avoid bias of electron density fitting 
towards the selected modifications we also generated a structure in Coot by replacing Cys 146 
with an Ala, and performed phenix.refine on this structure, allowing us to use the difference map 
from this analysis to validate our observations from the other modified structures.  This allowed 
us to observe how well these various modifications fit within their own refined electron densities, 
as well as the difference density present from the Ala 146 refinement. 
The initial unfilled electron density observed is shown in Figure 4.8 A.  Electron 
difference density corresponding to the Ala 146 refinement, and the positioning of either Sulfenic 
Acid or S-nitrosocysteine at residue 146 are shown in Figure 4.8 B-D.  The comparative electron 
densities observed with an S-nitrosocysteine positioned at residue 146 following structure 
refinement is shown in Figure 4.8 E. 
By comparison of the various potential post-translational modifications applied to C146 
in our structures, the S-nitrosocysteine showed the best correlation with the observed density 
differences.  With the data available to us it is therefore most likely that the additional electron 
density detected between C146 and H180 corresponds to an S-nitrosocysteine residue. 
Comparison of our p85-BH structures with the previously solved p85 BH domain 
structure (Musacchio et al., 1996) shows good agreement between the orientations of residues 
within this region of the protein.  However, in the structure by Musacchio et al. there is an 
unmodified cysteine residue at location 146.  Without examination of their electron density data 
we are unable to know if any additional density were present around residue 146 in their structure 
to know if this residue frequently undergoes post-translational modification, or if our observed 
additional electron density present corresponds to an uncommon occurrence. 
Based on these observations it will be important for future experiments to determine if 
nitrosylation of cysteine residues occurs under physiological conditions for the p85 protein, as 
such modifications can play important structural roles in stabilizing proteins or altering their 
activity. 
4.1.6 Crystallization of p85 (78-319) in the presence of 8 carbon PI4,5P2 
To increase the available protein surface for potential binding partners to interact with we 
performed crystallization trials using a bovine p85 (78-319) protein fragment with 8 carbon 
PI4,5P2 added to its crystallization buffer.  We wished to see if the additional residues would  
56 
Figure 4.8 Examination of a modified cysteine at p85-BH residue 146.  The region between 
residues C146 and H180 observed within our determined crystal structures visualized in Coot.  
Amino acids are shown as sticks, with the 2Fo-Fc electron density map shown as blue mesh 
contoured to 1.0 σ, and the electron density difference map shown as green and red mesh 
contoured to 3.0 σ.  A.  Unfilled density region observed in our p85-BH crystal structure.  B.  
Electron density difference observed following replacing C146 with an Ala residue and 
performing phenix.refine.  C and D.  Sulfenic acid (C) or S-nitrosocysteine (D) positioned at 
residue 146 compared to the A146 electron density map.  E.  S-nitrosocysteine residue 
positioned at residue 146 positioned within electron density maps following phenix.refine. 
improve the lipid binding in the presence of high SO4 ion concentration in the crystallization 
solution. 
Diffraction data was collected and the crystal had unit cell dimensions of 84.12, 91.56, 
93.14, 90, 90, 90; had P212121 symmetry and diffracted to a resolution of 2.75 Å. 
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Data collection and refinement statistics for p85 (78-319) with 8 carbon PI4,5P2 are 
shown in Table 4.5. 
Table 4.5 Data collection and refinement statistics for p85 (78-319) with 8 carbon PI4,5P2 
Beamline CMCF-BM 
Resolution range (Å) 46.57 – 2.75 (2.848 – 2.75) 
Space group P212121 
Unit cell 84.12 91.56 93.14 90 90 90 
Total reflections 141928 
Unique reflections 19249 (1889) 
Multiplicity 7.4 (7.52) 
Completeness (%) 99.70 (99.53) 
Mean I/sigma(I) 22.6 (2.9) 
Wilson B-factor 61.48 
R-merge 7.8 (79.0) 
R-work 0.2066 (0.2804) 
R-free 0.2430 (0.3256) 
Number of non-hydrogen atoms 2855 
     macromolecules 2813 
     non-water solvent 20 
     solvent 22 
Protein residues 356 
RMS (bonds) 0.003 
RMS (angles) 0.81 
Ramachandran favoured (%) 93.49 
Ramachandran outliers (%) 3.25 
Rotamer outliers (%) 0.63 
Clashscore 4.20 
Average B-factor 65.24 
     macromolecules 64.96 
     non-water solvent 117.78 
     solvent 52.19 
Statistics for highest resolution shell are shown in parenthesis 
Molecular replacement using our 2.25 Å resolution p85-BH structure was performed in 
order to locate our protein within the determined electron density.  This was performed because 
the p85 (78-319) protein crystallized such that the BH domain dimer was oriented differently 
within the asymmetric unit.  A comparison between the structure orientations of p85-BH and p85 
(78-319) and an overlay of the two crystal structures are shown in Figure 4.9.  Visible electron 
density was lacking for residues 168-171 and 277-279 in both Chains, as well as residue 280 in 
Chain A. 
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Figure 4.9 Comparison of p85-BH and p85 (78-319) crystal structures.  Crystal structures 
of p85-BH to 2.25 Å (green) and p85 (78-319) to 2.75 Å (yellow).  A.  Comparison of the 
different orientations present within the unit cells of the p85-BH and p85 (78-319) crystals 
including a 90° rotation in Coot.  Unit cell axes are labelled.  B.  Overlay of the crystal 
structures of p85-BH and p85 (78-319).  Sulfate and cacodylate molecules are represented in 
stick format.  C.  Close up view of the potential binding pocket region with sidechains of 
involved residues, sulfate, and cacodylate in stick representation, and the 2Fo-Fc electron 
density map represented as a grey mesh and contoured to 1.0 σ. 
Comparing the overlaid crystal structures of p85-BH and p85 (78-319) showed that the 
domain structure remained consistent between the two.  The same residues of 113-297 were also 
visible between the two structures, no additional residues from the linker region were visible in 
the p85 (78-319) structure.  There were no visible electron densities that would have 
corresponded to binding of the PI4,5P2 to the p85 (78-319) structure.  Of interest was an increase 
in the size of one of the electron densities present in the potential novel binding pocket.  A 
cacodylate molecule, present within the crystallization buffer, fit well within this larger electron 
density region.  The second density within this region remained consistent in its size.  The 
potential binding pocket regions is shown with electron density map overlay in Figure 4.9 C. 
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4.2 Purification of PTEN (7-353, Δ286-309) 
The p85 protein has previously been shown to interact with and stimulate the lipid 
phosphatase activity of the protein PTEN (Chagpar et al., 2010; Rabinovsky et al., 2009).  
Obtaining a crystal structure of the p85-BH:PTEN Crystal complex would better elucidate the 
residues involved in this interaction, and the mechanism of the catalytic stimulation.  To pursue 
this we would need to generate quantities of PTEN Crystal suitable for complex formation and 
crystallization trials.  We also generated a PTEN Crystal C124S catalytically dead mutant for 
these experiments. 
Initial protein inductions of BL21-pGEX6P1-PTEN Crystal and PTEN Crystal C124S 
resulted in low protein yields that made pursuit of complex formation or co-crystallization 
experiments unfeasible.  Due to these low protein yields we examined a variety of alternate 
growth conditions, to determine which resulted in the greatest protein yield. 
Overnight incubations were performed at a temperature of 16 °C to slow the rate of PTEN 
induction with the intent of increasing total yields of soluble protein.  We transformed Rosetta 
cells with expression plasmids for our protein of interest for use as our expression system. 
Rosetta cells contain plasmids that code for tRNAs for codons more frequently used for certain 
amino acids in eukaryotic proteins than bacterial proteins, which can improve expression of some 
eukaryotic proteins in bacteria.  We also grew cultures in Hyper Broth in place of LB, with Hyper 
Broth containing a glucose supplement mixture to increase the available nutrients for bacteria 
growth to encourage larger bacterial yields. 
Comparing results of cultures grown under combinations of the described conditions it 
was determined that growth using BL21 cells in Hyper Broth with our standard overnight 
incubation temperatures would be pursued for future growth.  This combination resulted in 
substantial increases in total bacterial wet weight per litre (before ~4 g/L, altered conditions ~9 
g/L) and a greater protein yield following harvesting. 
For both individual batch protein purification and large scale ÄKTA Purifier Glutathione-
Sepharose column purification the PTEN proteins suffered from extensive precipitation upon 
incubation with 3C Prescission Protease for cleavage of the GST-tag.  During this 72 hour 
incubation at 4ºC, samples of the PTEN proteins that did not have 3C Prescission Protease also 
precipitated.  These challenges were not resolved and attention was redirected to aspects of the 
project that were progressing well. 
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4.3 Size exclusion chromatography analysis of complex formation between bovine p85 
fragments and Rab5 
As the p85 protein has been shown to interact with Rab5 and stimulate the intrinsic 
GTPase activity of Rab5 (Chamberlain et al., 2004) we wished to obtain structural information 
of this protein complex to better visualize the residues important for this interaction and catalytic 
function.  In order to accomplish this we needed to purify a complex between the p85-BH domain 
and Rab5 so that we could prepare crystallization trials for the obtained complex. 
Both p85-BH and Rab5 proteins were generated in BL21 cells as GST-tagged proteins, 
purifying these proteins by binding the GST-tag to Glutathione-Sepharose media and cleavage 
of the GST-tag.  Protein concentrations were determined using NanoDrop analysis with 
concentrations checked via SDS-PAGE of the protein against known concentrations of BSA 
visualized with Coomassie Blue staining.  Equimolar amounts of both proteins were mixed, 
incubated together at room temperature, and underwent SEC to separate protein complex formed. 
Due to the similarity in MW between the p85-BH fragment (~24.15 kDa) and Rab5 
(~23.66 kDa) identification of proteins present in the SEC fractions was determined using 
western blot analysis rather than Coomassie Blue stain gels.  Differences were observed between 
Rab5 calculated concentrations using NanoDrop versus observed concentration based on 
Coomassie Blue stained gels loaded with known concentrations of BSA.  Variation was also 
observed between batches for the fractions in which the Rab5 fragment eluted from the column, 
in some cases suggesting complex formation between p85-BH and Rab5, whereas others 
suggested co-elution of individual proteins without formation of complex.  SEC chromatograms 
for different preparations of Rab5 mixed with p85-BH are shown in Figure 4.10.  Western blots 
of elution fractions from these protein preparations are shown in Figure 4.11. 
These results suggest that generation of a p85-BH:Rab5 complex may be possible, but 
that further optimizations will be required to obtain concentrations of the protein complex 
suitable for pursuing crystallization experiments.  These were not pursued due to time constraints 
within my graduate studies program. 
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Figure 4.10 SEC chromatograms for p85-BH:Rab5 complex formation experiments.  
Purified samples of p85-BH and Rab5 proteins were mixed in equimolar amounts, incubated 
at room temperature, and underwent SEC to detect formation of a p85-BH:Rab5 protein 
complex.  A. Chromatogram for SEC purification Experiment A.  B.  Chromatogram for SEC 
purification Experiment B. 
4.4 Size exclusion chromatography and Native PAGE of recombinant full-length human 
p85 wild-type and mutants 
In order to determine if mutations found in the p85 SH3 and BH domains alter protein 
oligomerization, we performed SEC coupled with Native PAGE.  Identifying mutants that affect 
the protein oligomerization state might clarify some of the different crystallization behaviours 
observed for several of the p85-BH mutants. 
To this end we analysed full-length human p85 protein wild-type, and containing cancer-
associated or engineered point mutations.  Cancer-associated mutations were located in the SH3 
domain (L30F, F69L, I82F), or the BH domain (E137K, I177N, E217K, R262T, K288Q, or 
E297K) (Cheung et al., 2011; Ross et al., 2013).  Engineered mutations examined (D168R, 
E212R, H234D, Q241D) were previously shown in our lab to decrease PTEN binding (Figure 
1.10) and H234D and Q241D are both present within our potential novel binding pocket. 
Samples of each protein at 0.70 mg/mL were loaded on the Superdex 200 SEC column 
connected to the ÄKTA Purifier, with their chromatograms recorded.  Samples of the input and 
peak elution fraction based on the SEC chromatogram were loaded onto Native PAGE gels for 
analysis.  The overlays of the various protein SEC chromatograms are shown in Figure 4.12.  
Corresponding Native PAGE gel images are shown in Figure 4.13.  Elution volumes for each 
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Figure 4.11 Western blot analysis of p85-BH and Rab5 complex formation SEC 
experiments.  Equimolar quantities of p85-BH and Rab5 were incubated together at room 
temperature prior to SEC purification.  Fractions were selected for Western blot analysis based 
on absorbance at 280 nm during SEC to check for presence of one or both proteins in the 
elution fractions.  Western blots were probed with p85-specific or Rab5-specific antibodies 
and visualized using infrared secondary antibodies and a LICOR ODYSSEY infrared scanner. 
Protein bands of interest indicated using red arrows.  A.  Western blot using anti-p85-BH (left) 
or anti-Rab5 (right) primary antibodies from SEC Experiment A showing co-elution of p85-
BH and Rab5 only in later fractions.  B.  Western blot using anti-p85 (left) or anti-Rab5 (right) 
primary antibodies from SEC Experiment B showing Rab5 eluting in early fractions as well as 
later fractions. 
protein, and the corresponding MW, can be found in Table 4.6.  The calculated elution volume 
for a p85 dimer (170 kDa) is 12.13 mL, and for a p85 monomer (85 kDa) is 13.63 mL. 
All proteins examined had elution volumes that corresponded with molecular weights that 
best approximated those of a protein dimer.  The p85 E137K and p85 R262T proteins both had 
more noise in their chromatogram signals potentially due to increased protein degradation, but 
still had their primary elution peak within the dimer range as well.  Peak elution fractions were 
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Figure 4.12 Size exclusion chromatography chromatograms for full-length human p85 
and mutants.  Overlay of SEC elution chromatograms of full-length human p85 wild-type and 
containing endometrial cancer mutations in the SH3 (L30F, F69L, I82F, A) or BH (I177N, 
E217K, E297K, B) domain, bladder cancer mutations (E137K, R262T, K288Q, C), or 
engineered BH domain mutations (D168R, E212R, H234D, Q241D, D) to observe the 
oligomerization state of the proteins.  The expected elution volumes for a p85 dimer (170 kDa, 
12.13 mL) and monomer (85 kDa, 13.63 mL) are displayed for reference. 
further analysed using Native PAGE gels and these results were consistent with dimer formation 
(Figure 4.13). 
At the protein concentrations we performed the SEC experiments at the mutants did not 
appear to significantly affect p85 oligomerization status. 
4.5 MALS analysis of recombinant full-length human p85 
In order to determine how the p85 concentration used in the SEC experiments may have 
affected the observed oligomerization state of our protein, we analyzed varying concentrations 
of full-length human p85 using the Wyatt MALS System with Refractive Index Measurement 
operated by the PCCF which was connected to a Superdex 200 Increase SEC column and an 
ÄKTA Purifier. 
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Figure 4.13 Native PAGE analysis of SEC fractions for full-length human p85 and 
mutants.  Samples of the protein solution loaded for SEC analysis (Input) along with a sample 
from the elution fraction with the highest absorbance value (Peak) were analyzed using Native 
PAGE analysis to verify the oligomerization state determined by SEC.  We examined full-
length human p85 wild-type, as well as proteins containing point mutations that were BH 
domain engineered (D168R, E212R, H234D, Q241D), endometrial cancer associated 
mutations in the SH3 (L30F, F69L, I82F) or BH (I177N, E217K, E297K) domains, or bladder 
cancer associated mutations (E137K, R262T, K288Q).  Protein was visualized by Coomassie 
blue staining.  Dimer locations are indicated with red arrows. 
We analyzed human p85 samples at concentrations of 4 mg/mL, 2 mg/mL, 1 mg/mL, 0.7 
mg/mL, and 0.5 mg/mL.  Overlays of the MALS chromatograms are shown in Figure 4.14.   
Summary of peak elution volume and determined MW for the different p85 concentrations are 
shown in Table 4.7. 
For the 4 mg/mL p85 concentration there was a great deal of aggregation observed in the 
protein sample.  Also observed in this sample was an elution peak that corresponded to a 
molecular weight of approximately 130 kDa.  This elution peak was observed to have a tailing 
end, and the molecular weight distribution for the peak showed larger molecular weight 
population at the start of the peak, and lower molecular weight at the end of the peak, suggesting 
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Table 4.6 Elution volumes and corresponding MW for SEC analyzed p85 
Protein Name Elution Volume 
(mL) 
Calculated MW 
(kDa) 
Dimer/Monomer 
p85hu wild-type 12.02 178.9 Dimer 
p85hu L30F 12.44 147.5 Dimer 
p85hu F69L 12.41 149.5 Dimer 
p85hu I82F 12.29 158.0 Dimer 
p85hu I177N 12.23 162.4 Dimer 
p85hu E217K 12.27 159.5 Dimer 
p85hu E297K 12.34 154.4 Dimer 
p85hu E137K 12.32 155.8 Dimer 
p85hu R262T 12.20 164.7 Dimer 
p85hu K288Q 12.14 169.3 Dimer 
p85hu D168R 12.01 179.7 Dimer 
p85hu E212R 12.11 171.7 Dimer 
p85hu H234D 11.9 181.4 Dimer 
p85hu Q241D 12.05 176.5 Dimer 
Table 4.7 Elution volumes and corresponding MW for MALS analysis of full-length p85 
Concentration Elution Volume (mL) Calculated MW 
(kDa) 
Dimer/Monomer 
4 mg/mL 13.18 130 Mixture 
2 mg/mL 11.7 128 Mixture 
1 mg/mL 12.34 111 Mixture 
0.7 mg/mL 12.65 72 Monomer 
0.5 mg/mL 12.86 88 Monomer 
a mixture of dimeric and monomeric population present within the same peak.  The resolution of 
the column was not high enough to determine relative amounts of the different oligomeric states. 
The 2 mg/mL concentration of p85 had much less aggregation present.  The elution peak 
at this protein concentration suggested a molecular weight of approximately 128 kDa, once more 
potentially a mix of protein dimers and monomers.  The 1 mg/mL p85 concentration had an 
elution peak corresponding to a molecular weight of approximately 111 kDa and had a very 
uniform molecular weight distribution.  The 0.7 mg/mL p85 concentration had an elution peak 
corresponding to a molecular weight of approximately 72 kDa, which is smaller than the 
calculated molecular weight for the p85 monomer and there was a shifting molecular weight 
distribution across this peak.  The 0.5 mg/mL p85 concentration had an elution peak 
corresponding to a molecular weight of between 80-90 kDa, suggesting monomeric p85. 
66 
Figure 4.14 Multi-angle light scattering chromatograms for full-length p85.  
Chromatograms for the MALS results for full-length p85 at several concentrations. 
Differential refractive index (RIU) is the left y-axis, mean square radius (nm2) is the right y-
axis, elution volume (mL) is the x-axis, with the aggregate (A, red dots), and elution peak (P, 
green dots) are indicated in red boxes. 
4.6 Lipid binding of p85 SH3 and BH domains using phosphatidylinositol phosphate lipid 
strips 
The p85 protein is known to be a key regulatory protein of the PI3K/PTEN pathway, one 
of its mechanisms acting through binding to PTEN and facilitating the PTEN-mediated 
dephosphorylation of PI3,4,5P3 to PI4,5P2.  Since the SO4 ions observed in our p85-BH structures 
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could serve as a structural analogue for PO4, and the lipids in the PI3K/PTEN pathway contain 
PO4 groups, additional experiments were carried out to determine if the p85 BH domain could 
directly bind various phospholipids.  Due to the high concentrations of SO4 ions present within 
the crystallization solutions potentially preventing physiological binding partners from being able 
to bind within the potential novel binding pocket we wished to pursue binding experiments using 
soluble protein free of the high SO4 concentrations.  To these ends we performed PIP lipid strip 
analysis using several p85 protein fragments to check for binding between our protein and various 
lipids. 
4.6.1 Determination of p85 regions required for lipid binding 
To determine which regions of the p85 protein were required for any observed lipid 
binding we probed PIP lipid strips with 37 nM of p85 (1-319), p85 (78-319), or p85-BH protein. 
PIP strips probed with no protein were used as a control.  Following anti-p85 antibody probing 
and visualization using LICOR ODYSSEY software we could clearly see signal indicating that 
p85 protein bound to several lipids. 
The analyzed PIP Strips are shown in Figure 4.15. 
All three p85 fragments showed binding to the following lipids: (PI3P, PI4P, PI5P) > 
(PI3,4P2, PI3,5P2, phosphatidic acid) > (PI4,5P2, PI3,4,5P3) > lysophosphatidic acid.  Lipids 
grouped based on degree of binding observed. The p85 (1-319) protein fragment showed less 
signal but the same binding profile.  As all three p85 fragments were able to bind to the lipid this 
demonstrates that the BH domain on its own is capable of lipid binding.  All lipids that we 
observed binding were negatively charged and contained phosphate groups on the periphery, 
while we observed little binding for non-phosphorylated lipids such as PI and uncharged lipids 
or those without peripheral phosphates. 
4.6.2 Determination of concentration dependence of observed p85 lipid binding 
In order to determine that the lipid binding observed was concentration dependent, and 
would not provide the same signal intensity with lower protein concentrations used, we 
performed additional PIP strip analysis using 37 nM, 3.7 nM, and 0.37 nM of p85 (78-319). 
PIP strips from the concentration dependence experiments are shown in Figure 4.16. 
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Figure 4.15 PIP strip analysis of p85 lipid binding.  To test if p85 has lipid binding ability, 
and to determine which regions are required for any observed binding, we probed PIP strips 
containing various lipids bound to nitrocellulose with equimolar amounts of p85 (1-319), p85 
(78-319) or p85-BH protein.  PIP strips probed with no protein were used for control.  Bound 
protein was detected using anti-p85-BH primary antibody, with an infrared secondary antibody 
and visualized using a LICOR ODYSSEY infrared scanner. 
There was a clear correlation between the strength of signal observed and the 
concentration of p85 (78-319) that had treated the individual PIP strips.  In addition, at the 
decreased protein concentrations the same lipid binding profile was seen for the p85 (78-319) 
protein fragment as at higher concentrations. 
These results raise the interesting possibility that the potential new binding pocket seen 
within the p85 BH domain can bind phospholipids. 
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Figure 4.16 Concentration dependence of p85 (78-319) PIP strip binding.  To determine if 
the observed lipid binding behaviour of p85 (78-319) was concentration dependent we 
incubated PIP strips containing various lipids bound to nitrocellulose with decreasing 
concentrations of p85 (78-319).  PIP strips probed with no protein were used for control. 
Bound protein was detected using an anti-p85-BH primary antibody, with an infrared 
secondary antibody and visualized using a LICOR ODYSSEY infrared scanner. 
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5.0 Discussion 
5.1 Combining High Resolution Structural Data with Protein Function Studies 
The combination of high resolution structural data with the data collected from protein 
functional studies allows for a synergistic analysis of the data collected from both methods, 
resulting in more in depth understanding of the research subject.  One excellent example, which 
served as an inspiration for the work pursued in this project, was Huang et al. crystallization of 
the p110α protein in complex with a p85 fragment containing the N-terminal SH2 domain and 
the inter-SH2 domain region important for p110 binding (Huang et al., 2007).  Based on the 
crystal structure obtained for the protein complex they examined the locations of various cancer-
associated mutations in p110α to determine which would alter the interactions between p110ɑ 
and the p85 fragment.  One example was for mutations located in the p110 α C2 domain that had 
previously been thought to alter lipid binding affinity were located within hydrogen-bonding 
distance of several residues on the p85 inter-SH2 domain, meaning that mutations could likely 
alter the interaction between these two proteins rather than lipid binding affinity (Huang et al., 
2007). 
Using these different techniques in tandem can allow for improved interpretation of 
experimental observations, granting deeper understanding to the mechanisms responsible for 
observed phenotypes.  They can serve to reinforce theories on the potential mechanisms of 
interaction, and also help to correct misinterpretations that could be made from data from one 
technique in isolation.  By observing disparities between the results of different techniques it can 
serve to guide further experiments in order to determine the correct interpretations.  Agreement 
between data collected across different techniques can increase confidence in the interpretation 
of the data. 
5.2 Insights from bovine p85 BH domain crystal structures 
Crystallization progress for our various fragments of bovine p85 revealed identical visible 
residues despite the different length protein fragments used for crystallization.  All of our crystal 
structures for p85-BH, p85 (78-319) and p85 (1-319) had residues 113-297 visible in both 
monomers of the BH domain homodimer within the asymmetric unit.  These are consistent with 
the human p85 BH domain previously solved (PBI: 1PBW) where residues 115-298 were 
visualized (Musacchio et al., 1996). 
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The similarity between the p85 (1-319) and p85-BH regions visible can most likely be 
explained by a proteolytic cleavage of the p85 (1-319) protein during the crystallization process. 
As the previous crystallization of the p85 SH3 domain (Liang et al., 1996) revealed well defined 
structure we would expect this domain to be visible in a crystal containing both SH3 and BH 
domains.  Another possibility is that the SH3 does not have a single orientation when expressed 
with the BH domain, so mobility of this domain may have prevented the visualization of the 
domain within the X-ray diffraction data.  However, we note that all the p85 structures we 
determined shared nearly identical unit cell dimensions (~84, 92, 93, 90, 90, 90).  If the SH3 
domain was present within the crystal we would anticipate a difference in the observed unit cell 
dimensions to account for the additional domain present, so with no significant difference 
observed it is more likely that the SH3 domain was excluded during the crystallization process. 
The reason behind the altered orientation of the p85 (78-319) protein within its 
asymmetric unit when compared to the p85-BH has several possibilities.  Due to the consistency 
of the unit cell dimensions (84.12, 91.56, 93.14, 90, 90, 90) with the p85-BH crystals it is possible 
that the additional residues of the inter-domain linker region were cleaved similar to what is 
suspected of the SH3 domain for p85 (1-319).  However, it is notable that examining the packing 
of molecules within the p85 (78-319) crystal X-ray diffraction data that a large region lacking 
protein molecules and electron density is located adjacent to the N-terminal region of the protein 
structure (Figure 5.1).  It is also possible that the inter-domain linker region is present, but highly 
flexible, having no single predominant conformation, resulting in the lack of visible density in 
that region.  However, the observed gaps could also correspond to solvent channels present within 
the protein crystals.  With our current data collected a definitive answer to this difference in 
protein orientation cannot be made. 
5.2.1 Observations from nucleotide, phosphoamino acid, and phospholipid additive analysis 
Attempts to obtain structural information of the p85-BH with potential binding partners 
bound proved unsuccessful.  None of our additive cocktails of nucleotides (ATP, GTP, and 
GppCp), phosphoamino acids (pSer, pThr, pTyr), or phospholipids (I1,3P2, I1,4P2, I1,5P2, 
I1,3,5P2) showed any notable regions of increased binding to suggest interaction between protein 
or additive.  The same was true for our individual 8 carbon chain phosphatidylinositol lipids soaks 
(PI4P; PI3,4P2; PI4,5P2; PI3,4,5P3) as well as our PI4,5P2 soak with p85 (78-319). 
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Figure 5.1 Crystal packing of p85 (78-319).  Example region of packing between various BH 
domain dimers present in our p85 (78-319) protein structure.  A homodimer of the p85 (78-
319) is shown with yellow carbons, with symmetry molecules shown as strings of alpha-
carbons in grey.  Large open cavities are visible between the protein molecules, with channels
that connect the cavities throughout the crystal.  The lower image is rotated 45° relative to the
top image to provide a different perspective of the crystal packing.
One possible explanation for this lack of observed binding is that these molecules do not 
interact with the p85 BH domain.  All additives were selected as candidates based on the 
coordinated SO4 ions observed within our structure, with PO4 being a physiologically relevant 
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ion of a similar size and charge.  These observed coordinated ions may not correspond to a 
physiological activity of the protein, and instead only exist as a crystallographic artifact. 
Another explanation is that the high concentrations of SO4 ions present within the 
crystallization screens (~1.5 M) excluded any physiologically relevant molecules from being able 
to bind to regions they interact with.  Because the concentrations of additives we were using were 
in the ranges of 10 – 30 mM the SO4 ions were present at a concentration at least 50 times greater 
than that of the additives.  This excess may have forced the interaction with SO4 ions to 
predominate over any physiologically relevant interactions that could normally occur in 
biological systems.  Densities corresponding to SO4 or cacodylate molecules were also observed 
for p85 (78-319) crystallization screens in which a 1:1 molar ratio of 8-carbon PI4,5P2 was added 
to the protein solution prior to crystallization. 
5.2.1.1 Future experiments to check for binding between additives and p85 
In order to determine if any of the small molecules we have been examining bind to the 
p85 protein we will want to examine these interactions in solution and free of the high SO4 ion 
concentration present under crystallization conditions.  Several experimental techniques could be 
pursued to this end. 
A technique that we will avoid using is surface plasmon resonance.  Previous work 
performed by myself and others in the Anderson Lab have found the p85 protein does not yield 
good experimental data using this technique.  The protein would bind to both activated and 
inactivated regions of the chips used for performing the experiments, causing significant 
background noise and preventing accurate baseline determination or data collection.  Extensive 
attempts to optimize the activation and deactivation conditions of the experimental chip, 
concentrations of proteins used, buffers used for protein storage and experimental stages, as well 
as solutions for regeneration of the experimental chip failed to overcome these experimental 
difficulties.  This high background prevented usable data collection using this method.  We will 
place an emphasis on solution-based techniques for future binding experiments, to remove the 
challenges encountered when binding the protein to a surface. 
One technique would be the use of isothermal titration calorimetry.  Descriptions of the 
technique and various applications for protein interaction analysis by isothermal titration 
calorimetry are provided in (Ghai et al., 2012; Liang, 2008; Velazquez-Campoy et al., 2004).  
74 
Briefly, recording the changes in energy required to maintain a constant temperature for the 
calorimeter following addition of ligand to a vestibule containing our protein solution of interest 
(or adding protein to a vestibule of potential ligand). This allows determination of binding and 
dissociation constants of interactions, as well as the number of ligand molecules interacting with 
each protein molecule.  Isothermal titration calorimetry has the advantages of using relatively 
small amounts of sample, not requiring any modification or immobilization of our protein of 
interest, and a large range of kinetic data that can be determined per experiment. 
Another method for investigating potential interactions would be fluorescence anisotropy. 
A description of the experimental methodology, applications, and considerations is provided in 
(Heyduk et al., 1996).  Briefly, fluorescence anisotropy utilizes the behaviour of macromolecule 
rotation within solution, in which larger molecules rotate more slowly than smaller molecules. 
Coupling one type of molecule to a fluorophore and allowing it to bind to another molecule results 
in an increase in size and decreased rate of rotation. This leads to a measurable increase in the 
polarity of the light emitted which is recorded by the instrument.  Using a fluorophore-bound 
potential ligand within the reaction chamber we can titrate in increasing amounts of our protein 
of interest (without fluorophore).  If our protein of interest binds to the ligand it will lead to a 
decrease in the ligands rate of rotation, having bound to become part of a larger complex, 
observed by the change in polarity.  From the observed change in polarity we can determine the 
binding constants for the interaction between protein and ligand.  Fluorescence anisotropy has 
the advantages of using small amounts of sample, and the determination of binding kinetics 
through experimental data.  Modification of the ligands is required, through coupling of the 
fluorophore, which could potential alter the binding behaviour, so control experiments of adding 
protein to fluorophore alone to test for non-specific interactions may be required.  Fluorophore-
coupled phosphatidylinositol lipids and DNA are commercially available, and techniques for 
fluorophore-coupling proteins are also well characterized and fluorophores with reactive groups 
commercially available (Waggoner, 1995; Echelon Biosciences Inc., Salt Lake City, UT; Thermo 
Fisher Scientific). 
For both isothermal titration calorimetry or fluorescence anisotropy experiments we can 
use various fragments of p85 (full-length, SH3 and BH domains, BH domain alone) in order to 
also determine the regions important for observed interactions.  The dissociation constants 
determined using these experiments can then be used to determine levels of ligand required to 
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improve our chances of visualizing it through crystallization, either to compete with the present 
SO4 ions or through searching for different crystallization conditions containing lower 
concentrations of sulfate compounds. 
If binding between the p85 BH domain and additives is observed, we can further 
characterize the residues important for the interaction through mutagenesis studies.  Initial 
experiments could focus on the residues that compose the potential novel binding pocket 
observed (K224, R228, H234, W237, and Q241).  Characterization of this region, including 
analysis of mutations, is discussed in later sections. 
5.2.2 Interpretation and future analysis of potential post-translational modification of C146 
The consistent presence of additional electron density between residues C146 and H180 
in our various p85 BH domain structures was an unexpected observation.  Our comparisons of 
various oxidized states of cysteine, as well as the nitrosylated S-nitrosocysteine, against the Fob-
Foc difference map obtained during refinement of p85-BH with an Ala replacing C146 showed 
that S-nitrosocysteine best fit the electron density (Figure 4.6).  For this reason further 
refinements of our determined structures used S-nitrosocysteine residues at amino acid 146. 
A summary discussing cysteine nitrosylation and its roles in protein function and 
signalling pathways is provided in (Gould et al., 2013).  As a brief introduction to the roles of 
cysteine nitrosylation, S-nitrosylation is the addition of a –NO group to the thiol group of the 
cysteine sidechain.  Nitrosylated cysteine residues have been identified in proteins belonging to 
a wide variety of tissues, with many present in mitochondrial enzymes important in various 
metabolic and energy producing pathways (Gould et al., 2013).  Due to the sensitivity of neuronal 
cells to excess levels of NO, neuronal cells have been specifically examined for the presence of 
nitrosylated cysteine residues, with proteins including GAPDH, glycogen phosphorylase, heat 
shock protein 72, ß-tubulin, and actin amongst others have been identified (Jaffrey et al., 2001).  
The effect of excessive NO species and protein S-nitrosylation has also been examined for its 
role in various neurodegenerative diseases, reviewed in Nakamura and Lipton 2016, as well as 
cancers, reviewed in Monteiro et al. 2015 (Monteiro et al., 2015; Nakamura and Lipton, 2016). 
Examination of previously characterized post-translational modifications in p85 have 
identified polyubiquitination, acetylation, and phosphorylation, but no modification to cysteine 
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residues (UniProtKB ID P27986).  If this is a physiologically occurring post-translational 
modification of the p85 protein it has, to our knowledge, not previously been characterized. 
An important next step will be to determine whether this post-translational modification 
occurs in eukaryotic cells.  Without such confirmation it is possible that the observed 
modification is an artifact of the bacterial expression of our protein fragment. 
Some reviews that discuss cysteine nitrosylation and some of the methods of detecting 
these post-translational modification are provided in (Gould et al., 2013; Murray and Van Eyk, 
2012).  One of the techniques used for detections of S-nitrosocysteine is the biotin switch assay 
(Jaffrey et al., 2001).  Briefly, unmodified cysteine residues are blocked, then S-nitrosocysteine 
is reduced by exposure to ascorbate and the exposed sidechains are reacted with biotin.  This 
allows for purification of the previously nitrosylated protein through use of avidin or streptavidin 
purification of the biotin labelled proteins of interest.  These proteins can then be identified using 
protein specific antibodies, or using mass spectrometry.  There are also anti-S-nitrosocysteine 
antibodies commercially available that can be used for western blot detection of proteins 
containing S-nitrosocysteine (Abcam Cat# ab94930).  These experiments can be performed with 
both full length p85, and our p85-BH fragment, as C146 is the only cysteine residue present 
within the p85 BH domain.  Doing so will allow us not only to determine whether nitrosylation 
occurs to p85 in eukaryotic cells, but also if C146 is converted to S-nitrosocysteine. 
If we detect nitrosylation of the p85 protein we can perform mutagenesis studies on C146 
to determine the effect of such mutations on stability of the p85 protein.  Further experiments 
could also be performed to determine how C146 mutation affects interaction with known protein 
binding partners p110, PTEN, and Rab5 through co-immunoprecipitation or pull down 
experiments (Carpenter et al., 1990; Chagpar et al., 2010; Chamberlain et al., 2004).  In addition, 
various functional assays can be performed to determine how a C146 mutation alters the activities 
of these various binding partners: kinase assays for p110 activity, GAP assay for Rab5, and lipid 
phosphatase assays for PTEN (Liu and Li, 1998; Myers et al., 1997; Witt and Roskoski, 1975). 
The results of these studies will provide us with a greater understanding of the role that 
cysteine nitrosylation plays in structural and functional regulation of the p85 protein, its 
interactions with various binding partners, and any role in the regulation of the PI3K/PTEN 
pathway. 
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5.2.3 Effect of cancer-associated and engineered mutations on the bovine p85 BH domain 
Having collected X-ray diffraction data for p85-BH containing the cancer-associated 
mutations E137K, E217K, R262T, and E297K, as well as the engineered mutation R228E, we 
can examine any structural changes these mutations formed in the p85 BH domain. 
None of the cancer-associated mutations crystallized resulted in any major structural 
changes for our protein.  This is not surprising given the great similarity in crystallization 
conditions that were able to obtain crystals for the wild-type protein and these mutants. 
Crystallization condition trials had yet to be performed for the K288Q mutant, but if it were to 
also crystallize using very similar conditions to all the others this would lead us to suspect, prior 
to collecting X-ray diffraction data for confirmation, that the changes to the overall domain 
structure would be limited. 
The I177N mutation (F177N in bovine) is a particularly interesting cancer-associated 
mutation that we had been working on.  It did not crystallize using conditions similar to our 
previous p85-BH crystals, and currently crystallization condition screens are underway to 
identify conditions that will yield diffracting crystals.  Due to the position of residue 177 being 
one of the residues that forms the BH domain dimerization pocket for the M176 of the opposite 
BH domain (Musacchio et al., 1996) mutation of this residue could disrupt the dimerization 
interface in the crystal structure.  Residues important for this BH domain dimerization site are 
shown in Figure 5.2 for the bovine and human proteins.  There is some debate regarding whether 
the dimerization between the BH domains exists in physiological systems, with a study by Harpur 
et al. showing a weak interaction with a dissociation constant in the mM range (Harpur et al., 
1999), whereas a more recent study by LoPiccolo et al. using a protein fragment containing p85 
residues 78-322 did not detect any oligomerization (LoPiccolo et al., 2015).  It would be 
interesting to see if any disruption of that crystallographic BH domain interface would disrupt 
this site of homodimerization and require the formation of different crystal contacts for 
crystallization, or if it leads to any large changes to the overall structure of the BH domain. 
As the crystal structures for the obtained cancer-associated mutations are all found on the 
surface of the p85 BH domain and cause negligible structural differences to the domain they may 
instead exert effects through alterations in interaction profiles with binding partners that could 
contribute to the associated cancerous phenotype.  In order to examine this we can use proteins 
containing the mutations for isothermal titration calorimetry or fluorescence anisotropy  
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Figure 5.2 Homodimerization region overlay of human and bovine p85 BH domains.  A.  
Examination of the BH domain homodimerization interface of bovine p85 proteins where 
M176 of one protein fits into a hydrophobic pocket generated by L161, F177, and V181 of the 
other protein.  Sidechains are represented in stick format, and the two BH domains are coloured 
in green and cyan for differentiation.  B.  Overlay of the BH domain homodimerization 
interface between our bovine p85 BH domain structure and the previously solved human p85 
BH domain structure (Musacchio et al., 1996: PDB: 1PBW).  Sidechains involved are 
represented in stick format, with F177 found in the bovine protein, and I177 found in the human 
protein.  The two bovine BH domains are coloured in green and cyan, and the two human BH 
domains are coloured in yellow and orange for differentiation. 
experiments as mentioned above.  By comparing the experimental results of these mutant proteins 
with those of wild-type protein for molecules that showed detectable binding we can see if the 
mutants result in increased or decreased interaction with these binding partners. 
In order to determine if the cancer-associated mutants detected in bioinformatics screens 
(Cheung et al., 2011; Ross et al., 2013) are sufficient to induce a cancerous phenotype we can 
knockout wild-type p85 from cells and transfect these cells with the various cancer-associated 
mutant p85 proteins and assay for their oncogenicity.  For those mutants that result in 
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transformation we can examine altered phosphoAKT (the activated form; pAKT) levels, contact 
inhibition, motility, and colony formation in soft agar. Analysing results from these experiments 
will further elucidate the mechanism behind their oncogenicity and their biological effects. 
 
5.2.4 Observed potential novel binding pocket 
 One of the most interesting observations made within our p85-BH structure were a pair 
of highly coordinated electron densities oriented by residues K224, R228, H234, W237, and 
Q241 in both BH domains.  Based on the size of the electron densities seen, and the contents of 
our crystallization buffer, SO4 ions have currently been modeled in these regions, and they agree 
well with the observed densities. 
 In our p85 (78-319) structure one of these observed electron densities was larger than in 
other structures.  Based on the components of the crystallization buffer we modeled a cacodylate 
ion into this larger density and it agrees with this density better than the previously modeled SO4.  
Based on this observation it is worth noting that the ions modeled within these densities are based 
on the best agreement of ions present in the crystallization solution with the X-ray diffraction 
data, but do not have further confirmation experiments.  Therefore it is possible that cacodylate 
molecules were bound in our p85-BH structures, or that the p85 (78-319) increased density is a 
SO4 that has larger mobility within the structure.  We cannot confirm which ions were bound, but 
they are chosen based on agreement to the X-ray diffraction data. 
 The fitting of SO4 ions within the observed densities served to guide our selection of 
potential binding partners that we treated the crystals with for our additive treatments discussed 
above.  Due to the structural similarities between SO4 ions and PO4 ions, and the frequent usage 
of PO4 in biological systems, we focused our additive screens on molecules containing PO4 
molecules (nucleotides, phosphoamino acids, and phospholipids). 
 
5.2.4.1 Comparison of potential binding pocket region in bovine and human p85 
 An overlay of the bovine p85-BH crystal structure we have solved and the previously 
solved human p85 BH domain ((Musacchio et al., 1996) PDB: 1PBW) is shown in Figure 5.3. 
 While there are shifts to the overall positions of structural features, the overall secondary 
structures and orientation are conserved between the human and bovine proteins.  In the potential 
binding pocket region the important residues of K224, R228, H234, and W237 have largely 
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conserved final sidechain positions, with the R228 sidechains using different orientations in order 
to end in the same region despite a shift in the loop positions between structures.  Residue Q241 
displays different sidechain positioning between the two species, with bovine facing towards the 
coordinated SO4 ions observed in the structure whereas in the human structure the Q241 sidechain 
is oriented directly away from this region.  If this region is found to be important for binding to 
different partners, mutational studies of Q241 can determine if this residue plays a direct role in 
binding, adjusting sidechain orientation upon presence of ligand for example, or a nearby residue 
that does not have a role in binding. 
5.2.4.2 Effect of mutations on the potential binding pocket 
Comparison of the structures of p85-BH and p85-R228E it was observed that one of the 
coordinated densities around the potential binding pocket region vanished in the mutant structure. 
As this residue was identified as being important for the interaction between p85 and PTEN, this 
visible difference is of interest for further analysis. 
Figure 5.3 Overlay of potential binding pocket for bovine and human p85.  Comparison 
of the sidechain orientation for residues involved in the potential binding pocket for both the 
bovine p85-BH structure (green), and the previously solved human p85 BH domain (magenta; 
Musacchio et al., 1996; PDB: 1PBW).  Structures are represented in cartoon format, with 
important sidechains, and SO4 ions from the bovine structure, represented in stick format. 
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 If this region is important for a direct interaction between PTEN and the p85 BH domain 
we would expect that our experiments described previously would show binding between the BH 
domain and phosphoamino acids.  If this is the case we could use this information to search for 
residues that are phosphorylated on the surface of the PTEN protein that could be accessible for 
interaction, and use that information to assist modelling analysis prior to obtaining co-crystal 
structural information. 
 It would also be possible that the p85:PTEN interaction may be indirectly mediated 
through the presence of a phosphatidylinositol lipid at the protein interface, likely PI4,5P2 or 
PI3,4,5P3 due to their role in the PI3K/PTEN pathway.  Observed interaction between the p85 
BH domain and phospholipids determined by experiments described previously provides support 
for this possibility.  If this is the case then for both modelling studies and co-crystallization trials 
it would be important to include this lipid in attempts to determine the structure of the p85:PTEN 
complex. 
 Determining the effect of mutations on any experimentally observed binding can provide 
further support and evidence for these analyses.  We have p85-BH containing K224-5E, R228E, 
H234D, and Q241D, which could be used for isothermal titration calorimetry or fluorescence 
anisotropy to determine any changes to the kinetics of interaction caused by the mutations.  
Previously we obtained crystals for the p85-BH-K224-5E and p85-BH-Q241D mutations, but X-
ray diffraction data was not collected for these mutants.  Observing any effects that these 
mutations have on the potential binding pocket region could also provide additional insight into 
potential binding interactions.  Crystals were obtained for p85-BH-H234D, but they did not 
diffract across a wide enough range to obtain an X-ray diffraction data set suitable for processing.  
Identification of new crystallization conditions for the p85-BH-H234D mutant could yield 
crystals of a different form that diffract better. 
 The mutants described above for the potential binding pocket residues are charge reversal 
mutations.  It may be that this dramatic change of charge altered binding and lead to the observed 
electron density difference in our R228E mutant structure.  If ligand binding is observed, and the 
above mutations affect this binding, examination of mutations of those residues to Ala may be 
warranted to ensure that it is the presence of the wild-type residue that is important in attracting 
the binding partner rather than an off-target repulsion from the mutant residue that is leading to 
the observed results. 
82 
 
 
5.2.4.3 Future experiments for characterization of the potential binding pocket 
 Many of the experiments to help further characterize the potential binding pocket were 
described previously.  Experiments that displayed binding between the various compounds and 
p85 would be repeated with protein containing mutations of the various residues near the binding 
pocket; K224-5E, R228E, H234D, and Q241D, or mutating the residues to Ala.  These would 
help to identify the roles these residues play with interacting to various binding partners. 
 Collection of X-ray diffraction data for the crystallized p85-BH-K224-5E and p85-BH-
Q241D would allow us to see how these mutations affect the region around them.  Identification 
of new crystallization conditions for p85-BH-H234D could yield crystals that diffract well 
enough for structure solution, allowing us to see the effects of this mutation as well. 
 
5.3 Purification progress of PTEN (7-353, Δ286-309) 
 Improving yields of the bacteria expressing PTEN (7-353, Δ286-309) through growth in 
Hyper Broth has greatly increased our available protein following bacterial lysis.  However, the 
consistent precipitation of the PTEN protein during the 4 °C incubation used for cleavage of the 
GST-tag has to be overcome to pursue further experiments. 
 With precipitation occurring during the 72 hour incubation at 4 °C during 3C Prescission 
Protease cleavage, solving this problem will be required in order to advance our experiments with 
this protein.  As we have tested, in parallel, protein samples with 3C Prescission Protease added 
or only buffer added and observed precipitation in both cases it is unlikely the precipitation is 
triggered by removal of the GST-tag. 
 To determine the role that the incubation time and conditions have on the observed 
precipitation, we can alter these parameters to determine if this results in improved protein yield 
and quality.  Decreasing the incubation times from 72 hours to a 16 hour overnight incubation, 
or even briefer 8 hour or 4 hour during the day, can allow us to extract various protein samples 
across these various time points.  These samples can then be analyzed by SDS-PAGE to 
determine the amounts of proteins cleaved of the GST-tag after this time, and how much of the 
protein remains tagged.  The incubation steps could also be performed at a higher temperature 
than the 4 °C used, such as incubating at room temperature for one of the decreased incubation 
times.  Samples could be extracted and analyzed as above, and with a higher temperature 
83 
 
incubation it would also be important to determine that the protein does not denature or undergo 
major structural differences during incubation.  One technique to ensure the secondary structures 
of the protein do not undergo significant changes is circular dichroism.  Protein in solution is 
exposed to left and right circularly polarized light, which results in differential absorption 
between the left and right circularly polarized light based on the chiral nature of proteins and 
contributions of secondary structure features, forming a spectrum that can be interpreted to 
determine general ratios of various secondary structures features present in the protein structure 
(Greenfield and Fasman, 1969).  The PCCF at the University of Saskatchewan has a Chirascan 
Plus CD Spectrometer (Applied Photophysics; Surrey, United Kingdom) instrument for 
performing circular dichroism experiments. 
 One potential reason for the observed precipitation would be due to high protein 
concentration of our initially Glutathione-Sepharose purified protein.  As the precipitation at this 
step was noted following improving our protein yields through the Hyper Broth growth, it may 
be that the PTEN (7-353, Δ286-309) concentration at purification leads to spontaneous 
precipitation over time.  In order to examine this possibility closely monitoring the concentration 
of our GST-PTEN (7-353, Δ286-309) at all stages of purification may allow us to observe if 
precipitation occurs at a certain concentration threshold.  We can also dilute our protein in 
additional buffer, or add detergent to increase solubility, but for complex and crystallization 
experiments these solutions may decrease the chance of success.  Low protein concentration 
could prevent crystallization, and presence of detergent molecules could interfere with complex 
formation between p85 and PTEN, as well as complicate co-crystallization condition 
determination. 
 Another potential reason for the precipitation could be the presence of a contaminating 
protease persisting through the purification protocol and slowly cleaving the PTEN over time.  
This could explain why the precipitation is observed during a longer incubation period, as it could 
provide the protease with the time required to degrade enough protein to lead to mass 
precipitation.  One method to treat this problem would be the addition of additional purification 
steps to further remove any contaminating protein, some purification possibilities described 
below. 
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5.3.1 Additional purification steps for PTEN (7-353, Δ286-309) 
 In order to remove any possible contaminating proteases persisting through the initial 
purification steps of PTEN, additional purification may be required. 
 As the PTEN Crystal protein fragment has a calculated isoelectric point of 8.70, 
calculated using the ExPASy ProtParam tool, we could use cation exchange chromatography to 
further purify the protein. 
 Glutathione-Sepharose purified PTEN Crystal would be bound to a cation exchange 
column (potential column media of Source 15S, GE Healthcare, cat# 17-0944) based on the 
positive charge the protein possesses at pH 7.0.  We can then elute the bound protein across a 
gradient of increasing NaCl, as described for our anion exchange purification of the p85 proteins 
above. 
 Based on the success of our anion exchange purifications of the p85 proteins use of cation 
exchange chromatography could assist in the removal of any contaminating proteins that may 
have been causing our PTEN Crystal to precipitate.  
 
5.4 Complex formation progress between bovine p85 protein fragments and Rab5 as 
analyzed by SEC and Western blot analysis 
 Current attempts to form the complex between p85-BH and Rab5 have been hindered by 
the variation in behaviour between different preparations of the Rab5 protein.  We have observed 
differences between protein preparations with some having small amounts of complex formation, 
and others showing separate elution of both proteins with no observable interaction.  Identifying 
the source of this inconsistency will be important prior to pursuing further complex formation 
and co-crystallization experiments. 
 Previous research showed that presence or absence of bound nucleotide (GDP or GTP) 
did not significant alter the binding of Rab5 to p85 (Chamberlain et al., 2004).  These experiments 
were performed using ELISA and pull-down analysis, which may not take into account changes 
to the equilibrium of the complex formation.  Because we need the protein complex, which may 
exist in a state of equilibrium with the proteins not in a complex, ensuring equal loading of 
nucleotide may increase the consistency of behaviour for the purified proteins. 
 It is also possible that contaminating proteins or proteases could have remained 
throughout the Glutathione-Sepharose purification.  Additional purification steps could help to 
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solve this situation if additional proteins present are the source of the inconsistencies.  Full-length 
Rab5 has a calculated isoelectric point of 8.32, calculated using the ExPASy ProtParam tool, 
which could make this protein another candidate for cation exchange chromatography, as 
mentioned above, as an additional purification step for PTEN Crystal.  However if we use Rab5 
(15-184), the protein fragment that previously had a crystal structure solved, this protein fragment 
has an isoelectric point of 6.93, which would make it unsuitable for purification using either anion 
exchange or cation exchange at pH 7.  This would require different additional purification steps 
of the Rab5 (15-184) protein fragment, such as SEC to remove any contaminating proteins based 
on difference in MW. 
 
5.4.1 Future experiments for p85-BH:Rab5 co-crystal screening 
 Upon optimization of large quantities of highly purified p85-BH:Rab5 protein complex 
we would begin our screening for crystallization conditions.  To this end we will start with 
automated screens using the GRYPHON robot operated by the PCCF, testing our protein 
complex against the various commercially available crystallization screens as described above.  
Promising conditions can then be selected for optimization screens using the hanging drop vapour 
diffusion method as described above, with crystallization conditions pursued based on the 
automated sparse matrix screens. 
 One important consideration for observing initial promising crystallization conditions is 
the possibility of individual crystallization of the p85-BH or Rab5 protein.  If a selected 
crystallization condition serves as an ideal condition for one protein this could result in the 
dissociation of that protein from the complex, to form a crystal with the free molecules of itself 
while excluding our other protein from the crystal.  Visual inspection of crystals alone would not 
be enough to identify whether this individual crystallization had occurred, potentially resulting 
in the collection of X-ray diffraction data of crystals that only contain one protein rather than our 
complex of interest. 
 In order to identify the possibility of this individual crystallization, without collecting X-
ray diffraction data of a crystal that doesn’t contain the protein complex, comparison of the 
crystallization conditions previously used for the respective proteins could provide us with 
insight.  If the crystallization conditions are the same as we used for p85-BH (0.1 M sodium 
cacodylate pH 6.0, 1.5 M Li2SO4, 4-8% [w/v] glycerol), that Musacchio et al. used for the human 
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p85 BH domain structure (3.6 M sodium formate pH 5.0) (Musacchio et al., 1996), or that Zhu 
et al. used to solve the Rab5 (15-184) structure (50-100 mM 4-morpholineethanesulfonic acid 
pH 6.0, 0.2 M NaCl, 1 mM MgCl2, 10% [w/v] PEG 6000, 0.1% [v/v] ß-mercaptoethanol) (Zhu 
et al., 2003), closer examination of the crystals to determine presence of one or both proteins 
would be warranted.  Crystallization under the same or similar conditions could result in the 
crystallization of an individual protein rather than the complex.  Comparison of the crystal forms 
obtained under these conditions and for the individual proteins previously crystallized can allow 
us to observe additional similarities and differences prior to collecting X-ray diffraction data.  For 
more quantitative analysis crystals could be removed from the crystallization drop, washed in 
fresh crystallization solution to remove proteins not incorporated into the crystal, dissolved in 
SDS, and then analyzed by SDS-PAGE followed by Western blotting to detect the presence of 
one or both proteins in the crystal.  If both proteins are detected then collection of X-ray 
diffraction data at the CLS would be warranted. 
 Once X-ray diffraction data is collected we would process this data using HKL2000 
software installed at the CLS (Otwinowski and Minor, 1997).  Structure solution would be 
performed using PHENIX software (Adams et al., 2010) with previously solved p85-BH and 
Rab5 structures used for molecular replacement search motifs.  Improvement of the accuracy of 
the determined structure would be performed by using Coot software (Emsley et al., 2010) and 
the phenix.refine operation in PHENIX. 
 
5.5 Dimerization status of full-length human p85 wild-type and mutants using SEC and 
MALS 
 Following our SEC and MALS analysis of the full-length human p85 protein, the potential 
concentration dependent nature of protein dimerization requires further examination. 
 Having examined the dimerization state of human p85 wild-type and cancer-associated 
and engineered mutants (L30F, F69L, I82F, E137K, D168R, I177N, E212R, E217K, H234D, 
Q241D, R262T, K288Q, E297K) at 0.7 mg/mL concentration through SEC and Native PAGE 
we did not observe any significant effects of these mutants on dimerization.  Our analysis of p85 
wild-type through MALS analysis showed a decrease in determined MW to correspond with 
decreasing protein concentration (concentrations used were 4 mg/mL, 2 mg/mL, 1 mg/mL, 0.7 
mg/mL, 0.5 mg/mL), suggesting mixed populations of dimer and monomer at 2 mg/mL and 1 
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mg/mL protein concentrations, and monomeric populations at 0.7 mg/mL and 0.5 mg/mL.  The 
4 mg/mL concentration showed extensive aggregation of protein.  The determined oligomeric 
state at 0.7 mg/mL p85 is different when detected through SEC with Native PAGE (dimeric) and 
our MALS data (monomeric). 
 One possible reason for the discrepancy between the SEC and Native PAGE results as 
compared to the MALS results could be due to the shape of the p85 molecule.  Molecular shape 
can affect the rate of movement through the media of the SEC column or gel matrix of Native 
PAGE, resulting in the calculated sizes based on elution volume or gel migration varying from 
what is actually biologically present.  However, it seems unlikely that a monomeric p85 molecule 
would run so that it appears to be twice its actual MW.  The MW determined by MALS is 
supposed to take into account the dimensions of the molecule in solution, avoiding such potential 
problems (Wyatt, 1993).  However, our MALS analysis of 0.7 mg/mL p85 protein had a 
determined MW of 72 kDa, which is smaller than the 85 kDa MW for a p85 monomer. 
 
5.5.1 Future experiments for examining the role of concentration and mutations in 
determining the oligomeric state of p85 
 Further experiments are required to better characterize the role of concentration and 
mutations on p85 oligomerization. 
 One experiment to provide comparison between the SEC and MALS results will be to 
perform SEC on a wider range of human p85 wild-type proteins to observe any changes in their 
elution volume, and therefore calculated MW.  We will load 2 mg/mL, 1 mg/mL, and 0.5 mg/mL 
p85 concentrations for SEC analysis.  Any observed changes in the elution volume could also 
help us to observe how significantly the protein shape affects the SEC results, for if we see a 
large increase in calculated MW at the higher protein concentrations this could suggest that the 
shape of the p85 protein significantly changes the elution volume for SEC experiments.  If we do 
not observe a significant shift in elution volume at these different concentrations, we could also 
pursue these multiple concentrations of SEC experiments for the various p85 mutants to examine 
any changes to the oligomerization state. 
 Analysis of the p85 mutants via MALS at concentrations of 2 mg/mL, 1 mg/mL, 0.7 
mg/mL, and 0.5 mg/mL can allow us to better characterize any changes to the dimerization status 
of the protein that these mutations might cause across the range of concentrations.  These 
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experiments would be important for determining how these mutants affect the oligomerization 
state of p85 if we observe a significant difference in the elution volumes and calculated MW 
during the range of concentration experiments for SEC, as molecular shape should have less 
effect on the MALS results. 
 Results from these experiments can be further verified by Native PAGE, by running 
samples from across the various protein concentrations. 
 
5.6 Binding of lipid by p85 through PIP strip analysis 
 Observed binding of various phosphorylated lipids by p85 was one of our most interesting 
results (Figure 4.13, Figure 4.14).  With the observed potential novel binding pocket in our 
structure serving as the basis for our search for novel binding partners, the selective interaction 
between lipids containing solvent accessible phosphates was quite pronounced.  The prevalence 
of PIP lipids that showed binding with p85, and that unphosphorylated phosphatidylinositol 
showed no appreciable binding, also raise interesting possibilities for physiological significance 
behind this lipid binding activity that is worth further examination. 
 
5.6.1 Potential physiological significance for observed lipid binding 
 Based on the important regulatory role that the p85 protein plays in the PI3K/PTEN 
pathway, observing the ability of p85 to directly bind to various PIP lipids that play important 
roles in that pathway raises several exciting possibilities.  One is that through direct binding to 
PI4,5P2 and PI3,4,5P3 the p85 protein brings these lipid substrate molecules into better proximity 
to its protein partners p110 or PTEN, helping to promote the catalytic activity of these proteins 
on their lipid substrates.  If the lipids are bound in the potential novel binding pocket which 
contains several residues that were shown to be important for p85 binding to PTEN (Figure 1.10) 
it could also suggest that the interaction between p85 and PTEN may be enhanced by, or 
dependent on, the presence of lipid between the two proteins.  If this is the case further 
considerations would need to be taken into account for characterization experiments based on 
purified p85 and PTEN proteins, as this lack of lipid present could alter the results of such 
experiments. 
 The fact that PI4,5P2 and PI3,4,5P3, the key PIP lipids in the PI3K/PTEN pathway, show 
less binding than the other PIP lipids tested against p85 is also interesting.  As these lipids serve 
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as substrate and product for the reactions performed by p110, and in reverse PTEN, as the 
products for these reactions it makes sense for p85 to not bind them too tightly, to ensure their 
release and normal cellular function following catalysis, as well as to allow for binding of another 
substrate.  It would be interesting to determine if interacting with p110 would alter the lipid 
binding profile of p85 to more strongly bind PI4,5P2, or more weakly bind PI3,4,5P3 to promote 
the p110 directed path of the reaction, and if the opposite would occur during p85 binding to 
PTEN. 
 
5.6.2 Comparison of p85-BH SO4 positions with inositol head groups 
 Due to the observed binding between the p85 BH domain and the various phosphorylated 
lipids through our PIP strip experiments, we wanted to compare the positions of the electron 
densities we assigned to SO4 ions with the phosphates attached to PIP lipid head groups.  This 
would allow us to compare the distances between the electron densities and the PIP phosphate 
groups to determine whether they would fit within this region. 
 To examine this we used the structure of inositol 1,3,4,5-tetrakisphosphate present in PDB 
ID# 1BWN (Baraldi et al., 1999).  We then positioned the inositol 1,3,4,5-tetrakisphosphate 
within our p85-BH structure near the potential binding pocket in Coot, and used the Real Space 
Refine Zone and Regularize Zone commands to finalize the position based on the previously 
calculated electron density (Emsley et al., 2010).  A resulting structure is provided in Figure 5.4.  
The phosphate groups located two carbons apart from each other on the six-carbon ring, carbon 
3 and carbon 5 for example, fit extremely well within the calculated electron densities. 
 In Figure 5.4 two possible orientations of the bound inositol 1,3,4,5-tetrakisphosphate 
have been presented.  The first involves the binding at phosphates 1 and 3.  As phosphate 1 would 
contain the lipid chain in PIP lipids, positioning the lipid chain adjacent to the p85 protein surface.  
This interaction orientation would be affected by membrane-bound PIP lipids, as binding to 
phosphate 1 would require the BH domain to be in very close proximity to the plasma membrane, 
which could result in steric interference depending on binding partners or the orientation of other 
domains of p85.  The second orientation involves the binding at phosphates 3 and 5.  As these 
phosphates are not involved in the lipid chain that serves to anchor PIP lipids to the plasma 
membrane they may be more easily accessible for the protein to bind and interact with. 
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Figure 5.4 p85-BH potential binding pocket with overlaid inositol head group.  Close up 
of the potential binding pocket of p85-BH with an inositol 1,3,4,5-tetrakisphosphate placed 
based on the positions of the SO4 ion previously positioned.  Side chains of involved residues 
and the inositol group are represented in stick format, and previously modelled SO4 ion regions 
are represented as clouds of magenta dots.  Inositol groups are positioned so that phosphates 
at positions 1 and 3 (A) or phosphates at positions 3 and 5 (B); are located where the electron 
densities assigned to SO4 ions were present. 
This examination suggests that the potential novel binding pocket could serve to bind 
PI3,4,5P3 based on the positions of the calculated electron densities observed.  The effect of 
mutations on lipid binding can provide biochemical evidence towards these initial observations. 
5.7 Computer modelling of the p85-BH homodimer and PTEN complex 
In order to determine a potential orientation between the p85 BH domain homodimer and 
the PTEN protein, we performed protein docking analysis using ClusPro server (Comeau et al., 
2004a, b; Kozakov et al., 2006; Kozakov et al., 2017).  We selected this server due to its ease of 
use and its previous success in structural interaction competitions such as CAPRI (Critical 
Assessment of Predicted Interactions) (Kozakov et al., 2017).  Previous docking studies had been 
performed between the p85 BH domain and PTEN by Cheung et al. incorporating data from 
mutations that affected p85 homodimerization (I177N) or binding to PTEN (I127A, I133A, 
E137A) (Cheung et al., 2015).  This study did not include the residues important for p85 binding 
PTEN (our unpublished data; Figure 1.10), and so we wished to pursue this docking analysis 
incorporating this knowledge as well.  This would help us to determine if the p85 protein could 
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have an uncharacterized role in helping orient lipid molecules that could explain the enhanced 
PTEN phosphatase activity we have observed upon p85 binding (Chagpar et al., 2010). 
 Docking analysis was performed using the previously solved PTEN crystal structure, 
PDB ID# 1D5R, as our “receptor” molecule (Lee et al., 1999).  Our p85-BH structure was used 
as the “ligand” molecule, including both chains of the homodimer as homodimerization was 
shown to be important for p85:PTEN binding (Cheung et al., 2015).  Attraction residues were 
assigned for D168, E212, H234, Q241 of the A chain due to their role in p85 binding to PTEN in 
the purified protein binding experiments (Figure 1.10).  We only assigned attraction residues to 
the A chain as the corresponding residues in the B chain of the p85 BH homodimer are oriented 
facing in opposite directions relative to the A chain residues, making it unlikely that a single 
PTEN protein would be interacting with these residues on both p85 BH domains at the same time.  
This prevented generation of additional possible structures of the same orientation on different 
protein chains, as the two chains have nearly identical structures.  The ten output clusters of 
highest scoring arrangements were collected, the structures examined using PyMOL. 
 Summary of the ClusPro output clusters are provided in Table 5.1.  A comparison of the 
various output clusters are shown in Figure 5.5. 
 
Table 5.1 ClusPro output clusters statistics 
  Representative Weighted Score 
Output Cluster Cluster Members Center Lowest Energy 
0 61 -713.4 -836.5 
1 60 -751.2 -835.2 
2 45 -740.4 -933.1 
3 44 -736.2 -1004.3 
4 43 -688.1 -895.0 
5 36 -776.0 -908.5 
6 32 -725.9 -770.4 
7 32 -745.9 -748.1 
8 26 -700.6 -808.3 
9 26 -764.8 -764.8 
 
 For examining the ClusPro Output Clusters we used several criteria to determine which 
clusters to exclude from further analysis and which clusters to examine more thoroughly, based 
on biochemical analysis of the p85 and PTEN proteins.  Cheung et al. have shown that PTEN 
binding to p85 is dependent of p85 dimerization, so we would expect the PTEN to interact with  
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Figure 5.5 ClusPro docking results for p85 BH domain homodimer binding PTEN.  
Overlays of the calculated docking clusters of the p85 BH domain homodimer with PTEN 
(orange-C2 domain and yellow-phosphatase domain). Note the positions of the PTEN domains 
remains fixed, whereas the various possible orientations differ for the docked p85 BH domain 
homodimers.  A. The ten most populous high scoring p85 BH docking clusters (0=magenta, 
1=white, 2=lavender, 3=violet, 4=green and cyan, 5=blue, 6=olive, 7=brown, 8=grey, 9=black) 
with PTEN.  B.  Clusters 0 and 8.  C.  Clusters 2, 7 and 9.  D.  Clusters 1, 3, 5 and 6.  E.  Cluster 
4 
both members of the p85 BH homodimer (Cheung et al., 2015).  As p85 binding to PTEN 
stimulates PTEN phosphatase activity we would expect the p85 protein to bind near the catalytic 
pocket present in the PTEN phosphatase domain (Chagpar et al., 2010).  Das et al. determined 
that basic residues R161, K163, and K164 in the PTEN phosphatase domain are important for 
plasma membrane association, so we would expect these residues to not be concealed, and that 
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p85 proteins bound would not be oriented to extend into the plasma membrane (Das et al., 2003).  
In addition we would expect the PTEN to associate with residues in p85 where mutation disrupted 
binding to PTEN, while not forming extensive interactions with residues where mutations did not 
alter PTEN binding (Figure 1.10). 
All Output Clusters generated by ClusPro except for Cluster 4 show the PTEN protein 
interacting with the cleft formed at the homodimerization interface of the two p85 BH domains. 
Clusters 0 and 8 show this interaction primarily with the PTEN phosphatase domain on the 
opposite side of the protein from the catalytic pocket, with some minor contacts to the PTEN C2 
domain, p85 is located on the opposite face of PTEN from the PTEN catalytic pocket, and many 
of the interaction sites are located around p85 residues that did not affect PTEN binding (Figure 
5.5 B).  Clusters 2, 7, and 9 interact exclusively with the PTEN phosphatase domain away from 
the catalytic pocket and are oriented such that they would extend into the plasma membrane 
(Figure 5.5 C).  Clusters 1, 3, 5, and 6 interact exclusively with the PTEN C2 domain, are distant 
from the PTEN catalytic pocket, and are oriented so that they may extend into the plasma 
membrane (Figure 5.5 D).  None of these observed interaction clusters are positioned to include 
residues D168, E212, H234, or Q241 within their interaction surfaces.  In addition these 
interaction orientations often place the terminal S113 residue of the p85 BH domain tightly 
against the PTEN protein, which may not allow the addition of the inter-domain linker region 
that connects the p85 BH domain to the SH3 domain.  Due to the lack of interaction with expected 
p85 residues, potential structural interference due to the orientation of the terminal p85 residues, 
and distance from the PTEN catalytic pocket, these Output Clusters are not consistent with the 
experimental data available. 
The most interesting results from the ClusPro docking analysis are for Cluster 4 (Figure 
5.5 E, Figure 5.6).  Here both the C2 and phosphatase domains of the PTEN protein interact with 
the p85 protein, a loop of the C2 domain interacting with both of the monomers in the p85 BH 
domain homodimer and near the D168 residues for both p85 monomers as well.  The PTEN C2 
and phosphatase domains then continue to make contacts with a single p85 BH domain, in close 
proximity with p85 residues H234 and Q241, with these residues labeled in Figure 5.6.  This 
orientation also positions the catalytic pocket of the PTEN phosphatase domain towards the p85 
protein without obstructing the pocket.  In addition, the PTEN protein is near the p85 potential 
binding pocket we had previously observed. 
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Figure 5.6 Examination of ClusPro Cluster 4 of p85 BH dimer PTEN complex.  
Orientation of Cluster 4 ClusPro server docking analysis between the p85 BH dimer and PTEN. 
The p85 BH domains are represented in green and cyan, PTEN C2 domain in orange, and 
PTEN phosphatase domain in yellow.  Sidechains for protein function or potential interactions 
are represented in stick format, with PTEN residues important for membrane binding in blue, 
PTEN catalytic pocket residues in brown, and PTEN catalytic C124 in magenta. 
The interface region between the PTEN C2 domain and the p85 BH dimer is shown in 
Figure 5.7.  From the docking analysis there are a number of potential hydrogen bonding 
interactions between residues on PTEN and p85, either from side-chain to side-chain or side-
chain to backbone.  In addition, most of the PTEN residues involved in such interactions are 
found in flexible loop regions of the protein, which could allow for adjustments to their position 
to improve these possible interactions in the protein complex.  A list of residues that have the 
potential to form hydrogen bonds can be found in Table 5.2. 
D168 was one of the residues identified to be important for p85 binding to PTEN, and its 
presence in this region agrees with that, as does its sidechain belonging to a potential hydrogen 
bonding site (Figure 1.10).  Determining if mutations to PTEN residues K263, K266, K327, 
R335, or Y336 affect the binding to p85 could clarify if this region is involved in complex 
formation.  Furthermore, point-mutation of Y336 residue has been found in human cancers, as 
recorded in the Catalogue of Somatic Mutations in Cancer database 
(http://www.sanger.ac.uk/genetics/CGP/cosmic) and Y336 has been shown to be a site of 
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Table 5.2 Potential hydrogen binding sites between PTEN and p85 based on docking results 
PTEN Residues p85 Residues 
Y336 (sidechain) T114 (backbone nitrogen) 
R335 (sidechain) S113 (backbone oxygen) 
K327 (sidechain) T114 (backbone oxygen) 
K266 (sidechain) D166 (backbone oxygen) 
L265 (backbone oxygen) D168 (sidechain) 
K263 (sidechain) D166 (Chain B, backbone oxygen) 
Q17 (sidechain) S229, R228, K225 (sidechains) 
D19 (sidechain) R228, K225 (sidechains) 
D22 (sidechain) R228, K225 (sidechains) 
phosphorylation by FRK, also called Rak (Yim et al., 2009).  Phosphorylation of PTEN Y336 by 
FRK was shown to protect PTEN from ubiquitin-mediated proteosomal degradation mediated by 
the E3 ubiquitin ligase Nedd4-1, while mutations of Y336F prevented PTEN phosphorylation 
and resulted in a significant increase in the rate of PTEN protein degradation (Yim et al., 2009).  
Our current model of the interaction region between the p85 BH domain and PTEN, shown in 
Figure 5.7, there could be space for the Y336 residue to be phosphorylated following a 
reorientation of the p85 D166 sidechain, and the phosphate could potentially form hydrogen 
bonds with the backbone nitrogens of p85 S113 and T114.  It is also possible that the increase in 
protein stability for PTEN by binding to p85 is due to this interaction interface preventing Nedd4-
1 from binding to and ubiquitinating PTEN.  If PTEN was not phosphorylated interaction with 
p85 could also prevent binding to and phosphorylation of PTEN by FRK. 
Examination of the docking results from the perspective of the plasma membrane was 
performed, determined based on the location of PTEN residues R161, K163, and K164 which 
had been identified as important for PTEN to associate with the plasma membrane (Das et al., 
2003).  As shown in Figure 5.8 there is a cavity between the two proteins that allows access to 
the PTEN phosphatase catalytic pocket.  To determine if this cavity would be large enough to 
accommodate a PI3,4,5P3 molecule we manually modelled in a 4-carbon PI3,4,5P3 obtained from 
the PDB (PDB ID# 4PT) using the ideal conformation for the ligand molecule.  This 4-carbon 
PI3,4,5P3 was successfully positioned within the observed cavity and into the PTEN phosphatase 
catalytic pocket. 
A comparative view of the PTEN phosphatase catalytic pocket can be found in Figure 
5.9, showing the tartrate molecule present within the crystal structure of PTEN solved by Lee et 
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Figure 5.7 Docking analysis interface between p85 BH domain dimer and PTEN C2 
domain.  Close up view of the interface between the PTEN C2 domain (orange) and the p85 
BH dimer (green and cyan) determined in ClusPro docking Cluster 4.  Sidechains of residues 
near the protein interface are represented in stick format.  Potential hydrogen bonding sites are 
indicated with dotted lines and their distances labelled in Angstoms.  PTEN residues are 
labelled in black, p85 residues are labelled in blue.  Potential hydrogen bonding sites are: PTEN 
R335 sidechain with p85 S113 backbone oxygen, PTEN K327 sidechain with p85 T114 
backbone oxygen, PTEN Y336 with p85 T114 backbone nitrogen, PTEN K266 sidechain with 
p85 D166 backbone oxygen, PTEN L265 backbone oxygen with p85 D168 sidechain, PTEN 
K263 sidechain with p85 Chain B D166 backbone oxygen.  Perspective rotated 180° relative 
to Figure 5.6. 
al. (Figure 5.9A), or the manually modelled 4-carbon PI3,4,5P3 molecule (Figure 5.9B) (Lee et 
al., 1999). 
For the manually modelled 4-carbon PI3,4,5P3 it currently has the phosphate in the 4 
position closest to the catalytic C124 residue, where we would expect the phosphate in the 3 
position to be based on the catalytic function of PTEN.  This is likely due to the rigidity of the 
idealized bond arrangement for the 4-carbon PI3,4,5P3 used, and with the flexibility found in the 
actual molecule proper positioning of the phosphate in the 3 position could be possible within the 
catalytic pocket.  It is also interesting to note that the p85 residues found near the PTEN catalytic 
pocket are in position to frame it, with the closest residues being prolines and a serine residue 
with its sidechain facing away from the pocket.  These residues would not interfere with the entry 
of lipid molecules to this catalytic pocket and are positioned to frame the PTEN catalytic pocket, 
potentially helping to orient the bound lipid. 
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Figure 5.8 Potential cavity leading to PTEN catalytic pocket.  A.  View from the plasma 
membrane perspective of the ClusPro Docking Cluster 4, with p85 BH domains in green and 
cyan, PTEN phosphatase domain in yellow, PTEN C2 Domain in orange, and PTEN residues 
important for lipid binding in blue.  A cavity containing a modeled 4-carbon PI3,4,5P3 
molecule is highlighted with a dashed circle.  B.  Close up view of the PTEN phosphatase 
catalytic pocket, shown in brown with the catalytic C124 in magenta, with the 4-carbon 
PI3,4,5P3 shown in purple with its phosphate groups in orange shown in the same orientation 
as panel A. 
Examining the positions of the PTEN catalytic pocket with the p85 potential binding 
pocket, shown in Figure 5.9 C, reveals that the two regions are separated from each other and 
not in direct contact.  This means that it would be unlikely for the p85 potential binding pocket 
to assist PTEN catalytic function by helping to bind lipid and position it in the PTEN catalytic 
pocket. 
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Figure 5.9 Examination of the PTEN phosphatase catalytic pocket, with spatial 
comparison to p85 BH domain potential binding pocket.  PTEN phosphatase domain is 
shown in yellow, with catalytic pocket residues in brown and the catalytic C124 residue in 
magenta.  Shown bound within the pocket are A. the tartrate (violet) present in the previously 
solved PTEN crystal structure (Lee et al., 1999) B. Or the modelled 4-carbon PI3,4,5P3 
molecule (purple).  C.  A view showing the relative positioning between the PTEN catalytic 
pocket and the p85 BH domain potential binding pocket, including the SO4 molecules that had 
been placed within the p85-BH structures solved. 
A closer examination of the p85 potential binding pocket with respect to the PTEN 
phosphatase domain is shown in Figure 5.10. 
Within the docking structure there is a large conformational adjustment of the p85 R228 
sidechain, positioning itself to potentially form hydrogen bonds with Q17 or D22.  Other potential 
hydrogen bonds can occur between p85 K225 with PTEN Q17 or D19, and the p85 S229 with 
Q17.  It is possible that these residues play a role in binding between p85 and PTEN, as 
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Figure 5.10 Interface between PTEN and p85 near the p85 potential binding pocket.  
ClusPro docking of PTEN:p85 BH domain dimer examining the interface near the p85 
potential binding pocket.  PTEN phosphatase domain is in yellow, and the p85 BH domain is 
in green.  SO4 molecules from the p85-BH crystal structure determined are also shown.  PTEN 
residues are labelled in black and p85 residues are labelled in blue.  Potential hydrogen bonding 
sites are shown as dashed lines with their distances labelled in Angstroms. 
mutagenesis of p85 residues R228 and K225 showed decreased binding strength in the cell based 
binding assays previously performed by Ruan et al. (Figure 1.10).  The sidechain of PTEN R47 
is oriented towards the p85 potential binding pocket region, and may be able to replace the p85 
R228 sidechain that has altered its orientation to interact with the PTEN protein.  Comparison of 
the positions of involved sidechains between our previously solved p85-BH structure and the 
docking results show only minor adjustments to the positions of the other residues surrounding 
the potential binding pocket, K224, H234, W237, and Q241. 
This docking model incorporates a number of the observations for residues important in 
the interaction between p85 and PTEN (Figure 1.10).  The interaction between the PTEN C2 
domain with both p85 BH domains in the homodimer also agrees with the observed dependence 
of p85 dimerization on PTEN binding (Cheung et al., 2015).  The positions of D168, K225, and 
R228 from p85 allowing for potential hydrogen bonding with PTEN residues offers a potential 
explanation for the observed effects of mutations to these residues on PTEN binding.  H234 is 
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also located in close proximity to the p85:PTEN interface, although no potential binding 
interactions were observed for it in the observed model. 
Examining the predicted interfaces between the two proteins provides additional 
mutagenesis targets to observe if they alter the binding between p85 and PTEN.  The position of 
the PTEN catalytic pocket and the p85 potential binding pocket suggest that this region of p85 
would not stimulate PTEN activity through additional coordination of lipid molecules for PTEN 
catalysis.  Mutational studies of PTEN residues at the interface between p85 and the PTEN C2 
domain, shown in Figure 5.7 and Table 5.2, can help determine if they play a role in complex 
formation with p85.  
This study has combined data collected from biochemical studies, high resolution 
structural data, and computation protein docking.  From our protein experiments we have 
observed a novel function for the p85 protein, direct binding to lipid molecules.  Examination of 
the structural data obtained provided us with a region of interest to examine regarding this novel 
biological function, the potential binding pocket observed in the p85 BH domain.  Finally our 
docking studies have provided a potential orientation to the complex formed between the PTEN 
protein and the p85 BH domain homodimer, revealing additional residues worth examining 
through mutagenesis studies in order to support or disprove this possible orientation.  Better 
understanding of how this interaction between PTEN and p85 regulates PTEN activity and 
protein stability may reveal a role in cancers with low PTEN protein levels but where PTEN 
expression levels are not altered. 
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